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ABSTRACT  
 
Schizophrenia is a neuropsychiatric disorder lying at the extreme of a spectrum of 
disorders that possibly share a common abnormality in neural connectivity. Efforts 
to reverse the core cognitive manifestations of schizophrenia using drug treatments 
have so far been unsuccessful. This thesis investigates the cognitive abnormalities 
and their electrophysiological correlates across the schizophrenia spectrum in order 
to identify and validate biomarkers for proof of concept studies of cognitive 
enhancers.  Such studies in milder disorders of the schizophrenia spectrum such as 
schizotypal personality trait may be a crucial method in identifying new effective 
compounds, as reviewed in Chapter 3, and tested in Chapter 4. The latter features 
the results of a large three-centre study which probed the sensitivity of several 
neuropsychological measures to the schizotypy phenotype, as well as to the effects 
of amisulpride, risperidone and nicotine. Schizotypal volunteers showed impaired 
performance only on the more difficult tasks. The most consistent pharmacological 
finding was that amisulpride tended to improve performance in the high schizotypy 
group but to impair it in the average schizotypy controls. One interpretation is that 
the ability of low dose amisulpride to enhance dopamine function in frontal cortex 
reversed an impairment of dopamine function present in the high schizotypes which 
is thought to occur in schizophrenia. Chapter 5 explored the methodological 
question of whether low or average schizotypy individuals should be used as 
controls in cognitive comparisons versus high schizotypy. The results suggest that 
low schizotypes have the most intact cognitive performance and are therefore the 
control group of choice. Chapters 6, 7 and 8 tested the hypothesis that cognitive 
deficits are part of a larger information processing abnormality in the schizophrenia 
spectrum. In accordance, both high schizotypy and schizophrenia patients exhibited 
reduced amplitude of an early visual evoked potential P1 (Chapters 6 and 8, 
respectively) and disruptions of the underlying evoked neural oscillations (Chapters 
7 and 8). The pattern of abnormalities suggested an inefficient top-down modulation 
of perception in the schizophrenia spectrum. These data argue that cognitive 
abnormalities and their electrophysiological correlate may be sensitive biomarkers 
of the core dysconnectivity deficit in schizophrenia. This thesis supports their use in 
proof of concept studies to foster the development of cognitive enhancers.
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CHAPTER 1 
 
 
GENERAL INTRODUCTION 
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1.1. Schizophrenia 
 
Schizophrenia is a clinical syndrome based on the presence of a collection of mental 
and behavioural phenomena. These include the so-called positive (abnormal 
perceptions and delusions) and negative (emotional flattening, lack of drive and will) 
symptoms, as well as widespread cognitive abnormalities and behavioural 
disorganization (bizarre behaviour and thought disorder). However, none of these 
symptoms are patognomic and a variety of presentations are possible.  
 
1.2. Aetiology of schizophrenia 
 
Despite more than a hundred years of research, the factors that cause schizophrenia 
are still unclear. What we know is that it affects just under 1% of the general 
population and that it is characteristically rare before puberty reaching its peak 
incidence is in the early adulthood (Tandon et al. 2009). This implicates a 
vulnerability of the nervous system that becomes exposed only during late maturation 
of the brain.  This key vulnerability is likely to be familial with genetic factors 
accounting for  more than 80% of the liability to schizophrenia (Tandon et al. 2008). 
However, only a small fraction, around 5-10% of all first degree relatives of 
schizophrenia patients go on to develop schizophrenia in their life time. This indicates 
that a significant proportion of those at genetic risk remain unaffected. These 
genetically vulnerable individuals however have been shown to be more prone to 
certain psychiatric illnesses (schizoaffective disorder) and personality disorders 
(schizotypal, paranoid and schizoid personality disorders) that resemble schizophrenia 
(Kendler, McGuire et al. 1993; Kendler, McGuire et al. 1993; Kendler, McGuire et al. 
1993). This has led to the hypothesis that schizophrenia-related personality and 
schizophrenia are the increasingly extreme manifestations of a continuously 
distributed dimension of risk (Meehl 1989; Lenzenweger 2006). It is plausible that the 
very same basic abnormality of the nervous system is present across this spectrum, 
but depending on its extent and the influence of other risk factors it might results in 
the symptoms of schizophrenia: its ultimate complication. 
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The importance of non-genetic factors in the development of schizophrenia has been 
highlighted by research into environmental risk factors. These have been generally 
divided into early and late ones. The former take place during pregnancy or birth and 
therefore have the potential of disturbing the neurodevelopment of the fetus. These 
include influenza infection (Sham et al. 1992) and malnutrition (Susser et al. 1992) in 
the first trimester. In addition, obstetric complications (Lewis et al. 1987) and 
premature birth (Geddes et al. 1999) have both been linked to higher incidence of 
schizophrenia in adult life. These environmental risk factors probably interfere with 
normal neurodevelopment in those with genetic vulnerability.  The group of later 
factors encompasses circumstances of the childhood and early adulthood of the 
individual. The most important ones are: i) being reared in immigrant communities 
(‘lack of culturalization’) (Selten et al. 1997; Kirkbride et al. 2006); urban rearing 
(Lewis et al. 1992), childhood abuse (Janssen et al. 2004) and cannabis consumption 
(Henquet et al. 2005). This group of factors probably serve to increase the risk of 
schizophrenia in those with genetic or neurodevelopmental vulnerability. 
Additionally, other environmental factors such as negative life events (Birley et al. 
1970) or living with high emotion expressing relatives increase the risk for relapse in 
the established disease (Leff et al. 1980). Both early and late environmental factors 
therefore probably interact with the genetic vulnerability to trigger and decompensate 
a neurodevelopmental abnormality that may manifest itself as schizophrenia. 
  
1.3. Schizophrenia: Is it in the brain? 
 
The validity of this theory of schizophrenia thus depends on a crucial question – is 
there any evidence for an organic abnormality, a primary neuronal deficit, in 
schizophrenia? If so, is a similar pattern detectable in the milder cases of the 
spectrum? 
 
The answer to the first part of the question has been the subject of prolonged debate. 
This controversy dates back to Kraeplin, the first psychiatrist to define schizophrenia 
or dementia praecox, as he named it. As the name suggests, he saw the syndrome as a 
form of early onset dementia. At a time when interest in neuropathology was at a 
peak, he understandably hypothesized that dementia praecox has its own 
Page |   
 
22 
neuropathological substrate. The search for post-mortem abnormalities in patients 
however has been notoriously futile and controversial at best (Powchik et al. 1998). 
This encouraged alternative explanations to the pathophysiology of the disease, 
linking it to abnormal early life experiences. This view was inspired by the 
development of psychoanalysis and was at the heart of a powerful anti-psychiatric 
movement in the middle of the 20th century. 
 
1.4. The dopamine evidence 
 
Three important developments in the second half of the 20th century aided the case 
for an organic cause of schizophrenia. The first one came with the advent of a class of 
drugs known as neuroleptics. The first agent, chlorpromazine was developed as an 
antihistamine to be used in surgery but in 1952 was reported to be particularly useful 
in controlling the symptoms of patients with schizophrenia. The efficacy of the new 
drug surpassed the other alternatives at the time so convincingly that it took only a 
few years before it had established itself as first line of treatment. In the early 1960s 
Avid Carlsson found that chlorpromazine blocked the behavioural effects of the 
dopamine-releasing agent amphetamine. He postulated the existence of dopamine 
receptors that mediate the effects of dopamine and that these are blocked by 
chlorpromazine and related drugs – the dopamine hypothesis of psychotic action 
(Carlsson 1978). These discoveries won Carlsson the Nobel Prize in Medicine. The 
corollary hypothesis that schizophrenia involves excessive dopamine release 
(Carlsson 1977) was stimulated by the clinical insight that amphetamine can trigger 
schizophrenia-like psychotic episodes (Connell 1958). The original dopamine 
hypothesis therefore states that the disorder is due to excess dopamine action in the 
brain, specifically along the mesolimbic dopamine pathways. Direct evidence of 
dopamine hyperfunction in schizophrenia emerged from the use of PET to quantify 
radioligand binding in living human subjects (Abi-Dargham et al. 2000). Abi-
Dargham et al. used alpha-methyl-para-tyrosine to induce acute dopamine depletion 
in patients and controls. As the duration of the challenge was too short to cause D2 
receptor up-regulation, the difference between D2 receptor availability at baseline and 
the depleted state was hypothesized to reflect the amount of receptors normally 
occupied by dopamine. The authors found that after dopamine depletion raclopride 
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binding was higher in patients relative to controls dopamine and this was interpreted 
as evidence for higher baseline D2 receptor stimulation in schizophrenia. These 
results build on previous reports that amphetamine administration displaces more D2 
receptor ligands in patients than in controls (Breier et al. 1997; Abi-Dargham et al. 
1998). Amphetamine increases endogenous dopamine release which competes with 
the D2 ligands for postsynaptic dopamine receptor binding sites thus causing a 
reduction in radioligand binding as measured by PET.  That this happens more in 
patients than controls is indicative of greater endogeneous dopamine release in acute 
schizophrenia.  
 
The dopamine hypothesis was revised in the 1990s to account for several converging 
lines of evidence of prefrontal cortex dysfunction in schizophrenia. Firstly, Ingvar and 
Franzen showed reduced prefrontal cortex blood flow in patients (Ingvar et al. 1974) 
that was linked to psychomotor poverty syndrome in schizophrenia (Liddle et al. 
1992). Secondly, using functional neuroimaging methods schizophrenia patients were 
shown to have lower degree of prefrontal cortex activation during demanding 
cognitive tasks, such as the Wisconsin Card Sorting Test (Weinberger et al. 1986; 
Wolkin et al. 1992; Kawasaki et al. 1993). These two findings indicated that 
schizophrenia is characterized by a prefrontal cortex dysfunction. The next 
development came with the work in primates by Goldman-Rakic demonstrating that 
prefrontal cortex function is facilitated by dopamine (Goldman-Rakic 1987). This 
suggested that a hypodopaminergic state might be responsible for the prefrontal 
cortex abnormality in schizophrenia. The paradoxical implication of co-existing hypo- 
and hyper-dopaminergic states were reconciled by evidence that neurotoxin lesion of 
mesocortical dopamine rejections cause the remaining projections to be over-reactive 
(Pycock et al. 1980). The revised dopamine hypothesis therefore argues that the 
increased dopamine release in the striatum is secondary of an impairment of frontal 
dopamine function (Weinberger et al. 1988; Davis et al. 1991); the former mediating 
positive symptoms and the latter impaired cognition and negative symptoms.   
 
Whether this dopamine dysfunction characterizes only patients with psychosis or also 
the proposed milder forms of the schizophrenia spectrum is still an open question. The 
lack of overt psychosis in the latter group argues against excessive dopamine release 
in the mesostriatum. However, some evidence exists to suggest that people with high 
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levels of schizotypal personality traits (high schizotypy) have suboptimal activity in 
the prefrontal cortex (Koenigsberg et al. 2005). In support of this, a study 
administering a compound enhancing dopamine activity (a mixed D1/D2 dopamine 
receptor agonist) found improvement of prefrontal cortex function in patients with 
SPD (McClure et al. 2010). The improvement of function with dopamine 
enhancement appears to be specific to schizophrenia-related personality disorder as a 
study using amphetamine in patients with schizotypal and non-schizophrenia related 
personality disorders demonstrated (Kirrane et al. 2000). It is thus possible that one of 
the organic substrates of the schizophrenia spectrum is a sub-optimal dopamine 
prefrontal cortex function. This hypothesis was investigated in the current thesis by 
exploring the modulation of prefrontal cortex functions in schizotypy by agents 
affecting dopamine neurotransmission.  
 
1.5. The structural evidence 
 
The second major breakthrough came with the invention of an imaging technique, 
computer tomography (CT). It allowed for the first time the observation of the 
neuroanatomy of a living subject. A landmark study in schizophrenia patients 
revealed that there is an enlargement of the lateral brain ventricles (Johnstone et al. 
1978). Such enlargement typically follows the loss of adjacent brain tissue and is a 
common finding in degenerative disease. This finding was replicated by numerous 
studies, including later ones which used a new class of imaging equipment, magnetic 
resonance imaging (MRI). It boasts the advantages of more precise delineation of the 
different brain regions, and lack of radioactivity-related side effects. The MRI data 
from schizophrenia patients has confirmed brain volume loss in multiple grey and 
white matter regions (Shenton et al. 2001).  
 
Structural MRI studies have extended these findings to schizotypal personality 
disorder (Siever et al. 2002; Raine 2006). Schizotypy is also associated with lateral 
ventricle volume increase (Buchsbaum et al. 1997; Silverman et al. 1998), as well as 
gray matter reductions in the temporal lobe and thalamus (Dickey et al. 1999; 
Downhill et al. 2001). Compared to patients these structural abnormalities are 
generally of lesser magnitude and sparing some brain regions. Nonetheless, it appears 
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that structural brain abnormality is a feature associated with the risk for 
schizophrenia. 
   
1.6. The cognitive evidence 
 
The third development that aided the case for an organic abnormality in schizophrenia 
was the finding that impaired cognition is a core symptom domain (Green 2006). This 
is important as virtually all conditions that feature brain damage and degeneration 
feature cognitive impairment. In schizophrenia, the cognitive deficits typically predate 
the onset of the disease (Sorensen et al. 2006) and remain stable despite the symptom 
fluctuations and variance (Heinrichs 2005). The currently available antipsychotic 
medication has been shown to have at best only marginal impact on cognition, despite 
being broadly effective in controlling psychotic symptoms (Heinrichs 2005). They are 
also the single best predictor of functional and social outcome (Hofer et al. 2005; 
Milev et al. 2005). In fact, meta-analyses have shown that cognitive measures are the 
only research method that manages to distinguish a majority of schizophrenia patients 
from healthy individuals (Heinrichs 2005). It is thus increasingly likely that in the 
face of cognitive impairment schizophrenia research has found not only further proof 
of the organic nature of the disease, but also an objective and inexpensive measure of 
one of its core, currently unaffected by therapy features.  
 
Cognitive impairment is also evident in schizotypy (Mitropoulou et al. 2002; 
Mitropoulou et al. 2005) and unaffected relatives of schizophrenia patients (Keefe et 
al. 1994; Sitskoorn et al. 2004). Similar to the structural abnormalities, these deficits 
are of lesser severity and affecting only a subset of the cognitive functions impaired in 
schizophrenia (Siever et al. 2004; Raine 2006). This data supports the suggestion that 
a subtle organic disruption of the nervous system unifies the schizophrenia spectrum 
disorders. 
 
1.7. Pathogenesis: Theories 
 
The accumulated evidence of disruptions in various neural processes and 
morphological changes in schizophrenia has indicated that it is increasingly unlikely 
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for the core disruption to affect a single region, such as the prefrontal cortex. Instead 
current theories favour a more distributed pathogenesis. On the assumption that the 
separate symptom domains can be attributed to specific brain regions one prominent 
theory likens schizophrenia to systemic diseases such as multiple sclerosis or cerebral 
lupus where discrete lesions in different sites produce a heterogeneous and varied 
clinical syndrome (Carpenter et al. 1985; Andreasen 1986). Another one implicates a 
dysfunction in the processes that mediate neuronal communication (Friston 2005). 
Such a primary abnormality in the connectivity or “wiring” of the brain will also 
produce multiple heterogeneous deficits depending on the neural circuits it affects. 
The advent of imaging techniques that allow the investigation of functional 
connectivity such as functional MRI (fMRI), positron emission tomography (PET) 
and time-frequency analysis using electroencephalography or 
magnetoencephalography lent support to the latter hypothesis. Studies in patients 
using these methods have demonstrated disruptions in neural connectivity during 
cognitive tasks and in resting state.   
 
1.8. Status quo: Operational diagnostic criteria 
 
Despite these advances in our understanding of the neuropathological underpinnings 
of schizophrenia, from diagnostic point of view it is still a functional, syndrome-based 
disorder. In fact, known sufficient organic causes of the schizophrenia syndrome 
automatically exclude the diagnosis of schizophrenia. Instead, the current operational 
definitions of schizophrenia (laid out in the tenth revision of the International 
Classification of Diseases, ICD-10, and the fourth revision of the Diagnostic and 
Statistical Manual of Mental Health Disorders, DSM-IV) put the accent on the 
presence of psychotic symptoms for sufficiently long period of time as well as some 
degree of functional impairment. Despite providing a much needed consensus 
regarding the characteristic features of schizophrenia (Kendler et al. 1994; Kety et al. 
1994), DSM-IV and ICD-10 diagnoses suffer from inherent fundamental problems. 
Firstly, the overreliance on psychotic symptoms introduces diagnostic ambiguities 
both in respect to other conditions that feature psychosis (Tandon et al. 2009), as well 
as when drawing the line between schizophrenia, personality disorders and even 
healthy volunteers (Kendler et al. 1996). In addition, longitudinal studies have shown 
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that psychotic symptoms are poor at predicting the course of the disease and response 
to drugs (Jansson et al. 2007). Finally, basing the diagnosis solely on the patients’ 
reports and clinician’s observations introduces a subjective element that could account 
for the operational diagnoses’ modest reliability (Jansson et al. 2007). This is perhaps 
most relevant in regards to schizophrenia spectrum research, where all the key 
features are based on the clinician’s judgement (Jones et al. 2006). The drawbacks of 
the operational schizophrenia diagnosis have wide ranging implications, affecting the 
reliability of fundamental and clinical research. In respect to genetic studies for 
example, none of the identified risk genes are specific to schizophrenia, but rather 
indicate general vulnerability to mental health disorders or personality 
psychopathology (Allan et al. 2008).  
 
1.9. Towards mechanism-based understanding of schizophrenia: 
Biomarkers 
 
The search for an aetiology-based rather than syndrome-based definition of 
schizophrenia has stimulated research into biological correlates of disease process in 
schizophrenia. The NIH Biomarker Definitions Working Group defines biomarkers as 
quantifiable outcomes which are modified by the disease and therapeutic intervention. 
Defining the neurobiological substrate of schizophrenia through biomarkers can help 
negate the drawbacks of the currently used operational criteria.  
 
In terms of diagnosis reliability, successful biomarkers could help delineate it from its 
related disorders or subtype the condition into distinctive disorders that are currently 
grouped together by the DSM-IV and ICD-10 criteria. It has been argued that 
subtyping of schizophrenia could lead to significant empowerment of genetic and 
other basic research (Stober et al. 2009). 
 
The benefits of an ideal biomarker go further than improving diagnosis and include 
predictive power for disease course and treatment outcome. Such property will 
improve patient management by informing the time, type and course of interventions.  
In the context of drug development, such predictive power can help reduce the size 
and duration of clinical trials by substituting traditional clinical end points with 
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biomarker measurements. Also, a successfully developed biomarker would provide an 
insight into the key pathophysiological mechanisms of the disease and therefore 
validating targets for novel therapeutic interventions. Finally, validating biomarkers in 
milder versions of the disorder would allow earlier evaluation of efficacy of novel 
compounds which may reduce the risk associated with drug development.  
 
1.10. The current thesis: Topic, hypotheses and predictions 
 
The promise of a successfully developed biomarker in schizophrenia to revolutionize 
its diagnosis, treatment options and management has stimulated the work that forms 
this thesis. The focus of this thesis was on the development of biomarkers that 
objectify the cognitive impairment in the schizophrenia spectrum. Cognition was 
chosen because of the data implicating it as a core feature of schizophrenia and the 
lack of efficacy of currently available medication on this core set of symptoms. The 
aim was to establish tests that reliably detect the cognitive deficit in the schizophrenia 
spectrum and are sensitive the action of agents modulating key neurotransmitter 
systems. This builds on the extensive knowledge regarding the neuropharmacology of 
cognitive biomarkers in schizophrenia spectrum which is reviewed in detail in Paper 
1. The ultimate goal of this biomarker validation in schizotypy was to allow the early 
testing of efficacy of novel cognitive enhancing agents. Another priority of the work 
constituting thesis was the exploration of the neurophysiological mechanisms that 
underlie cognition in the schizophrenia spectrum. The aim was to gain better 
understanding of the key pathophysiological abnormality in this disorder and to 
elaborate better and more precise biomarkers to detect it. Based on these goals the 
following hypotheses and their corresponding predictions were generated:  
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Hypothesis 1: Schizophrenia is the extreme of a spectrum of disorders that is 
characterized by cognitive deficits 
Prediction 1.1: Schizotypy is associated with cognitive deficits similar to the 
ones found in schizophrenia 
Prediction 1.2: Schizotypy will feature abnormalities in trait but not state 
dependent cognitive domains as it represents a less extreme deviation from the norm 
than schizophrenia 
 
Hypothesis 2: Cognitive abnormality in the schizophrenia spectrum is a continuously 
distributed trait 
Prediction 2.1: Cognitive performance decreases with the increase of 
schizotypal personality traits 
 
 
Hypothesis 3: The deficits in executive function in the schizophrenia spectrum are 
modulated by dopamine 
Prediction 3.1: Cognitive abnormalities in schizotypy will be affected by 
drugs altering dopamine 
 
Hypothesis 4: Impairment in higher cognitive function in the schizophrenia spectrum 
is a manifestation of a general abnormality in information processing  
Prediction 4.1: Information encoding in both schizotypes and schizophrenia 
patients will be associated with reductions in the amplitude of early visual ERPs 
Prediction 4.2: Early perceptual deficits correlate with cognitive deficits 
 
Hypothesis 5: The information processing deficit in schizophrenia spectrum reflects a 
pathological change in cortical connectivity  
Prediction 5.1: Cortical connectivity will be abnormal in both schizotypes 
and schizophrenia patients resulting in abnormalities in the power and phase 
relationships of neural oscillations evoked by visual stimuli 
Prediction 5.2: Both groups will have evidence of dysfunctional long-range 
cortical connectivity during tasks that require top-down modulation. 
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1.11. Studies undertaken to address the thesis hypotheses 
 
As part of this PhD thesis 4 studies (“Schiz01”, “Low Schizotypy”, “Schizotypy 
EEG” and “Schizophrenia EEG” studies) were undertaken to address the 5 
hypotheses.   
 
In the first study (“Schiz01”), is a study designed by an academic-industrial 
consortium in which high and average schizotypy scorers were recruited across three 
sites of the UK (Manchester, London and Cardiff). The two participant groups were 
compared using several cognitive measures. The results of this study were used to 
address Hypothesis 1 and specifically the prediction that high schizotypy scorers will 
feature cognitive abnormalities similar to the deficits reported in schizophrenia 
patients (Prediction 1.1). 
 
The cognitive performance of the volunteers in the Schiz01 study was also challenged 
by the acute administration of 3 psychotropic agents (risperidone, amisulpride and 
nicotine) in a placebo-controlled, randomized, double-blind design. The effects of 
these compounds on the cognitive performance of the average and high schizotypy 
scorers were interpreted in the context of Hypothesis 3 and specifically in light of the 
prediction that the cognitive abnormalities in high schizotypy can be altered by drugs 
affecting dopamine neurotransmission (Prediction 3.1). The results of this analysis are 
presented in Chapter 4.  
 
The second study (“Low Schizotypy”) involved the recruitment of a sample of low 
schizotypy scorers who completed the same neurocognitive battery as the participants 
in the Schiz01 study. The cognitive performance of this low schizotypy group was 
then compared to the placebo-arms of the average and high schizotypy groups in the 
Schiz01 study. This comparison was used to test Prediction 1.2 which stated that 
schizotypy will be associated with deficits in the trait (e.g. working memory, 
antisaccade  tasks) but not state neurocognitive biomarkers of schizophrenia (e.g. 
Salience Attribution Task) that were part of the battery. Hypothesis 2 which states that 
cognitive abnormality in the schizophrenia spectrum is a continuously distributed 
trait, was also tested by comparing the cognitive performance of the low, average and 
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high schizotypy scorers. The prediction was that the degree of cognitive impairment 
will increase linearly with the severity of schizotypal symptoms (low schizotypy < 
average schizotypy < high schizotypy, Prediction 2.1). These data form Chapter 5.  
 
The results from the first and second studies, as well as the extensive evidence 
documenting cognitive impairment in the schizophrenia spectrum led to the 
completion of two studies which aimed to clarify the pathophysiology of cognitive 
abnormalities in the schizophrenia spectrum (“Schizotypy EEG” and “Schizophrenia 
EEG” studies). It was hypothesized that the cognitive deficits in the schizophrenia 
spectrum are part of a general abnormality in neural information processing 
(Hypothesis 4). The specific prediction in respect to this hypothesis was such 
generalized deficit would manifest itself through early event-related potential (ERP) 
abnormalities in samples of schizotypal individuals and schizophrenia patients 
(Prediction 4.1). Testing the validity of Prediction 4.1 in respect to schizotypal 
individuals was the aim of the third study (“Schizotypy EEG”) whereby low and high 
schizotypy scorers were compared them in terms of the characteristics of their early 
visual ERPs, an analysis featuring in Chapter 6. The fourth study (“Schizophrenia 
EEG”) probed Prediction 4.1 in schizophrenia patients by administering the same 
study design as the one in the Schizotypy EEG study to patients and average scoring 
schizotypy scorers. These results are presented in Chapter 8.  
 
The datasets of the third and fourth study were used to test the idea that the perceptual 
abnormalities are related to cognitive impairment in the schizophrenia spectrum 
(Prediction 4.2). This possibility was tested by correlating the ERP abnormalities with 
cognitive performance in the schizotypy (“Schizotypy EEG”) and schizophrenia 
samples (“Schizophrenia EEG”). The results are presented in Chapters 6 and 8 
respectively.  
 
Hypothesis 5 extended Hypothesis 4 by making the specific assumption that the 
generalized information deficit in the schizophrenia spectrum is due to a deficit in 
neuronal connectivity. The datasets of the Schizotypy and Schizophrenia EEG Studies 
were again used to explore this hypothesis by testing the predictions that 
schizophrenia spectrum will be charcterized by both local (Prediction 5.1) and long-
range dysconnectivity (Prediction 5.2) patterns during perception. The validity of 
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these predictions in schizotypy (“Schizotypy EEG”) and schizophrenia populations 
(“Schizophrenia EEG”) were reported in Chapters 7 and 8 respectively.  
 
1.12. Contribution of the author to the experimental work and 
manuscipts featuring in the thesis 
 
The Schiz01 study was designed by an academic-industrial consortium before the 
start of the PhD programme of the thesis author. Ivan Koychev’s studentship involved 
part-time work at the Manchester site of the study as study physician (medical 
screening of volunteers, administration of study drugs) and research assistant 
(volunteer recruitment, data collection). The author also analyzed the presented study 
data along the statistical plan laid out in the design of the study but also completed 
original post-hoc analyses that feature in Chapter 4. Ivan Koychev wrote the first draft 
of the article, coordinated the ensuing input from the co-authors and finalized the 
version submitted to European Neuropsychopharmacology.    
 
The Low Schizotypy study was designed by the author with the aim of clarifying the 
results from the Schiz01 study. The author recruited the low schizotypy sample and 
collected the study data from this sample of volunteers; he participated in the 
recruitment and data collection of the placebo-treated average and high schizotypy 
samples of the Manchester site of the Schiz01 study; he analyzed the presented study 
data, wrote the first draft of the article that is featured in this thesis and is currently 
coordinating the input from the co-authors.    
 
For the Schizotypy and Schizophrenia EEG studies, Ivan Koychev designed the 
studies, managed ethical and research approvals, recruited the volunteers and patients, 
collected and analyzed the study data, wrote the first drafts of the articles featuring in 
Chapters 6, 7 and 8, coordinated the ensuing input from the co-authors and after 
submission of Chapters 6 and 7 to Neuropsychologia was responsible for amending 
the two articles in response to reviewers’ comments.  
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CHAPTER 2 
 
 
 
GENERAL METHODOLOGY 
 
 
Abstract 
 
Chapter 2 reviews the recruitment procedures for the four experiments that feature in 
this thesis. It also provides information on the neurocognitive, eye-tracking and 
electrophysiological methods that were used.
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2.1. Vulnerability and SPQ scores  
 
The healthy volunteer participants that feature in the experiments contributing to this 
thesis were recruited on the basis of their online scores of the Schizotypal Personality 
Questionnaire in its full (SPQ, (Raine 1991), full list of questions in Appendix 1) or 
short version (SPQ-B, (Raine et al. 1995), full list of questions in Appendix 2). The 
full SPQ is a 74-item “yes/no” self-reported questionnaire that probes the presence of 
schizotypal personality traits according to the DSM-IV criteria for Schizotypal 
Personality Disorder (SPD). It has high test re-test reliability and good internal 
consistency  (Raine 1991). The scores can be decomposed into three dimensions 
(Cognitive-Perceptual, Negative Interpersonal and Disorganised) by summing the 
number of positive responses to items contributing to each factor. SPQ-B is a 14 item 
“yes/no” self-reported questionnaire that also has high test reliability and adequate 
internal consistency. 
 
SPQ was used to recruit individuals with high level of schizotypal personality traits 
(high schizotypy) for the experiments reported in Chapters 4, 5, 6 and 7. In Chapters 6 
and 7 a high schizotypy scorer was defined as an individual with a SPQ score of 43 or 
more. These SPQ cut-off scores were based on results from a previous study using 
SPQ in 760 students from the Manchester University (Barkus et al. 2008) and the 
Manual for the SPQ (http://www-rcf.usc.edu/raine/spqrel.html). The high schizotypy 
cut-off was subsequently revised to a score of 41 or more in Chapters 4 and 5 in view 
of the SPQ scores of a sample of 14,000 individuals reported in Chapter 4.  
 
The experiments reported in Chapters 4, 5 and 8 included a control group of average 
scoring individuals. For Chapters 4 and 5 these were defined as SPQ scorers in  the 
range of 21-36 as reported by Raine et al. (Raine 1991).  This range was subsequently 
redefined in Chapter 8 to 11-36 in light of the mean and standard deviation of SPQ 
scores obtained in the UK-based sample reported in Chapter 4.  
 
The Chapter 5, 6 and 7 studies included a control group consisting of participants 
scoring low on the full SPQ (scores 0-9). The rationale for this decision was based on 
the lack of agreement on the optimal SPQ scores of control groups in schizotypy 
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studies. The aim was to address this by comparing the cognitive performance of low, 
average and high SPQ scorers and the results are reported in Chapter 5. The initial 
plan was to merge the samples reported in Chapters 6, 7 and 8 and report 
electrophysiological (EEG) differences between low, average, high schizotypy scorers 
and schizophrenia patients in an ensuing paper. However, due to facility availability 
different EEG amplifiers and experiment rooms were used for the two studies (low 
schizotypy vs. high schizotypy and average schizotypy vs. schizophrenia patients), 
which severely limited their comparability. 
 
2.2. Participants: Other inclusion and exclusion criteria  
 
The healthy volunteers recruited for the currently reported studies were from both 
sexes and in the age group 18-45 for Chapters 4, 5, 6 and 7, while in Chapter 8 the age 
range was revised to 18-55. The participants were also subjected to exclusion criteria 
aimed at limiting the effects of psychiatric or neurological symptoms, nicotine or 
caffeine abuse and medication intake. Therefore exclusion criteria were: i) history or 
presence of mental health disorders (using the Mini-International Neuropsychiatric 
Interview); ii) history or presence of epilepsy or other major neurological condition; 
iii) consumption of more than 5 cigarettes per day; iv) consumption of more than 8 
standard caffeinated drinks or intake of caffeine in the two hours prior to the 
appointment; v) prescribed medication (apart from the contraceptive pill). Also, the 
visual nature of the paradigms used in the current thesis required the inclusion of 
participants with normal or corrected-to-normal vision only.  
 
In the Chapter 4 experiment, participants were excluded if they had history of a 
medical disorder that might have affected the pharmacokinetics and 
pharmacodynamics of the study drugs. For the same reason participants were 
excluded if they had Body Mass Index (BMI) outside of the 18-30 range or had taken 
part in another drug trial in the 84 days prior to the experiment. In order to ensure 
comparability of the samples reported in Chapter 5, these three criteria were 
maintained when recruiting the additional low schizotypy control group. For the 
Chapter 4 study only, participants were excluded if they had a positive result on 
pregnancy or drugs of abuse urine dipstick tests or a positive alcohol breath test. For 
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the same study, in order to ensure minimal risk of hypotension-related adverse events 
participants outside of the normal blood pressure (diastolic BP of 60-90 mmHg, 
systolic BP of 100-140) were also excluded.  
 
The following exclusion criteria were retained for the patient sample reported in 
Chapter 8: history or presence of neurological conditions, uncorrected visual 
impairment, and excessive caffeine use (drinking more than 8 standard caffeinated 
drinks). Prescribed medication, history of mental health disorders and heavy smoking 
were not exclusion criteria due to the nature of the sample. The potentially 
confounding effect of the first two factors was accounted for by covarying the 
electrophysiology results with daily antipsychotic dose, severity of psychiatric 
symptoms and duration of disease.  
 
2.3. Questionnaires  
 
All healthy volunteers completed the SPQ questionnaire at their first appointment at 
the research facility. The participants in Chapters 4 and 5 also completed the Oxford-
Liverpool Inventory of Feelings and Experiences (O-LIFE) questionnaire (Mason et 
al. 1995). The OLIFE is a 104 item questionnaire that provides an estimate of the 
level of schizotypal personality traits along four dimensions (Unusual Experiences, 
Cognitive Disorganisation, Introvertive Anhedonia and Impulsive Nonconformity; see 
Appendix 3 for a full list of the OLIFE questions). A commonly used approach in 
schizotypy research is to correlate the scores in each dimension to a cognitive 
performance related variable. This was done in the Chapter 5 data analysis in an 
attempt to replicate a previously reported correlation between Introvertive Anhedonia 
scores and performance on one of the neuropsychological tasks (Salience Attribution 
Test, (Roiser et al. 2009)).  
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2.4. Neuropsychological tests 
 
2.4.1. National Adult Reading Test (NART) 
 
All participants completed the National Adult Reading Test (Nelson et al. 1991), 
which is a reading-based estimate of IQ. It provides information regarding the 
premorbid IQ and is therefore well suited to account for differences in cognitive 
performance that are due to education rather than disease process. The NART was 
used to check whether the groups used in the individual studies were comparable in 
terms of their IQ. The procedure of this test requires that participants pronounce 
irregularly spelt words from a standardized written list (See Appendix 4 for the list of 
words and their correct pronunciation). The scores are then calculated on the basis of 
the number of correctly pronounced words.  
 
2.4.2. N-back task 
 
The N-back task is one of the most commonly used tests to probe working memory 
(Gevins et al. 1993). Abnormal performance on this task has classically been linked to 
prefrontal cortex dysfunction (Owen et al. 2005). In Chapters 4 and 5, N-back was 
used to probe the sensitivity of working memory paradigms to the schizotypy 
phenotype and the effects of drugs potentially affecting cognition.   
 
In this task, participants were required to monitor a stream of visually presented 
stimuli that appeared on a computer screen and were required to respond whenever 
the stimulus on-screen was the same as the one shown N trials previously. N is an 
integer that could have been either 1, 2 or 3 and was specified at the beginning of each 
trial (Figure 2.1). In order to test whether participants were paying attention to the 
task, there were also trials in which they needed to respond whenever a specific letter 
was onscreen (“X”). See Appendix 5 for a full description of the N-back task reported 
in Chapters 4 and 5.  
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Figure 2.1. N-back task. Participants indicated by pressing a mouse button whenever 
the letter on screen was the same as the letter presented 1, 2 or 3 screens before (1-, 
2- and 3-back respectively). 
 
2.4.3. Spatial Working Memory (SWM) task 
 
This computerized task was reported in Chapters 4 and 5 as a measure of spatial 
working memory. It corresponds to the Maryland LNS spatial working memory task 
from the MATRICS cognitive battery (Nuechterlein et al. 2008). Similarly to the N-
back task, abnormal results are also classically interpreted as an indication of 
prefrontal cortex dysfunction (Lee et al. 2005).  
 
In the SWM task, volunteers were presented with a number of treasure chests on a 
computer screen. The participants had to search for coins in the treasure chests using 
the mouse with only one treasure chest containing a coin at any one time (Figure 2.2). 
Once a coin had been found, it would move to another chest but never to a chest 
where it had already been within the current trial. The task had 3 levels of difficulty 
(trials with 4, 6 and 8 chests). See Appendix 5 for a full description of the SWM task 
reported in Chapters 4 and 5.  
 
See also Chapter 3 for a discussion of the relevance of working memory paradigms 
(such as the N-back and SWM tasks) as biomarkers of schizophrenia. 
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Figure 2.2. Spatial Working Memory (SWM) task. Participants searched treasure 
chests for coins with only one treasure chest containing a coin at any one time. Within 
the trial coins were never found twice in the same chest. Discovered coins mounted up 
on the right of the screen as shown on the figure to guide the participant on the 
number of remaining coins. 
 
2.4.4. Verbal Fluency (VF) task 
 
This pen-and-paper task was used to test verbal fluency in Chapters 4 and 5. 
Abnormal performance on variations of this task has also been linked to abnormal 
prefrontal cortex activation (Curtis et al. 1998).  
 
This thesis used a version of the VF task in which participants had to name as many 
words either beginning with a letter (F, A and S) or belonging to a category (animals 
and vegetables). There was also a condition in which two categories (fruit and 
furniture) were given and the participants had to alternate between them. See 
Appendix 5 for a full description of the VF task reported in Chapters 4 and 5. 
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2.4.5. Salience Attribution Test (SAT) 
 
The SAT was reported in Chapter 5 as a measure of aberrant salience attribution. This 
abnormality has been shown to correlate with psychotic symptoms in schizophrenia 
patients as wells as with the Introvertive Anhedonia OLIFE subscale score in healthy 
volunteers (Roiser et al. 2009). Functional MRI studies report reduced ventral striatal 
hemodynamic responses during reward cue conditions (Juckel et al. 2006; 
Schlagenhauf et al. 2008) which has promoted suggestions that aberrant salience 
attribution may be an indicator of dysfunction in that brain region. 
 
In the SAT coloured images of household objects or animals were presented prior to 
responding for possible rewards (money). One stimulus dimension (e.g. red vs. blue) 
very reliably predicted the availability or non-availability of money while the other 
(e.g. animals vs. household objects) was not a reliable predictor. If faster 
responding/greater reward rating occurred to one of the irrelevant features over the 
other (e.g. animals faster over household objects), this indicated aberrant salience. See 
Appendix 6 for full description of the SAT and Chapter 3 for a discussion of its 
relevance as a biomarker of schizophrenia.  
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Figure 2.3. Salience Attribution Test (SAT). The participants had to respond as 
quickly as possible to the presentation of a square in order to win possible reward. 
The stimulus was preceded by images that predicted the probability for reward. One 
of the dimensions of the stimulus was a good predictor (e.g. red vs. blue color) while 
another salient dimension was irrelevant (e.g. animals vs. household objects). The 
figure is reproduced from Jonathan Roiser’s work e.g. (Roiser et al. 2009) with the 
permission of the author.  
 
2.4.6. Working memory event-related potentials (WM ERP) task  
 
The experiments featuring in Chapters 6, 7 and 8 employed a working memory task to 
elicit event-related electroencephalographic or EEG activity (event-related potentials 
and oscillations). A very similar version of the task had been used previously by 
Haenschel et al. in a sample of schizophrenia patients (Haenschel et al. 2007; 
Haenschel et al. 2009). They reported aberrant modulation of the EEG activity by 
WM load in patients relative to controls. These results indicate that the EEG 
correlates of perceptual dysfunctions in schizophrenia might be the result of 
dysfunctional coordination between higher-order brain structures, such as the 
prefrontal cortex, and the sensory cortex.  
 
In the task featuring in the current thesis, the participants were required to remember 
images that were sequentially presented in series of one, two or three (Figure 2.4). 
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After a fixed delay period a target probe appeared on the screen and the participants 
had to indicate whether it was part of the initial sample set by pressing a button. Full 
description of the WM ERP task can be found in the method sections of Chapters 6, 7 
and 8.  
 
 
Figure 2.4. Working memory event-related potential task. During encoding one, two 
or three images were presented for 400 ms seconds each separated by an inter-
stimulus interval of 600 ms. A delay period of 6 seconds ensued (maintenance phase). 
A target image then appeared and remained onscreen for 3 seconds and the 
participants were required to indicate by pressing a button whether it was shown 
during the encoding phase or not (retrieval phase). An inter-stimulus interval of 1 
second separated the trials. 
 
2.5. Eye-movement analysis 
 
Two tasks probing the eye-tracking performance in low, average and high schizotypy 
were reported in Chapter 5. The inclusion of eye-tracking paradigms in the 
experiments was based on findings of various oculomotor deficits in schizophrenia 
(See sections 3.3.7 and 3.3.8. in Chapter 3).  
 
The first task examined the quality of saccadic eye movements (rapid eye movements 
that allow the fixation of a new object that has appeared in the visual field) and had a 
prosaccade and an antisaccade condition. In the prosaccade condition a novel visual 
target appeared in the periphery and the participants had to direct their gaze at it. In 
the antisaccade condition the participants had to inhibit the prosaccade response to a 
new stimulus and instead look at its mirror image location on the opposite side of the 
   
Encoding  
phase 
Maintenance  
phase 
Retrieval and 
response 
phase 
600 ms 400 ms 600 ms 400 ms 600 ms 400 ms 6 sec 3 sec 1 sec 
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screen. Schizophrenia patients are typically unable to suppress the automatic 
prosaccade in the antisaccade task which has been attributed to suboptimal inhibition 
ability underpinned by a prefrontal cortex dysfunction (Hutton et al. 2006).  
 
The second task required participants to follow a slowly moving target with their eyes 
only (Smooth Pursuit Eye Movement, SPEM). The first reports of aberrant smooth 
pursuit eye movements in schizophrenia patients date from 1908 (Diefendorf et al. 
1908), a finding that has been consistently replicated ever since (Hutton et al. 1998; 
Hutton et al. 1998). Evidence from structural and functional imaging studies indicate 
that the structures underlying the abnormality in schizophrenia are the frontal cortex 
(Ettinger et al. 2004) and the striatum (Raemaekers et al. 2002). 
 
See Appendix 6 for full details on the eye-movement procedures and Chapter 3 for a 
discussion of the biomarker status of eye-tracking in schizophrenia. 
 
 
Figure 2.5. Eye-tracking set-up. The participant was seated with their chin supported 
on a chin rest and looking directly into a presentation monitor (left-hand side 
monitor). The data from the infrared eye-tracker was recorded by a researcher on a 
separate computer (right-hand side monitor).  
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2.6. Event-related electroencephalographic activity 
 
Event-related potentials and oscillations were used to examine the processing of 
visual information in schizophrenia spectrum disorders in the experiments featuring in 
Chapters 6, 7 and 8. The next two sections deal with a general introduction to these 
electroencephalographic techniques, while full details on the procedures employed in 
this thesis can be found in the methods sections of Chapters 6, 7 and 8.  
 
2.7 Event-Related Potentials (ERPs) 
 
2.7.1. Background of ERPs  
 
The electroencephalogram (EEG) is a recording of neural electrical activity obtained 
by amplifying the signal from electrodes placed in contact with the scalp. EEG was 
reported for the first time in a set of experiments by Hans Berger in 1929 (Berger 
1929). Over the ensuing decades, it has been used in a variety of clinical and scientific 
contexts. The main drawback of raw EEG is that it represents a conglomeration of 
simultaneously occurring neural activities making the isolation of individual 
phenomena of interest problematic. Responses to sensory stimuli can however be 
extracted from the background EEG activity by simple averaging of data following 
the onset of each stimulus. This method is based on the idea that spontaneous EEG 
activity has no fixed temporal relationship with the time point in which the stimulus is 
delivered; in contrast neural responses to sensory stimuli are time-locked to their 
onset. Averaging the data immediately following uniform events therefore leads to 
augmentation of the sensory response and reduces the contribution of unrelated neural 
activity. These responses are called event-related potentials (ERPs), highlighting the 
fact that they represent electrical responses to controlled events.  
 
2.7.2. Neural basis of ERPs  
 
Two main types of electrical activity are generated by neurons and could thus be the 
neural basis of ERPs: action potentials and postsynaptic potentials. The former are 
voltage spikes that travel from the beginning of the axon to its terminals. At the 
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terminal they cause release of neurotransmitters into the synaptic cleft resulting in 
excitation of the post-synaptic neuron. The latter are voltages that arise when 
neurotransmitters bind to post-synaptic receptors. Action potentials have negligible 
contribution to the generation of the ERP signal, as they last only about a millisecond, 
occur at slightly different times even in neurons that fire in a coordinated fashion and 
are not fixed but rather travel rapidly down axons. In contrast, post-synaptic potentials 
last up to hundreds of milliseconds and occur instantaneously at fixed locations (cell 
body) which allows their summation. The simultaneous occurrence of postsynaptic 
activity in millions of spatially aligned neurons produces a signal which may be 
measurable at the scalp. These requirements are most likely to be met by pyramidal 
cells lying perpendicular to the scalp. It is thus assumed that the ERP peaks are 
produced almost exclusively by the post-synaptic signal of coherently activated 
pyramidal neurons (Luck 2005).   
 
2.7.3. Advantages and disadvantages of the ERP technique  
 
The graded waxing and waning of postsynaptic potentials is volume conducted to the 
scalp where it is picked up by the EEG electrodes. With this type of conduction the 
delay between the brain activity and its reflection in EEG signal is below the 
millisecond level. This renders the ERP technique superior to other neuroimaging 
methods in terms of its temporal resolution: it allows tracking of activity on 
millisecond basis. It is however poorer than other methods in regards to its spatial 
resolution (the ability to indicate where activities originate from). This is due mostly 
to the substantial blurring of signal resulting from the weak conductive capacity of the 
scalp (Luck 2005).  
 
2.7.4. ERP analysis 
 
Event-related potential data are analyzed by determining the latency and amplitude of 
peaks of interest in a single electrode or a group of electrodes and using these values 
in statistical comparisons. Latencies can be measured by visually identifying the peak 
of interest and determining the latency of its highest point. This method however may 
introduce a subjective element, especially given that peaks often reach their maximum 
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at different electrodes in different participants. A more robust approach is to 
determine the ERP latency of maximum activity using Global Field Potentials (GFP). 
This is a method that plots the overall ERP scalp activity which reduces the impact of 
individual topographical differences.   
 
The main outcome measure of most ERP studies is the amplitude of ERP components. 
The most common approach in measuring peak amplitude is to determine a time 
window for each component of interest and to determine the maximum amplitude in 
this window. This method is called peak amplitude measure. Another method is to 
define the mean amplitude for the time window of interest (mean amplitude measure)  
(Luck 2005). The latter is the preferred approach due to several reasons. Firstly, 
searching for peaks in large time windows often detects the rising or falling edge of 
an irrelevant overlapping component. Using shorter time windows and using a non-
automated approach to peak identification can help reduce the impact of this but 
introduces subjectivity of the data analysis, as each peak has to be individually 
selected by the researcher. Secondly, peak amplitude is susceptible to distortion by 
high-frequency noise. This is due to the possibility of noise deflection being 
registered as an ERP component, leading to artificially higher peak amplitudes in 
noisy recordings. Lastly, when there is substantial inter-trial variability in the peak 
latency, the peak amplitude of the averaged component will be lower than the 
individual ERPs. In contrast to peak amplitude, mean amplitude measurement allows 
shorter windows of interest and does not become biased by noise levels or latency 
jitter.  
 
2.7.5. Visual Evoked Potentials (VEPs) 
 
The current thesis dealt with the electrophysiology of early visual information 
processing in schizophrenia and consequently focused on several well characterized 
visual ERPs. Three major visual evoked potentials (VEPs) peak within the first 200 
ms post stimulus: the so-called C1, P1 and N1 (Figure 2.6). C1 is the first VEP 
peaking at approximately 80-100 ms and is largest at the midline occipital electrodes. 
Source analysis studies have suggested that it originates from the primary visual 
cortex (V1). C1 is positive in response to images presented in the lower visual field 
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and negative for stimuli appearing in the upper visual field (Di Russo et al. 2003). C1 
has traditionally been attributed to bottom-up processes, but recent data suggest that it 
is more sensitive to internal states than previously thought (Kelly et al. 2008; Rauss et 
al. 2009). C1 is followed by P1, which has a typical bilateral occipital distribution 
(Figure 2.7). It peaks around 100-130 ms but its latency varies significantly depending 
on the contrast of the stimulus. Its cortical generators have been suggested to be the 
middle occipital gyrus (dorsal visual stream) and the fusiform gyrus (ventral visual 
stream) (Di Russo et al. 2002). P1 is the earliest visual component that is under top-
down influence, as its amplitude is sensitive to the direction of spatial attention (Di 
Russo et al. 2003; Lalor et al. 2007). A cornerstone human lesion study showed that 
prefrontal cortex plays a key part in this top-down modulation (Barcelo et al. 2000). 
P1 is followed by N1, a negative potential peaking typically between 150 and 200 ms 
(Figure 2.6). It also has a bilateral occipital distribution and has been linked to activity 
primarily in the ventral visual stream (parietal cortex and lateral occipital cortex) (Di 
Russo et al. 2002). N1 amplitude is also modulated by spatial attention (Heinze et al. 
1990). Functionally, C1 is thought to represent activation of the primary visual cortex; 
P1 reflects early pattern detection processes; N1 represents discriminative processing 
(Luck 2005).  
 
This thesis focused on the characteristics of P1 and N1 potentials in schizophrenia 
spectrum disorders, as their amplitude and latency are a sensitive measure of the 
quality of early information processing. In addition, the fact that both of them are 
subject to top-down modulation renders them useful in testing the efficiency of long-
range connectivity in schizophrenia.   
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Figure 2.6. An example of occipitally recorded VEP. Arrows show all major visual 
peaks except for C1. Large vertical tick at stimulus onset, vertical ticks at every 200 
ms thereafter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Topographical distribution of the P1 potential. Data presented for pairs 
of frontal (F3, F4), central (C3, C4) and occipital (O1, O2) electrodes.  
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2.8. Electroencephalographic analysis of neural oscillations 
 
While the examination of ERPs has undoubtedly contributed to our understanding of 
the nature and timings of neuronal events, the rhythmic oscillatory EEG activity that 
ERPs arise from has in the past two decades become the focus of neurophysiology 
interest. This was due to increased access to computational power and proliferation of 
analysis techniques but perhaps most importantly of all to the discovery that neurons 
engage in synchronized oscillatory activity. It has been proposed that these neuronal 
oscillations are a fundamental mechanism that allows coordinated brain activity.  
 
Studies in animals and humans have shown that during cognitive acts neurons align 
the rhythm (phase) of their action potentials to establish precisely synchronized neural 
assemblies (Singer 1999; Fries 2009). The resulting coordinated discharges have 
much greater impact than competing unsynchronized activity and the transmitted data 
gains crucial advantage in information processing. The process of phase 
synchronization allows the integration of local, as well as large scale networks. The 
temporal correlation between the emergence of synchronized oscillations and various 
cognitive acts, such as perception, working memory and consciousness, supports the 
functional relevance of this mechanism (Varela et al. 2001). 
 
2.8.1. Types of oscillations  
 
Oscillations of various frequencies are detectable using EEG in humans. They were 
arbitrarily subdivided in the 5 major frequency band by the International Federation of 
Societies for Electroencephalography and Clinical Neurophysiology in 1974: delta 
(0.4 – 4 hertz), theta (4-8 hertz), alpha (8-12 hertz), beta (12-30 hertz) and gamma 
(>30 hertz). There is some evidence to suggest that this distinction is functionally 
relevant. Higher frequency oscillations have been proposed to establish 
synchronization within local neuronal networks while lower frequencies underlie 
long-distance communication (Buzsaki 2006; Uhlhaas et al. 2008). The exact 
functional significance of the different frequency bands in relation to perception and 
working memory are discussed in the appropriate chapters. 
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2.8.2. Principles of the Time-Frequency (TF) analysis 
 
The principal approach in analysing event-related EEG oscillations entails 
decomposition of EEG signal into its magnitude and phase information (the so-called 
“spectral decomposition”) and relating the changes in these variables over time with 
regards to task events (broadly defined as “time-frequency analysis”). Time-frequency 
analysis is based on a model that sees EEG data as a convolution of sine waves at 
different frequencies that occur at the same time and have different phase angles with 
respect to the onset of the stimulus. The frequency of a sine wave is defined as the 
number of full cycles or oscillations that occur in one second (expressed in hertz). The 
magnitude of an oscillation refers to the maximum height of the sine wave’s peaks 
relative to baseline. The phase provides information regarding where specific time 
points are located on the sine wave (expressed in degrees and ranging from -180º to 
180º). Spectral decomposition of EEG signal estimates a complex number for each 
time point that allows the extraction of 2 characteristics of the sine wave at a given 
frequency: its magnitude and its phase. This is accomplished using a technique called 
“convolution” – a windowed transformation (most commonly a Morlet wave 
transform) centered on an EEG segment that multiplicates the raw data. Moving the 
window one time point at a time produces a complex number for each time point in 
the EEG data. This process is done separately for each individual trial and at the end 
of the process the complex number values for each time point are collected together. 
Squaring and averaging of these complex numbers provides the mean signal power of 
a given frequency at a particular time point. Dividing the complex number by its 
magnitude provides a new set of complex numbers which retain phase but not 
magnitude information regarding a given frequency at a given time point. Averaging 
these magnitude-independent phase variables over trials provides information 
regarding the inter-trial consistency of oscillations at a given frequency and time-
point (phase-locking factor (PLF) or inter-trial coherence (ITC)).  
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2.8.3 Outcome variables of the TF analysis 
 
Time-frequency analysis outputs several variables that describe different 
characteristics of the EEG signal on a single electrode level. Signal power is the first 
one, reflecting changes in magnitude of neuronal oscillations at a given time point 
relative to the pre-event baseline. Two types of signal power are distinguished on the 
basis of their relationship to phase information: evoked and induced power. Evoked 
power refers to changes in EEG data that are phase-locked to the stimulus onset 
across trials (Figure 2.8A). Such phase-synchronized oscillations are extracted by first 
averaging data across trials in the time domain. Only oscillations that have been in the 
same phase in relation to stimulus onset across trials survive this process and 
contribute to the formation of ERPs. In contrast, oscillations that were in different 
phases across trials in relation to stimulus onset cancel each other out during this 
averaging step. Evoked power is therefore extracted by performing a spectral 
decomposition on data that is already averaged over trials. Such phase-locked activity 
typically occurs in the first 250 ms and has been linked to perceptual (Tallon-Baudry 
et al. 1996; Fries et al. 2001) and top-down cognitive processes (Tiitinen et al. 1993; 
Debener et al. 2003). In contrast, induced power takes into account the non-phase 
locked oscillations that are excluded from evoked power calculation. It is obtained by 
spectral decomposition on single trial level which removes the effect of phase-
information. Therefore induced power is also known as “asynchronous power” or 
“phase-invariant power”. Induced oscillations have been hypothesized to sustain 
various complex cognitive acts, such as working memory (Howard et al. 2003).  
 
The second variable is the phase-locking factor (Figure 2.8B). As mentioned 
previously, this measure is independent from signal magnitude and provides data 
regarding the phase angle consistency of oscillations in regards to the stimulus onset. 
It ranges from zero to one, 0 indicating a completely random distribution of phase 
angles and one reflecting identical phase angles across trials. PLF has been 
hypothesized to represent the degree of neuronal response variability (Roach et al. 
2008) and reductions in its value have been linked to increased “cortical noise” 
(Winterer et al. 2000; Winterer et al. 2004).  
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Figure 2.8. Example of evoked oscillations time-frequency plots. The plots represent 
the signal power (A) and phase-locking factor (B) of evoked oscillations in response 
to a visual stimulus in the 4-14 Hz frequency range for the -200 to 800 ms time period 
relative to the stimulus onset. The data is for 4 pairs of occipital electrodes 
(PO4/PO3; PO8/PO7; O1/O2; Oz/POz).  
 
2.8.4. Analyses of neural synchrony 
 
The time-frequency information can also be used to explore the degree of 
synchronized activity between pairs of electrodes. For this purpose, magnitude-
normalised data (the same as the one used to calculate PLF on the single electrode 
level) is extracted for each time point at a given frequency for both electrodes for each 
individual trial. The difference in phase angles between the two electrodes is then 
calculated for each time point and for every trial. The single-trial differences in phase 
are then averaged across trials. The resulting variable is called phase coherence and 
ranges between zero and one. Zero indicates a completely random phase angle 
distribution across trials and one indicates that the two electrodes had completely 
synchronized phase angles. High phase coherence is interpreted as an indication of 
coordinated activity between the neuronal populations contributing to the signal 
recorded by the two electrodes.  
 
Another way of inferring neuronal synchronization over long distances is by 
correlating activity of two electrode groups. This type of analysis requires the 
calculation of either power or PLF for two groups of electrodes at a given frequency 
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range and time period poststimulus (Figure 2.9). The averaged values for the two 
electrode groups are then correlated using Spearman’s or Pearson’s analysis. The 
disadvantage of this method is that unlike phase coherence it does not account for 
activity on a single trial level, but rather probes for overall correlation in activity. Its 
low computational requirements however make it a useful method for detecting 
general patterns of neuronal synchrony trends that could be probed further using 
phase coherence. 
  
 
 
 
 
 
 
 
 
 
Figure 2.9. Topographical distribution of evoked oscillations during perception. The 
plot represents the signal power (expressed in microvolts) of evoked oscillatory 
response to a visual stimulus in the 14-28 Hz range for the 50-200 ms time post-
stimulus period. View from above; frontal electrodes facing upwards and occipital 
electrodes facing downwards. The peak in signal power shows a central occipital and 
a fronto-central distribution. In this analysis, the central occipital and fronto-central 
sets of electrodes are correlated which could be interpreted as evidence for synchrony 
between the two topographical regions. 
 
The focus of this thesis was perceptual information processing in schizophrenia which 
necessitated the use of evoked power and PLF measures. Correlations of power and 
PLF of electrode groups were considered adequate methods for detecting general 
patterns of long-range neuronal synchronization (see Chapters 7 and 8).   
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CHAPTER 3 
 
Evaluation of state and trait biomarkers in 
healthy volunteers for new drug treatments in 
schizophrenia* 
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Abstract 
 
All drugs used in schizophrenia act on dopamine receptors. They have little effect on 
enduring negative symptoms or cognitive impairment and this is a major unmet need 
in the treatment of schizophrenia. Efforts to address this have led to the emergence of 
a number of novel candidate drug targets and potential compounds from preclinical 
research. Their clinical success rate however has been poor, highlighting the need to 
identify the likely efficacy of drugs early in their development. One way of achieving 
more efficient and objective assessment of the efficacy of novel compounds in 
schizophrenia is through the use of biomarkers for pathogenetically relevant 
processes. Validating such biomarkers in surrogate populations for illness could allow 
testing for drug efficacy as early as Phase 1 of drug development. In this article we 
review the relevance of several cognitive and physiological abnormalities as 
biomarkers in schizophrenia: their ability to detect state (dependent on symptom 
severity) and trait (present in full remission) abnormalities in patients as well as and 
the effect of available psychotropic drugs. We also evaluate these measures in three 
surrogates for illness: i) members of the general public with high trait schizotypy; ii) 
unaffected relatives of patients; iii) healthy volunteers in state of cortical glutamate 
disinhibition induced by low-dose ketamine. Several biomarkers are moderately 
abnormal in these groups when compared to schizophrenia patients and in some 
instances there has been exploratory work to determine their sensitivity to drug action. 
In perspective, the detection of efficacy of cognitive enhancing drugs in surrogate 
groups could be predictive of benefit for the cognitive and behavioural deficits of 
schizophrenia.  
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3.1. Background and rationale for biomarkers in drug development 
for schizophrenia  
  
3.1.1. Introduction  
 
The introduction of the first antipsychotic, chlorpromazine, in 1952 and the 
subsequent generation of typical and atypical D2 antagonists saw a dramatic 
improvement in the prognosis of schizophrenia and enabled the de-institutionalisation 
of patients to care in the community. However, many patients continue to experience 
symptoms in addition to the burden imposed by central nervous system (CNS) and 
metabolic side effects. Most patients change their treatment within the first 18 months 
(Lieberman et al. 2005). Furthermore, the efficacy of current treatments is largely 
confined to reduced psychotic or positive symptoms with limited efficacy in negative 
or deficit symptoms, resulting in poor levels of social and occupational functioning 
(Heinrichs 2005). Finding new pharmacological approaches to tackle these deficits 
remains a major unmet need in the treatment of schizophrenia (Nuechterlein et al. 
2008). In addition little progress has been made on a truly disease-modifying therapy 
that has the potential of preventing schizophrenia.  
 
The recognized limitations of schizophrenia therapy led to a rapid expansion of 
potential drug targets through technological advances such as genome sequencing, 
combinatorial chemistry and high-throughput screening (Hurko 2009). Novel drug 
development has mostly focused on compounds affecting single neurotransmitter 
systems that have been hypothesized to be pathogenetically relevant to schizophrenia 
(Roth et al. 2004). The main lines of development in relationship to the cognitive 
symptom domain have concerned the glutamate (e.g. glycine, metabotropic, AMPA 
receptor agonists; glycine transporter antagonists), acetylcholine (muscarinic and α7-
nicotinic receptor agonists), dopamine (e.g. D1 and D3 receptor agonists; D4 receptor 
antagonists; Catechol-O-methyltranferase inhibitors) and serotonin (e.g. 5-HT2A and 
5-HT6 receptor antagonists; 5-HT1A and 5-HT4 receptor agonists) systems (Gray et al. 
2007). The advances in compound generation however have not translated in 
increased clinical success rate. Instead, it has decreased sharply over the past two 
decades, as most novel compounds fail at the initial tests of efficacy in human disease, 
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phase 2 and 3 clinical trials (Hurko 2010). A recent review showed that practically all 
the agents that are currently in Phase 3 clinical trials have the same mechanism as the 
already available agents (D2 antagonism) (Gray et al. 2007).  
 
3.1.2. Obstacles to novel drug development in schizophrenia  
 
The currently observed high attrition rate for novel compounds has exposed several 
critical obstacles to drug development for psychiatric illnesses that may be 
particularly relevant to the development of an antipsychotic with potent cognitive 
enhancing action.  
 
Firstly, novel agents are classically screened on the basis of their molecular actions 
and efficacy in animal behavioural models. However, only 3-5% of the compounds 
that were effective in preclinical screens were launched on the market (Hurko 2010).  
This suggests that while animal models probably capture a certain aspect of the main 
disease process, they are still far from being its reliable and precise replication 
(Marcotte et al. 2001).  
 
Secondly, once a drug is introduced to a clinical population, its efficacy is assessed 
using traditional clinical end-points, such as clinical rating scales. Their sole 
dependence on the patients’ reports and clinician’s observations introduces a 
subjective element that reduces their sensitivity and precision (Jansson et al. 2007). In 
addition, these endpoints account poorly for the cross-ethnic differences in 
psychopathology (Brekke et al. 1997) which makes international comparisons 
difficult. This has been further complicated by placebo effects, which are especially 
elevated in clinical trials in psychiatry (Kemp et al. 2010; Kinon et al. 2011). All these 
factors obscure the true drug effects and inflate the sample sizes required to detect 
clinical efficacy in clinical trials. 
 
The final and perhaps most important obstacle to novel drug development in 
schizophrenia is a conceptual one. In contrast to many physical diseases, the aetiology 
of schizophrenia remains unknown which makes the choice of appropriate targets for 
drug development especially risky. Several neurotransmitter systems have been 
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implicated in the pathogenesis of psychosis but as mentioned previously few drugs 
targeting non-dopaminergic transmitters show evidence of efficacy (Miyamoto et al. 
2005). Given the probable complex components in schizophrenia, attributing the 
disease to a disturbance in a single neurochemical system is likely to prove too 
simplistic (Roth et al. 2004).  
 
3.1.3. Biomarkers: Increasing the probability of technical success 
 
The need to improve the probability of technical success of drug development has 
driven the identification and validation of biomarkers. A biomarker is defined by the 
USA FDA Food and Drugs Administration (FDA) as “A characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacological responses to a therapeutic intervention” 
(www.fda.gov). Biomarkers have the potential of augmenting the chances of 
successful drug development by the means of target validation, provision of surrogate 
end-points and patient segmentation (Breier 2005). 
 
3.1.3.1. Target validation 
 
Biomarkers relevant to target validation probe either disease-specific or drug activity 
processes. Disease biomarkers are used to explore the biological mechanisms 
involved in the disease pathophysiology. This information can then be used to 
improve the diagnosis of the condition, to mark its progression and to develop 
pathophysiologically relevant animal models. For instance, the finding of decreased 
TD4 cells in HIV gave not only an insight into the pathophysiology of the condition, 
but also provided a practical measure to track its outcome. Drug activity biomarkers 
provide information on whether the drug interacts with its respective target (Breier 
2005).  
 
3.1.3.2. Clinical surrogates 
 
Biomarkers that consistently predict traditional clinical end-points could replace them 
and become “clinical surrogates”. Clinical surrogates, being inherently more precise, 
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reliable and replicable than traditional end-points, could allow the detection of 
efficacy in smaller clinical trials. Also, classical clinical end-points, such as survival 
and quality of life, inevitably require long-term follow-up. If however a clinical 
surrogate predicts long-term treatment outcomes, it could reduce the duration of 
studies testing long-term benefit. Examples of successful clinical surrogates include 
blood cholesterol (predictor of cardiovascular mortality) and solid tumour size 
(predictor of mortality from a neoplastic cause). The MATRICS initiative has been 
developing a cognitive battery with the goal of providing of clinical surrogates for 
trials of cognitive enhancing drugs (Buchanan et al. 2007).  
 
3.1.3.3. Patient segmentation 
 
Some biomarkers also have the potential to stratify patients according to their likely 
treatment response or sensitivity to side-effects. Utilizing such biomarkers could help 
reduce the sample sizes of clinical trials by allowing selection more homogeneous 
patient population in phase 2 and 3 clinical trial which in turn reduces the variability 
of treatment response and decreases the likelihood of study discontinuation due to 
side effects.  
 
3.1.4. Biomarkers: Uncovering the likely failures  
 
Biomarkers could improve the chances of technical success of a drug by refining its 
targets, allowing its specific and precise assessment and selecting patient groups that 
are most likely to benefit. However, in the current situation of unclear 
pathophysiology of the main disease process, the vast majority of novel schizophrenia 
compounds are destined to fail. Therefore, a mechanism is needed to determine the 
likely failures as early as possible in their development and redirect resources to more 
promising compounds. This approach has been coined “quick win, quick kill” and 
aims to identify the likely failures fail as early as Phase I registration trial (Breier 
2005). These proof of concept studies function by selecting only a subgroup of 
patients that is more likely to respond or by recruiting groups of individuals that have 
only limited symptom profile, i.e. surrogate populations 
Page |   
 
61 
(Hurko 2009). Proof of concept studies precede the costly Phase 2 clinical trials which 
use more rigid diagnostic criteria, heterogeneous populations and traditional clinical 
end-points. 
 
Biomarkers are a key component of such proof of concept studies, as they can provide 
the precise assessment of efficacy that these clinical trials of small sample size and 
short duration require. The Phase 1 proof of concept biomarkers do not necessarily 
need to go through the same rigorous validation as clinical surrogates because they 
help guide internal decision and resource allocation rather than argue the case for a 
registration of a compound. Instead, their usefulness is determined by their sensitivity 
to the disease process (both in patients and in surrogate populations) and to the action 
of drugs that a prospective compound is aiming to emulate. 
 
3.1.5. Biomarkers in surrogate populations  
 
The appeal of proof of concept biomarker studies in surrogate populations lies in their 
practicality, as they involve populations that are easier to recruit than homogeneous 
patient groups and lack the major confounding factors of patient samples. In respect to 
cognition in schizophrenia such potentially confounding factors are prior or 
concomitant drug treatment, chronicity, lack of cooperation, lower educational and 
premorbid IQ levels. In addition, these samples provide the option of testing 
potentially disease-modifying therapies, as they feature the vulnerability pattern, but 
not the fully developed disease. 
 
Surrogate populations are defined as groups that feature a component of the main 
disease process but do not have the fully developed condition. Many medical 
disorders can be seen extremes of normally distributed functions such as blood-
pressure in hypertension and glucose regulation in diabetes. In psychiatry, anxiety and 
depressive neuroses have long been viewed as extremes of normal variation in 
fearfulness and mood. That psychoses may represent extremes of normally distributed 
cognitive functions such as reward processing (aberrant salience hypothesis), 
perception (hallucinations extended from vivid mental imagery) and frontal lobe 
executive function, is gaining momentum.  The continuum view of physical and 
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psychiatric disorders is encouraged by the absence of major gene effects, suggesting 
that many genes of small effect contribute to risk.  This increases the likelihood that 
many individuals in the general population will have some of these genes and 
therefore may express some of the phenotype associated with the full disease.  
 
The authors have been interested in the strategy to improve the sensitivity of 
biomarkers in surrogate populations. We believe that by studying biomarkers in 
individuals who lie further along the continuum of liability to experience psychosis 
will therefore improve the sensitivity of biomarkers to detect drug action relevant to 
the treatment of schizophrenia. We believe elevated psychosis liability through 
familial tendencies (unaffected relatives), predisposition to symptoms  (schizotypal 
personality), or through drug-induced schizophrenia-like states will provide 
individuals who possess characteristics which are found in patients with schizophrenia 
and therefore provide a useful groups for biomarker testing. They are discussed in 
turn in the following sections.  
 
3.1.6. Biomarkers in relatives: Endophenotypes and vulnerability 
 
One healthy group who might show greater sensitivity to novel schizophrenia 
treatments are the unaffected first-degree relatives of schizophrenia patients since they 
will carry more susceptibility genes than found in the general population. However 
these genes are probably in insufficient numbers or are combined favourably which 
prevents the development of psychosis. Several neurocognitive characteristics that are 
shared between relatives and patients have been reported (Allen et al. 2009) and some 
are described in later sections. These changes imply the presence of shared 
susceptibility genes and lie closer to genetic mechanisms of disease than the overt 
clinical phenotype. Therefore, these biomarkers are a subgroup of the disease-specific 
biomarkers that relate to genetic vulnerability only. With the inclusion of a number of 
other criteria they have been termed endophenotypes (Gottesman et al. 2003).  
In the psychosis literature they are primarily cognition or information processing 
related. Successful identification of endophenotypes could reveal neural pathways that 
underlie the schizophrenia phenotype. However, selecting volunteers for drug-
efficacy biomarker studies on the basis of familial liability will require both openness 
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and tact to avoid understandable fears of being treated like their ill relatives and 
identified with disorder. Drugs that prove effective on biomarkers in relatives would 
have the potential to affect mechanisms of vulnerability and therefore prevent onset of 
disorder in those with at-risk mental states. There is some tentative evidence that 
relatives of patients with schizophrenia who express psychosis liability characteristics 
benefit functionally from treatment with a low dose atypical antipsychotic (e.g. 
(Tsuang et al. 1999)). 
 
3.1.7. Biomarkers in schizotypy: Correlates of psychopathology 
 
In keeping with the continuum view of schizophrenia, systematic surveys suggest that 
brief schizophrenia-like experiences and beliefs are surprisingly common in the 
general population and are also more prevalent among first-degree relatives of 
patients (Van Os et al. 1997). Such phenomena may be sufficiently intense and long-
standing to interfere with everyday functioning and so warrant the diagnosis of 
schizotypal personality disorder. However, much evidence suggests that schizotypal 
personality traits are continuously distributed in the general population and that 
schizotypal traits may be quite prevalent in people with sufficient functioning to 
operate reasonably successfully in both social and occupational domains. In a later 
section we discuss evidence that healthy volunteers with high scores on schizotypal 
personality questionnaires show patterns of neurocognitive performance similar to 
these seen in schizophrenia. Selecting schizotypal populations may enhance the 
sensitivity of drug efficacy biomarker studies in the healthy population. Indeed, 
schizotypal symptoms themselves may be sensitive to new antipsychotic drugs and 
benefit from such interventions.  
 
3.1.8. Biomarkers in drug-induced states: Dopamine  
 
Administration of dopamine-releasing agents such as amphetamine and 
methylphenidate has been used extensively to model the symptoms of schizophrenia.  
These agents induce an acute schizophrenia-like syndrome in heavy users (Connell 
1958), exacerbate positive symptoms in patients (although improvements in 
spontaneity and activation have also been reported), and induce symptoms when 
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given experimentally to volunteers. However, high doses are required to induce 
paranoid ideation and hallucinations and acute doses do not reproduce the cognitive 
and negative symptoms of schizophrenia. These findings, along with the data showing 
improvement of positive symptoms with dopamine antagonism gave rise to theory 
that schizophrenia is due to excessive dopaminergic neurotransmission. That 
enhanced dopamine release occurs in schizophrenia has now been firmly established 
by positron emission tomography (PET) measuring dopamine displacement of D2 
radioligand binding (Laruelle et al. 1996; Abi-Dargham et al. 2000). Reports of 
increased uptake of fluoroDOPA suggest presynaptic dopamine neurones are more 
active in both acute and prodromal patients (McGowan et al. 2004; Howes et al. 
2009). However, only subcortical striatal dopamine function has been quantifiable 
with these techniques and indirect evidence suggests that frontal cortical dopamine 
release may be reduced in schizophrenia.  Indeed an important theory suggests that 
the primary abnormality in schizophrenia may be decreased frontal dopamine function 
with secondary increases in subcortical dopamine (Weinberger et al. 1988; Davis et 
al. 1991); the former mediating positive symptoms and the latter impaired cognition 
and negative symptoms.   
 
How increased striatal dopamine release translates into positive symptoms is not 
clear.  Dopamine clearly has an important role in perceived reward and learning in 
which its release by unexpected rewards (reward prediction error) triggers new 
learning. This has been visualised in humans for example in a study in which reward 
prediction error was associated with activity in dopamine areas that was attenuated by 
the dopamine antagonist haloperidol and facilitated by the dopamine precursor L-
DOPA (Pessiglione et al. 2006). Excessive dopamine release in schizophrenia is 
postulated to result in aberrant reward learning and the formation of positive 
symptoms (Kapur 2003). Biomarkers based on reward prediction error are discussed 
in section 3.3.2. of this chapter. 
 
Dopamine modulates frontal executive function and working memory (Goldman-
Rakic 1994). However, the relationship may not be linear. Animal and human 
literature suggests that enhancing dopamine function from a low baseline improves 
executive functions whereas increases beyond an optimal level result in decreases in 
executive function therefore suggesting an inverted U-shape relationship. A further 
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complication is that D1 and D2 receptors may exert opposite influences on frontal 
executive function.  The empirical evidence suggests acute amphetamine challenge 
improves rather than disrupts cognition in patients with schizophrenia (Pietrzak et al. 
2010). The improvement may be explained by a reversal of deficient stimulation of 
D1 receptors in schizophrenia that predominate in frontal cortex. As a result of this 
development, the experimental application of acute amphetamine challenge has 
recently shifted towards improving performance in states of sub-optimal cognition 
and this is reviewed in later sections of this chapter.   
 
It should also be noted that differences exist between the effects of acutely and 
chronically administered amphetamine. Repeated administration of amphetamine in 
experimental animals can result in increased hyperactivity responses and other effects 
of amphetamine. This is known as amphetamine sensitization and has been proposed 
a model for schizophrenia. Furthermore, sensitised animals also show evidence of 
cognitive deficits. Limited evidence suggests that amphetamine sensitisation can be 
demonstrated in healthy volunteers and further exploration of cognitive biomarkers in 
this paradigm would seem worthwhile. It might be possible, for example, to find 
drugs that prevent sensitisation without blocking the effect of amphetamine and these 
might be useful preventative treatments in high risk groups (Featherstone et al. 2007).  
 
3.1.9. Biomarkers in drug-induced states: Glutamate, GABA and 
acetylcholine 
 
Administration of the dissociative anaesthetic agent ketamine in sub-anaesthetic doses 
to healthy volunteers induces suspiciousness, thought disorder, some of the negative 
symptoms of schizophrenia and impairs performance on working memory (Pomarol-
Clotet et al., 2006, Krystal et al., 1999a, Deakin et al., 2008). Ketamine blocks the ion 
channel associated with the N-methyl D-aspartate (NMDA) glutamate receptor. The 
psychotomimetic effects of NMDA channel blockers gave rise to the glutamate 
deficiency theory of schizophrenia. However, this is now better termed the NMDA 
deficiency hypothesis because drugs such as ketamine produce a paradoxical 
disinhibition of cortical glutamate release that acts on non-NMDA receptors. Many of 
the subjective and behavioural effects of ketamine can be blocked by agents that 
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decrease glutamate release (Deakin et al 2008). Thus increased glutamate release may 
be responsible for psychosis-like symptoms after ketamine as may the symptoms of 
schizophrenia itself (Deakin et al, 1989; 1997). Whether there is a primary 
impairment of NMDA function in schizophrenia is not clear, although this has been 
described in post-mortem hippocampus and in a single in-vivo SPET radioligand 
binding study (Law et al. 2001; Pilowsky et al. 2006). 
 
The NMDA deficiency theory of schizophrenia has recently become pleasingly 
unified with GABA deficiency theories by evidence that a subclass of GABA 
interneurones that synchronise the firing of pyramidal neurones is driven primarily by 
NMDA receptors (Belforte et al. 2010). These so-called fast-spiking interneurones are 
thought to correspond to these containing parvalbumin which have repeatedly been 
reported to be deficient in post-mortem brain in schizophrenia (Lewis et al. 2006). 
Thus ketamine and related drugs may mimic NMDA hypofunction, impaired GABA 
neurotransmission and disinhibited glutamate release hypothesised to occur in 
schizophrenia. In-vivo methods of quantifying GABA and glutamate function are 
badly needed to test these theories.  
 
The cholinergic system has also been implicated in drug-induced psychotics. The 
administration of anticholinergic agents, such as scopolamine or atropine is known to 
have the potential of causing ‘antimuscarinic psychosis’, a state that shares some of 
the behavioural features of endogenous schizophrenia (Perry et al. 1978; Perry et al. 
1995; Minzenberg et al. 2004). Procyclidine, another antimuscarinic agent, was 
shown to block the antipsychotic effects of flupentixol in patients (Johnstone et al. 
1983). Together with data showing alterations of the muscarinic and nicotinic 
receptors in schizophrenia (Terry 2008), this evidence has suggested that the 
acetylcholine system may be important in the pathogenesis of schizophrenia. 
Cognition is a likely target of a cholinergic disturbance (Minzenberg et al. 2004), as 
this neurotransmitter system is known to play an important modulatory role in 
memory, learning and synaptic plasticity (Sarter et al. 1997). In demonstration of this, 
the use of cholinesterase inhibitors such as donezepil in Alzheimer’s disease has been 
linked to slowing of the progression of cognitive deficits in this condition (Birks 
2006). Unlike ketamine however, Procyclidine and other antimuscarinic agents are 
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limited in their use as pharmacological models of schizophrenia due to their 
unfavourable side effects profile.  
 
3.2. Purpose of the review 
 
The second part of the manuscript reviews the validity of several neurocognitive 
biomarkers from the major areas of interest in the literature with some more novel 
potential biomarkers developed by the authors. The emphasis is on potential 
biomarkers of drug efficacy in healthy volunteers that could be used in large-scale 
multi-centre studies. We focus on neurocognition because it is free of preconceptions 
about the neurochemical actions necessary for efficacy of a new drug and the need for 
treatments that improve cognition and negative symptoms. Functional brain imaging 
using positron emission tomography PET and functional magnetic resonance imaging 
(fMRI) is informative at identifying the involvement of neural systems in cognitive 
functioning. Neuroimaging is therefore showing promise as a modality for detecting 
drug-efficacy but there are many technical issues and it is beyond the scope of this 
article to provide a meaningful review of imaging biomarkers. 
 
We will assess representative neurocognitive biomarkers according to their: 
 
• Reliability (consistent effects reported by different laboratories or over time) 
• Criterion validity (abnormal in criterion groups: patients, unaffected relatives, 
high schizotypes and after amphetamine or ketamine in healthy volunteers)  
• Predictive validity (sensitive to the action of compounds effective in 
schizophrenia or cognition) 
• Construct validity (relates to a known neurobiological system implicated in 
the disorder) 
 
The importance of establishing the reliability of cognitive biomarkers in 
schizophrenia has been recognized by the MATRICS (Harvey et al. 2010) and 
CNTRICS (Carter et al. 2007) initiatives. These studies focus solely on schizophrenia 
patient samples and the results are useful in terms of establishing and standardizing 
cognitive clinical end points. However, as discussed previously, the various 
Page |   
 
68 
confounds in this group (chronic disease and treatment, polypharmacy, 
institutionalization, florid positive symptoms, reduced cooperation) limit the 
conclusions that can be drawn regarding the pathophysiology of the subtle cognitive 
deficits and the disease. MATRICS recommends that participants have not more than 
moderate scores on formal thought disorder, hallucinations and delusions, negative 
and depressive symptoms, have minimal extrapyramidal symptoms, have been 
maintained on the same dose for 2-4 weeks and take only one antipsychotic 
(http://www.matrics.ucla.edu/matrics-recommendations-frame.htm). This limits the 
number of appropriate participants and still does not fully account for all confounds. 
In contrast, each of the healthy volunteer criterion groups that we will review provides 
a different viewpoint of the pathophysiology (genetic, psychopathological and 
molecular) with little or no impact of these confounding factors. We suggest that this 
approach is contributing to our understanding of the mechanisms behind cognitive 
abnormalities in schizophrenia and accelerate the evaluation of novel drug treatments.  
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3.3. Validity of cognitive and physiological biomarkers of cognitive 
processes related to schizophrenia. 
 
3.3.1. Working memory: N-back and spatial working memory  
 
Background 
Working memory (WM) refers to a process for holding and managing information 
‘online’ over short periods of time, allowing its manipulation and usage in reasoning, 
comprehension and decision-making. The distinction between short-term memory and 
working memory is subtle and not always consistent (Reichenberg et al. 2007). 
Working memory generally implies that the information is both stored and 
manipulated. It has been proposed that separate systems for the maintenance of verbal 
and visuo-spatial information exist (Baddeley 1986). In accordance the working 
memory tasks used in schizophrenia research as a rule involve either of the two 
modalities (Lee et al. 2005).  
 
Paradigm description  
In the N-back task, a series of digits are presented and participants are required to 
respond if the current digit is the same as one presented N trials previously where N 
varies between 0 and 3 in different trial blocks. This requires that the current rule is 
held in mind and that the relevant digit is updated from trial to trial. However the task 
also draws on other cognitive processes such as response inhibition, strategy 
formation and checking. Spatial working memory involves remembering locations of 
objects. Computerised tasks such as the Cambridge Automated Test Battery 
(CANTAB (Cohen et al. 1992)) often require a visual search of locations to collect a 
target object. These, now empty, locations need to be avoided to efficiently collect 
remaining targets. Thus a constant updating of memory of searched locations is 
required. Again processes such as strategy formation and behavioural inhibition are 
required.   
 
Construct validity  
Classic single cell recoding experiments in primates by Goldman-Rakic showed that 
cells in dorsolateral prefrontal cortex represent the spatial location of a cue over short 
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delays until the information is used to obtain a reward (Goldman-Rakic 1994). 
Functional imaging studies in humans confirm that working memory paradigms 
engage a dorsal network including dorsolateral prefrontal cortex and that these 
responses are abnormal in schizophrenia (Callicott et al., 2003). The dorsolateral PFC 
dysfunction is associated with disorganized symptoms (Perlstein et al. 2001), while 
the performance on  the working memory tasks itself correlates with the negative 
symptoms (Carter et al. 1996).  
 
Criterion validity 
• Patients, relatives and high schizotypes 
Meta-analyses have indicated that schizophrenia patients are significantly impaired on 
both verbal and visuo-spatial WM tasks (Lee et al. 2005). WM deficits are stable 
across time and fluctuations in clinical status (Hill et al. 2004) and are present before 
the initiation of treatment (Barch et al. 2001). First-degree relatives also appear to be 
affected, with effect sizes ranging from small to moderate (Snitz et al. 2006). WM 
memory deficits have also been reported in schizotypal individuals with (Johnson et 
al. 2003) and without (Park et al. 1997) family history of schizophrenia. Although 
working memory is strongly correlated with IQ, deficits that survive correction for 
reduced IQ have been reported in patients and high-risk subjects (O'Connor et al. 
2009; Zanelli et al. 2010).  
 
• Glutamate antagonist challenges 
There is much interest in the role of impaired GABA function, possibly driven by 
deficient NMDA glutamate neurotransmission, in the impairment of WM in 
schizophrenia. In healthy volunteers, ketamine impaired WM performance in some 
but not all studies, especially when the task required manipulation of information; 
affinities with the WM deficits of schizophrenia have been noted (Fletcher and 
Honey, 2006, Morgan and Curran, 2006).    
 
Predictive validity  
• Dopamine antagonists 
Studies in patients treated both acutely and chronically with typical antipsychotics 
have found no beneficial effect on cognitive function (Meltzer et al. 1999) but see 
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also (Keefe et al. 2007). The benefit of atypical antipsychotic therapy on working 
memory is most likely to be marginal (Heinrichs 2005) despite some studies reporting 
modest improvement (Houthoofd et al., 2008, Meltzer and McGurk, 1999, Purdon, 
1999)(Houthoofd et al. 2008).  
 
• Dopamine agonists    
In healthy volunteers, compounds that increase dopamine activity have generally been 
shown to improve WM. Amphetamine has been shown to improve WM, especially in 
those individuals with low baseline performance (Mattay et al., 1996, Mattay et al., 
2000). Similar effects have been reported with methylphenidate (Elliott et al., 1997, 
Mehta et al., 2000), but see (Turner et al. 2003). The selective D2 agonist, 
bromocriptine, also improved performance on spatial WM tasks (Kimberg et al. 1997; 
Luciana et al. 1998), but see (Kimberg et al. 2001). The mixed results of D2 agonism 
could be interpreted in the framework that sees D1 receptor agonism as the key factor 
in cognition enhancement. In demonstration of this, the disruption of working 
memory induced in healthy volunteers by a D2 antagonist challenge was alleviated by 
pergolide, a mixed D1/D2 agonist, but not the D2 agonist bromocriptine (Muller et al. 
1998). 
 
Importantly, data have emerged on the efficacy of dopamine agonists in improving 
working memory in schizotypal personality disorder (SPD). Firstly, acute 
amphetamine benefited working memory in SPD but not other personality disorders 
(Kirrane et al. 2000). Again, the poorer baseline performers improved the most. The 
enhancement of cognition in SPD under dopamine agonism also holds true for chronic 
treatment, as pergolide improved working memory after 4 weeks treatment in patients 
(McClure et al. 2010).  
 
• Other agents                                                             
Cholinergic drugs modulate WM performance. Both muscarinic and nicotinic receptor 
antagonists impair WM performance in healthy volunteers (Green et al., 2005, 
Thompson et al., 2000). In one study abstinence from smoking in patients was 
associated with impaired WM performance but not in non-schizophrenic smokers and 
this was reversed with smoking reinstatement (Sacco et al., 2005).. Freedman et al 
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reported beneficial effects of a novel nicotinic agonist on some measures of WM in 
non-smoking patients along with improved negative symptoms (Freedman et al. 
2008). Cholinesterase inhibitors on the other hand improve WM in healthy volunteers 
(Furey et al. 2000; Furey et al. 2000). Studies exploring the potential of compounds 
stimulating the cholinergic system as an adjuvant therapy in patients largely report 
improved executive function (Ribeiz et al. 2010). 
 
3.3.2. Reward learning: Salience Attribution Test (SAT) 
 
Background  
Schulz and colleagues demonstrated that the presentation of unexpected (i.e. 
unpredicted) food rewards activates dopamine neurones in experimental animals. This 
is thought to act as a ‘prediction error’ or teaching signal (Schultz et al. 1997). Any 
initially neutral cue (stimulus) that predictably precedes a reward will itself acquire 
the ability to activate dopamine neurones. In this way predictive cues become imbued 
with ‘motivational salience’ (Berridge and Robinson 1998) and are able to capture 
attention and guide goal-direct behaviour. It has been hypothesized that in psychosis 
dysregulated dopamine release provides an inappropriate prediction error signal 
during the processing of irrelevant stimuli. This is thought to result in the 
inappropriate assignment of salience to external stimuli and internal representations 
such as thoughts or memories (Kapur 2003). According to the aberrant salience 
hypothesis, delusions and hallucinations form as cognitive misattributions of the 
origin and significance of the unusual and repeated experience of many 
inappropriately salient stimuli.  
 
Task description  
Studies exploring salience attribution use cognitive psychology paradigms in which 
stimuli are either coupled with reward or not. The degree of correct and aberrant 
learning is inferred from behavioural measures, including choices, reaction times or 
participant awareness judgements (Roiser et al. 2009). For example in the Salience 
Attribution Test (SAT), coloured images of household objects or animals are 
presented prior to responding for possible rewards (money). One stimulus dimension 
(e.g. red vs. blue – relevant dimension) very reliably predicts the availability or non-
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availability of money while the other (e.g. animals vs. household objects – irrelevant 
dimension) has no bearing on the outcome. The rewarded stimulus feature (e.g. blue) 
promotes faster responding for reward relative to the unrewarded one (e.g. red), 
providing a measure of implicit adaptive (i.e. appropriate) salience; participants are 
also able to report this association overtly using visual analogue scales (explicit 
adaptive salience). Faster responding/greater reward rating occurring to one of the 
irrelevant features over the other (e.g. animals faster over household objects) indicates 
aberrant salience.  
 
Such a distinction between adaptive and aberrant salience is important to directly test 
the aberrant salience hypothesis, since demonstrating an absence of normal reward 
processing is not necessarily directly indicative of the presence of context-
inappropriate associations, the central tenet of this model. The first study to 
investigate behaviour on the SAT in patients with schizophrenia reported elevated 
explicit aberrant salience in patients with delusions, but not in those without (Roiser et 
al. 2009), consistent with the aberrant salience hypothesis (Kapur 2003). 
 
Construct validity  
In apparent variance with the salience attribution hypothesis, functional imaging 
studies report reduced ventral striatal hemodynamic responses during reward cue 
conditions (Juckel et al. 2006; Schlagenhauf et al. 2008) in patients with 
schizophrenia; this effect also correlated with negative symptoms. The proposed 
explanation for this paradoxical finding is as follows: in the context of many stimuli 
of heightened significance generally, reward-related cues may not differentially 
activate the ventral striatum, and thus fail to motivate behaviour (Ziauddeen et al.; 
Roiser et al. 2009). Furthermore, explicit aberrant salience in the SAT was associated 
not only with delusions but also with negative symptoms (Roiser et al. 2009). 
Interestingly, in healthy volunteers, the degree of aberrant explicit salience correlated 
with hemodynamic responses in the prefrontal cortex, hypothesised to contribute to 
negative symptoms (Juckel et al. 2006). Such findings highlight the importance of the 
distinction between negative symptoms, including anhedonia, that are secondary to 
the psychotic state, and enduring negative symptoms in the absence of psychosis 
(primary negative symptoms) that have a separate pathogenesis that is not responsive 
to antipsychotic drugs. The construct validity of the aberrant salience measurements 
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provided by the SAT has also been investigated using principal components analysis 
in healthy volunteers (Schmidt et al. 2009). This study found that aberrant salience 
was not related to potentially confounding measures including working memory, 
selective attention, latent inhibition or reward learning. 
 
Criterion validity 
• Patients, relatives and high schizotypes 
Studies using reward-based paradigms have reported consistent abnormalities in 
schizophrenia patients (Waltz et al. 2007; Murray et al. 2008; Murray et al. 2008), 
especially in those with delusions (Roiser et al. 2009), as mentioned previously. Also, 
aberrant salience has recently been linked to high levels of schizotypy (Roiser et al. 
2009; Schmidt et al. 2009; Housden et al. 2010). There are currently no data regarding 
unaffected relatives of patients with schizophrenia, but evidence from psychophysical 
experiments suggests that abnormalities in reward processing increase linearly with 
genetic risk (Glatt et al. 2006). 
 
Predictive validity  
• Dopamine antagonists 
Normalisation of aberrant salience with successful antipsychotic treatment has been 
reported in patients using the SAT (Roiser et al. 2009). As predicted by the aberrant 
salience hypothesis, patients taking antipsychotics also scored lower on adaptive 
salience than controls (Kapur 2003). Additionally, the antipsychotic drugs haloperidol 
(Pessiglione et al. 2006) and olanzapine (Abler et al. 2007) have been reported to 
attenuate reward-related responses in ventral striatum in healthy volunteers. However, 
Juckel and colleagues reported a relative sparing of striatal reward-related responses 
in patients administered atypical but not typical antipsychotic drugs (Juckel et al. 
2006). 
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• Dopamine agonists 
The role of dopamine in aberrant salience attribution is supported by a study utilizing 
amphetamine challenge in healthy volunteers, which reported a loss of specificity of 
hemodynamic responses to rewards relative to punishments in the ventral striatum 
(Knutson et al. 2004). The effect of dopamine agonists on SAT performance has not 
yet been investigated. 
 
3.3.3. Biconditional Learning (BCL) 
 
Background  
Cohen & Servan-Schreiber have attempted to account for a broad range of cognitive 
deficits observed in schizophrenia by appealing to a unitary mechanism (Cohen et al. 
1992). They described the cognitive dysfunction seen in schizophrenia as a failure to 
produce the appropriate response as a consequence of an impaired ability to represent, 
maintain or apply task-setting information; a process that is thought to rely on intact 
function of the prefrontal cortex. Consequently the deficits in cognitive performance 
should be particularly evident when task-setting cues dictate when different responses 
are required to the same stimuli. 
 
Paradigm description  
Conditional discrimination paradigms may be used to assess the way in which task-
setting cues can control performance. In these tasks, participants are required to learn 
associations between arbitrary pairs of stimuli, or between arbitrary stimuli and 
responses (e.g. (Petrides 1985)). These associations are learned by trial-and-error and 
based on feedback, either from the experimenter in human studies or food 
reinforcement in animal studies. In a conditional discrimination task the performance 
of a particular response may be appropriate in the presence of a specific cue but is 
inappropriate at other times. For example, participants may learn that in the presence 
of A, response X (but not Y) is required, whereas in the presence of B, Y (but not X) 
is required. In biconditional discrimination tasks, correct responses are dictated by the 
particular combination of cues, usually represented by AX+, BX-, AY-, BY+, where 
A, B, X, Y represent cues, and + and – respectively represent the presence and 
absence of appropriate outcomes.  
Page |   
 
76 
 Construct validity  
In animal studies lesions to prefrontal cortex interfere with BCL (Haddon et al. 2006). 
Imaging studies in humans suggest prefrontal cortex is engaged in conditional 
discrimination learning (Mok et al. 2009).  
 
Criterion validity 
• Patients, relatives and high schizotypes 
A pilot study using an allergy prediction task (e.g. (Aitken et al. 2000)), in patients 
with schizophrenia revealed a deficit in the solution of a biconditional discrimination 
(Walters et al. Unpublished findings). Similar results have been found in a sample of 
high schizotypes(Haddon et al. in press).  
 
• Glutamate antagonist challenge 
There are no translational drug studies in humans using a BCL task but in 
experimental animals the NMDA antagonist phencyclidine disrupted performance on 
conditional and biconditional discrimination (Dunn M. et al. 2005; Dunn et al. 2006; 
Dunn et al. 2006).  
 
Predictive validity  
• Dopamine antagonists 
The NMDA-induced impairments on BCL in animals can be selectively reversed by 
the action of atypical, but not typical, antipsychotics (Dunn et al. 2007), and this 
action is likely to depend of prefrontal mechanisms (Dunn et al. 2007).  
 
• Dopamine agonists 
Animal data suggests that acute administration of amphetamine disrupts performance 
in a similar way to NMDA antagonists (Dunn and Killcross, 2006b). No data on the 
effects in humans are currently available.  
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3.3.4. Perception: Signal Detection Task (SDT) 
 
Background 
The cognitive mechanisms which underpin auditory hallucinations may be an 
extension of normal cognitive processes (Bentall 1990).The use of healthy volunteer 
proxies for hallucinatory phenomena such as inner and imagined speech have been 
used in functional imaging studies (Simons et al.; Shergill et al. 2000). However the 
use of a behavioural task which permits the identification of the cognitive 
mechanisms underpinning a propensity towards hallucinations would be most time 
and cost efficient as a biomarker for this symptoms.  The signal detection task 
(Barkus et al. 2007) aims to objectively determine proneness to auditory 
hallucinations without using suggestion (Young et al. 1987; Cahill 1996).   
 
Paradigm description 
Participants are asked to indicate whether they hear a voice during brief periods of 
white noise. There is a voice in sixty percent of the trials. A third of the voice 
presentations are clearly audible while the remainder are at auditory threshold. The 
clearly audible voices give participants an indication of what to expect and those 
presented at auditory threshold allows for some perceptions to be ambiguous. From 
these data four pieces of information are provided (e.g.(Green et al. 1966; McNichol 
1972)): hits (a voice is present and participants report hearing it), misses (a voice is 
present but participants do not report hearing it), correct rejections (a voice is not 
present and the participants do not report hearing it) and false alarms (a voice is not 
present but the participant reports hearing it) - the putative measure of hallucinatory 
proneness. Measures of sensitivity, specificity and response bias can be calculated 
using signal detection theory.    
 
Construct validity  
In a small fMRI study Barkus et al. reported that false perceptions (when compared to 
hearing a voice which was presented) activated closely similar areas to those 
associated with hallucinations in patients with psychosis (e.g.(Simons et al. 2009)) 
including the inferior and superior temporal gyri and the cingulate (Barkus et al. 
2007). Also, a specific association between positive response bias and hallucinatory 
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proneness items rather than items relating to visual or thought intrusions into 
cognition was reported (Varese et al. 2010). 
 
Criterion validity 
• Patients, relatives and high schizotypes 
A tendency to report false alarms has been reported patients with psychosis who 
report hallucinations (Bentall et al. 1985; Bentall et al. 1991). A similar pattern has 
been observed in healthy volunteers in association with high scores on questionnaire 
ratings of hallucinatory proneness or positive schizotypy (Bentall et al. 1985; Rankin 
et al. 1995; Barkus et al. 2007). Most of these studies report that this tendency exists 
in the absence of any difference in the ability to detect signal, although this is not a 
consistent finding (e.g. (Boecker et al. 2000)). Additionally performance on the SDT 
also seems to be mediated by age and positive schizotypy in a manner consistent with 
psychosis risk i.e. younger participants scoring higher on positive schizotypy 
reporting more false perceptions than older participants and younger participants 
scoring low on positive schizotypy (Barkus et al. Submitted). 
 
Drug-validation studies would be of considerable interest but have yet to be carried 
out. Given the focus of this task on auditory hallucinations samples in these studies 
should be recruited on the basis of a propensity towards these symptoms.  
 
3.3.5. Cortical electrophysiology: Early sensory Event-Related Potentials (ERPs)  
 
Background 
A number of studies suggest that schizophrenia is associated with impaired visual 
sensory perception: deficits have been demonstrated in motion, contrast sensitivity 
and spatial discrimination (Javitt 2009). ERPs recorded by electroencephalography 
have the temporal resolution necessary to identify the neural basis of impaired 
perception and are potential biomarkers of early sensory processing. Two promising 
measures of early sensory processing have been developed in the auditory and visual 
modalities (the mismatch-negativity (MMN) and P1 potentials, respectively). The 
MMN potential is a negative ERP wave peaking over the temporal cortical lobes at 
150-200 ms post-stimulus in response to auditory stimuli that deviate from an 
established pattern (Naatanen et al. 1978). The visual P1 potential is generated by any 
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perceived visual stimulus. It peaks between 100 and 150 ms and has a bilateral 
occipital distribution (Di Russo et al. 2003). 
 
Paradigm description  
MMN tasks involve participants listening to repetitive sound patterns which are 
infrequently interrupted by stimuli that deviate in terms of intensity or duration 
(Michie 2001). The process is attention-independent and the participants are usually 
instructed to ignore the sounds while watching a film or reading a book. The visual P1 
wave is typically evoked by watching a black and white checkerboard pattern 
repetitively flashed on a screen. The participants are instructed to ignore these stimuli 
but are visually engaged by an attentional task (e.g. pressing a button whenever an 
animal appears on the screen) e.g. (Yeap et al. 2006). In both cases the outcome 
measure is the peak amplitude or the mean amplitude of a window centred on the 
peak of interest.  
 
Construct validity  
Functional imaging studies have provided evidence for reduced activation during 
perception in both visual and auditory cortex of schizophrenia patients. In the case of 
MMN, a combined MEG/fMRI study demonstrated reduced activity within the 
secondary auditory cortex (planum temporale), an area proposed to be crucial for 
integration of the auditory stimuli (Kircher et al. 2004). A combined EEG/fMRI study 
of early visual potentials found reduced activation of the V1 and V2 visual areas 
(Martinez et al. 2008). Moreover, the P1 potential is predictive of performance on 
cognitive tasks that require visual encoding (Haenschel et al., 2007, Butler et al., 
2009). This has been interpreted as evidence that inefficient encoding contributes to 
higher-order cognitive deficits. Similarly, the MMN abnormalities in schizophrenia 
predict social and occupational impairment (Light et al. 2005). 
 
Criterion validity 
• Patients, relatives and high schizotypes 
MMN is reliably reduced both in patients (Umbricht et al. 2005) and at-risk 
individuals including unaffected relatives (Michie et al. 2000), schizotypal individuals 
(Niznikiewicz et al. 2009) and children at-risk for schizophrenia (Bar-Haim et al. 
2003). In the visual domain, the P1 potential has been consistently shown to be of 
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reduced amplitude in patients (Doniger et al. 2002; Foxe et al. 2005; Schechter et al. 
2005; Yeap et al. 2006), unaffected relatives (Yeap et al. 2006) and recently in high 
schizotypes (Koychev et al. 2010).  
 
• Glutamate challenges  
Ketamine challenge in healthy volunteers led to diminished MMN amplitude (Oranje 
et al. 2000; Umbricht et al. 2000; Kreitschmann-Andermahr et al. 2001) observed no 
effect on MMN. No studies of ketamine on visual P1 amplitude in healthy volunteers 
have been published but such effects have been reported in experimental animals 
(Heggelund et al. 1990; Kwon et al. 1991).  
 
Predictive validity  
• Dopamine antagonists 
Treatment with typical or newer antipsychotic drugs has no effect on the MMN 
abnormality (Schall et al. 1999; Korostenskaja et al. 2005). Also, unmedicated and 
recent onset patients have a pattern of MMN and P1 abnormalities similar to these of 
chronically medicated patients (Javitt et al. 2000; Umbricht et al. 2006; Yeap et al. 
2008). Finally, a recent analysis showed that there is no relationship between 
antipsychotic dosage or duration of treatment and the severity of the P1 potential 
abnormality (Yeap et al. 2008). 
 
• Dopamine agonists 
There have been no studies on the effects of acute dopamine agonist challenge in 
auditory MMN or P1 ERPs.  
   
• Other agents 
Benzodiazepine treatment in schizophrenia patients does not alter the MMN deficits 
(Kasai et al., 2002). 
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3.3.6. Cortical electrophysiology: Oscillation and coherence 
biomarkers 
 
Background 
Recent theories attribute the core dysfunction in schizophrenia to impaired 
connectivity between and within brain regions (Friston, 2005, Andreasen, 1999). 
Neural oscillations has been identified as the fundamental mechanism that enables 
coordinated brain activity and as such represents a natural target for schizophrenia 
research (Fries 2009). Single-cell and local field potential recordings have shown that 
neurons tend to synchronize their activity by aligning their action potentials in the 
same oscillatory rhythm. Oscillatory activity has been divided into low (delta 1-3 Hz; 
theta 4-7 Hz; alpha 8-12 Hz) and high frequency bands (beta 13-30 Hz and gamma 
30-200 Hz), a distinction which has been proposed to have functional relevance 
(Buzsaki 2006) . However, there is considerable overlap and the classical cut-offs 
between bands is somewhat arbitrary (for reviews see (Uhlhaas et al. 2008; Uhlhaas et 
al. 2010)). The oscillations can be characterized in terms of their power and the 
degree to which their phases coincide between trials (phase-locking factor) or 
electrodes (coherence). Also, two types of oscillations are analyzed: time-locked 
(evoked) and non time-locked (induced). Evoked oscillations are hypothesized to 
represent perceptual binding, while induced underlie cognitive processes (Buzsaki 
2006).  
 
Task description  
Neural oscillations are studied using event-related designs in EEG. Any task that 
evokes a repeated uniform cognitive response can be used to probe connectivity in 
schizophrenia. Working memory, perceptual binding and pattern deviance tasks have 
been employed in both visual and auditory domains.  
 
Construct validity 
A number of experiments have demonstrated a close link between synchronized 
oscillatory activity and the preparation, initiation and maintenance of cognitive and 
behavioural acts (Varela et al. 2001). Studies in patients have found that reduced 
evoked oscillations in the beta and gamma range predict working memory impairment 
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on a matching to sample task (Haenschel et al. 2009). Similarly, the disruptions of the 
non time-locked (induced) gamma oscillations have been linked to impaired 
performance on several cognitive tasks, suggesting that the neural processes 
underlying both induced and evoked oscillatory activity are critical to higher order 
cognitive processes (Cho et al. 2006; Basar-Eroglu et al. 2007). 
     
Criterion validity 
• Patients, relatives and high schizotypes 
Abnormalities of the gamma, beta and alpha oscillations are well documented in 
schizophrenia patients (Uhlhaas et al. 2008). Evoked gamma bursts time-locked to 
auditory and visual stimulation show reduced power and degree of synchronization in 
patients (Uhlhaas et al. 2006; Spencer et al. 2008; Haenschel et al. 2009) and 
unaffected relatives (Tsai et al. 2004). In a recently completed analysis we found 
evidence of power and phase abnormalities in a sample of schizotypal individuals 
(See Chapter 7). The pathogenesis of the observed oscillatory abnormalities has been 
attributed to dysfunction within local GABA inhibitory networks that set the rhythm 
within neuronal networks, deficits in the glutamatergic system which mediates long-
distance synchronization and/or demyelination that affects the cortico-cortical and 
cortico-subcortical connectivity (Uhlhaas et al. 2008).  
 
Criterion validity 
• Glutamate antagonist challenges  
A study using ketamine in a gating auditory paradigm found augmented gamma and 
reduced theta response in healthy volunteers (Hong et al. 2009).  
 
 
Predictive validity 
• Dopamine antagonists 
Data on modulation of oscillatory activity by antipsychotic drugs are limited with one 
group reporting reduced gamma activity in patients treated with atypical 
antipsychotics (Mayner et al. 2008). However, no correlation was found between 
chlorpromazine equivalents and amplitude of evoked and induced oscillations in 
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patient samples (Haenschel et al. 2009). Also, gamma band abnormalities have been 
reported in unmedicated patients (Gallinat et al. 2004).  
 
• Dopamine antagonists and other agents 
There are currently no data on the effect of dopamine agonists or other psychoactive 
compounds on neural oscillations in humans.  
 
3.3.7. Oculomotor control: Saccadic eye movements  
 
Background 
The study of eye movements has received much interest in the validation of potential 
biomarkers due to findings of various oculomotor deficits in schizophrenia. The 
saccadic eye movements (rapid eye movements that allow the fixation of a new object 
that has appeared in the visual field) are some of the most widely studied measures in 
the context of schizophrenia.  
 
Paradigm description 
In the prosaccade task a novel visual target appears in the periphery and the 
participants have to direct their gaze at it. In the antisaccade task the participants have 
to inhibit the prosaccadic response to a new stimulus and instead look at its mirror 
image location on the opposite side of the screen. The performance measures of the 
task are the number of error prosaccades, the latency and the spatial accuracy of the 
mirror antisaccade.   
 
Construct validity 
Imaging studies have demonstrated that the antisaccade is a complex task activating a 
dorsal fronto-parietal cortical network as well as subcortical project targets; 
specifically, dorsolateral and ventrolateral prefrontal cortex, frontal and 
supplementary eye fields, the intraparietal sulcus, striatum, and thalamus (Munoz et 
al. 2004). Evidence from structural and functional imaging studies indicate that the 
structures underlying the abnormality in schizophrenia are the frontal cortex (Ettinger 
et al. 2004) and the striatum (Raemaekers et al. 2002). Performance on the task has 
been demonstrated to have high temporal stability (Ettinger et al. 2003). Also, the 
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antisaccade error rate correlate with the measures of executive function in 
schizophrenia patients (Hutton et al. 2004).  
 
Criterion validity  
• Patients, relatives and high schizotypes 
Schizophrenia patients have been shown to have normal performance on the 
prosaccade task (Hutton et al. 2006; Haraldsson et al. 2008), although some reports 
suggest decreased latencies of the responses (Reilly et al., 2008a). In the antisaccade 
task however, they are consistently impaired, making significantly more errors, 
having slower antisaccade latencies, and showing deficits in calculating the spatial 
location of the mirror image (Fukushima et al. 1988; Hutton et al. 2006). Unaffected 
biological relatives and schizotypal individuals also show impaired antisaccade 
performance (Calkins et al. 2004).  
 
• Glutamate antagonist challenges  
Ketamine studies in healthy humans have found a decrease in prosaccade velocity and 
an increase in saccade latency but only non-significant impairments in antisaccade 
performance (Radant et al., 1998, Weiler et al., 2000). In contrast, a study in primates 
found that ketamine infusion impairs antisaccade performance (Condy et al. 2005). 
The discrepancy between studies may reflect the different dosages of ketamine that 
were used.  
 
Predictive validity  
• Dopamine antagonists  
Antipsychotic treatment of schizophrenia patients with both first and second 
generation antipsychotics led to a significant decrease in peak saccade velocity in 
several studies, but without major effects on antisaccade error rate or latency (Muller 
et al. 1999; Straube et al. 1999). However, switching from first generation 
neuroleptics to risperidone was related to improved antisaccade performance (Burke 
et al. 2002). Another longitudinal study showed that risperidone was associated with 
improvements in antisaccade latency whereas haloperidol was not (Harris et al. 2006). 
Studies of healthy volunteers have shown dose-dependent decrease in prosaccade 
peak velocity and either no effects or negative effects on antisaccades (Reilly et al. 
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2008). These negative effects could be due to the sedating effect of neuroleptics, as 
benzodiazepines have similar effects in healthy volunteers (de Visser et al. 2003). In 
fact, a reduction of prosaccade velocity is a highly replicated biomarker of a 
compound’s sedative effects (de Visser et al. 2003). 
 
• Dopamine agonists  
Methylphenidate and amphetamine have been reported to improve antisaccade 
performance (Klein et al. 2002; O'Driscoll et al. 2005; Wonodi et al. 2006). 
Importantly, beneficial effects of repeated amphetamine administration in the study 
by Wonodi et al. were seen only in individuals with high levels of schizotypy.  
 
• Other agents 
Antisaccade performance is also sensitive to the effects of nicotine (Newhouse et al. 
2004; Levin et al. 2006). In healthy smokers, nicotine reduces the rate of reflexive 
errors (Rycroft et al. 2006) and the latency of antisaccades (Ettinger et al. 2009). 
Healthy non-smokers also show reduced antisaccade latency with nicotine (Rycroft et 
al., 2007, Ettinger et al., 2009). A recent fMRI study suggests that the improvements 
in antisaccade performance with nicotine may be due to enhanced neural efficiency in 
the frontal cortex (Ettinger et al. 2009). Importantly, nicotine also improves 
antisaccade performance in schizophrenia (Depatie et al., 2002, Larrison-Faucher et 
al., 2004). Conversely, procyclidine, a cholinergic antagonist, leads to antisaccade 
impairments in schizophrenia (Ettinger et al. 2003).   
 
3.3.8. Oculomotor control: Smooth pursuit eye movements (SPEM) 
 
Background 
The first reports of the inability of people with schizophrenia to eye-track accurately a 
swinging pendulum date from 1908 (Diefendorf et al. 1908). About 100 years later, 
deficits in the smooth pursuit eye movements (slow eye movements that allow the 
stabilisation of a slowly moving target on the retina) are some of the most robust 
findings in schizophrenia research.  
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Paradigm description  
In the SPEM paradigm, participants have to follow a small visual target moving at a 
constant velocity without moving their head. The outcome measures include the ratio 
between the speed of the moving target and the eye movements and the rate of catch- 
up saccades that that bring the image back onto the fovea.  
 
Construct validity  
The existing data indicates SPEM are executed by a circuit linking the visual, 
mediotemporal (MT), medial superior temporal (MST), prefrontal and motor regions 
of the cortex (Newsome et al. 1988). The deficit in schizophrenia spectrum 
individuals has been attributed largely to dysfunction in frontal (O'Driscoll et al. 
1999) and motion sensitive (Lencer et al., 2003) regions. Similar to the antisaccade 
task, smooth pursuit performance has good temporal stability (Ettinger et al. 2003). 
 
Criterion validity 
• Patients, relatives and high schizotypes 
Schizophrenia patients are less able to follow the target accurately than healthy 
controls (i.e. they show reduced pursuit gain and make more catch-up and intrusive 
saccades) (Campion et al. 1992; Ross et al. 2002; Trillenberg et al. 2004). Studies in 
relatives have found similar deficits in gain (Ross et al. 2002; Ettinger et al. 2004) and 
intrusive saccades (Rosenberg et al. 1997; Ross et al. 2002). Schizotypal individuals 
have also been demonstrated to have smooth pursuit abnormalities (O'Driscoll et al. 
1998; Smyrnis et al. 2007).  
 
• Glutamate antagonist challenges 
Ketamine challenge studies have found a range of abnormalities, namely a dose-
dependent nystagmus (Radant et al. 1998), increase in the number of anticipatory 
saccades (Avila et al. 2002) and deficit in measures that test retinal (but not 
extraretinal) target processing (Weiler et al. 2000).  
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Predictive validity 
• Dopamine antagonists  
Initiation of antipsychotic treatment has been reported to be associated with a 
decrease of pursuit gain, indicating a sensorimotor impairment (Lencer et al., 2008). 
Chronic treatment appears to have similar effect, as long-term medicated patients 
perform worse than chronic non-medicated and treated first-episode patients 
(Sweeney et al. 1999; Hutton et al. 2001), but see (Thaker et al. 1999).A study 
administering low doses of haloperidol, amphetamine and placebo in a healthy 
volunteer sample reported an increase in saccadic intrusions during smooth pursuit 
with the haloperidol that were not present in the other groups (Malaspina et al. 1994). 
Similar to the antisaccade data, the observed effects could at least partly be attributed 
to the sedating action of antipsychotics, as benzodiazepines have been shown to 
decrease SPEM velocity in healthy volunteers (Reilly et al. 2008). Also, evidence 
from healthy volunteer and schizophrenia studies indicates that nicotine improves 
SPEM performance (Domino et al. 1997) and the anticholinergic compound 
procyclidine worsens SPEM performance in schizophrenia (Ettinger et al. 2003). 
 
• Dopamine agonism  
In the only currently available study of the effects of acute amphetamine on SPEM, 
no significant effect of the challenge was reported (Malaspina et al. 1994). 
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3.4. Discussion  
 
We have reviewed several cognitive and physiological biomarkers for schizophrenia 
for their potential as biomarkers for drug discovery in healthy volunteers. Several 
conclusions can be drawn on the basis of this literature.  
 
3.4.1. Reliability 
 
The MATRICS initiative stands out in terms of demonstrating reliability - that the 
same results in terms of group differences and correlations with outcome are seen in 
different centres and across time (Nuechterlein et al. 2008). This has been driven by 
the need to find drugs that improve the cognitive deficits of schizophrenia and to 
convince licensing authorities and Industry of the validity of MATRICS tests as 
markers of efficacy.  There have been no other systematic studies of reliability of the 
other biomarkers reviewed.  
 
3.4.2. Surrogate populations 
 
Many of the biomarkers show differences between controls and criterion groups - 
patients, unaffected relatives and schizotypal individuals. The lack of 
institutionalization, chronic disease and medication in the healthy volunteer groups 
confirms the idea that the abnormalities observed in schizophrenia are not due to the 
confounding factors of illness course and treatment. Instead, it indicates that cognitive 
dysfunction is a core feature of schizophrenia that is present across the disease 
spectrum (Heinrichs 2005). Familial abnormalities suggest the measures are 
endophenotypic trait biomarkers. This is not weakened if the biomarkers are also 
abnormal in schizotypal individuals since they may also carry risk genes (e.g. (Fanous 
et al. 2004)). Equally, however, unaffected family members may have schizotypal 
features – this is rarely checked in the literature – so familiarity may involve an 
element of state-dependency (see (Diwadkar et al. 2006) for effects of familial risk 
and schizotypy interacting with age for working memory performance).  
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3.4.3. Ketamine as a pharmacological model of schizophrenia 
 
The available data suggests acute ketamine administration has a general mildly 
disruptive effect on neurocognitive function in humans. The pattern of abnormalities 
has similarities to these observed in patients, relatives and high schizotypes (Krystal 
et al. 1999). It has been argue that the cognitive effects of ketamine and the symptoms 
it evokes may more closely mimic deficit symptoms and cognitive impairment in 
schizophrenia (Pomarol-Clotet et al., 2006) and this would be in keeping with lack of 
effect of haloperidol or clozapine on these phenomena. That ketamine also mimics 
some of the GABA/glutamate neurochemical abnormalities of schizophrenia suggests 
that ketamine-evoked biomarker changes in volunteers have significant construct 
validity.  
 
3.4.4. Dopamine and cognition 
 
Sensitivity to drug challenges aimed at improving cognition or clinical states was 
evident with several of the reviewed biomarkers. The most consistent finding is that 
dopaminergic treatments generally affect cognitive performance. An important 
characteristic is that enhancing dopamine function tends to selectively improve low 
baseline performance but worsen optimal performance. These findings fit in well with 
the idea that executive problems in schizophrenia spectrum disorders are due to 
suboptimal dopamine activity. Some authors have proposed a U-shaped curve to 
describe the relationship between dopamine and executive function, with hypo- and 
hyperdopaminergic states leading to cognitive abnormalities (Barch 2004). The 
proposed suboptimal dopamine function in the schizophrenia-spectrum has been 
attributed to the high activity version (val/val genotype) of the enzyme that 
metabolizes dopamine, catechol-O-methyl transferase (COMT). In support of this, 
tolcapone, an inhibitor of COMT, improved N-back performance in healthy 
volunteers at high loads (Mattay et al. 2000). Also, participants with the val/val 
genotype benefited preferentially by treatment with tolcapone in an episodic memory 
task. In a different study, low working memory performance in val/val participants 
was improved by a challenge with dextroamphetamine. The same agent led to 
deterioration at high working memory capacity in participants with the met/met 
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genotype (Fava et al. 1999). Abnormalities in other enzymes involved in clearing 
dopamine from the synaptic cleft have also been implicated, but evidence for direct 
involvement in  schizophrenia spectrum pathophysiology is scarce (Apud et al. 2006). 
A second important feature of dopamine effects is that D1 agonists appear to be more 
effective than D2 agonists and this may reflect the greater concentration of D1 
receptors in PFC than of D2. The implication of these findings is that frontal 
dopamine neurotransmission is a validated target for future drug development and a 
promising line of development.   
 
Also, the improvement of some of the biomarkers by compounds affecting non-
dopamine neurotransmitter systems in healthy volunteers (such as the benefit to eye-
tracking performance by cholinergic agonists) demonstrates that cognitive processes 
are a focal point of neuromodulatory input and the possible drug targets are not 
limited to the currently explored dopaminergic and glutamatergic systems. Secondly, 
it shows that the biomarkers have good sensitivity to efficacy, regardless of the 
mechanism of action.  
 
3.4.5. State and trait biomarkers 
 
The reviewed literature showed a variable relationship between clinical state and 
biomarker performance; some showed a degree of state-dependency whereas others 
did not. The state dependent biomarkers included salience attribution, eye-tracking 
and perhaps working memory tasks where there is some evidence for varying degree 
of improvement with atypical antipsychotics. This effect could be due to their lower 
affinity for the D2 receptor which may permit endogenous dopamine activity (Kapur 
et al. 2001). This might be particularly important for prefrontal cortical function and 
the performance on tasks that depend on its integrity, such as working memory and 
eye-tracking, reflects this. In support of this, no improvement is found with typical 
antipsychotics, despite their efficacy in controlling positive symptoms. The practical 
implication of such biomarkers is that they could potentially be validated as clinical 
end-points to assess efficacy of agents that ameliorate both cognitive and clinical 
state.  
 
Page |   
 
91 
Measures such as the MMN and P1 event-related potentials and evoked oscillations 
were generally not influenced by antipsychotic treatment or clinical state. This 
indicates that the underlying abnormality is probably state-independent and related to 
factors predisposing to schizophrenia. Findings of similar abnormalities in individuals 
at genetic or psychopathological risk for schizophrenia support this. Early visual 
ERPs and oscillatory synchrony and coherence can be informative about neural 
connectivity, dysfunction in which has been argued to be a core feature of 
schizophrenia. In other words the biomarkers relate to a neural process implicated in 
pathogenesis and so have some construct validity. Using such measures as biomarkers 
would be most useful in assessing novel agents that aim to modify the disease process 
through regulating connectivity. There is as yet little information about drug effects 
on early sensory EEG measures and this is an important priority for future research. It 
should be noted however that the state-independency most probably does not extend 
beyond early sensory ERP and oscillatory phenomena, as ERP components that mark 
later higher order cognitive information processing (e.g. P300) have been shown to 
normalize with antipsychotic treatment (Coburn et al. 1998).  
 
The state/trait distinction is not cut and dried. For example, despite the modest data 
suggesting improvement of working memory and eye-tracking performance with 
atypical antipsychotic treatment, these deficits are still found in first-degree relatives. 
This indicates that they are at least to a certain extent independent from clinical state 
and are likely to persist in a milder form even when complete remission is achieved. 
Trait biomarkers have the potential to detect drugs that prevent onset of psychosis by 
acting on mechanisms of vulnerability that may be distinct from mechanisms of the 
symptomatic state.  
 
Some studies suggest that biomarkers in the proposed target groups may have 
predictive utility for drug development. For example, McClure et al showed that 
pergolide improved visual-spatial working memory in a small sample of 25 people 
with Schizotypal Personality Disorder (diagnosed according to DSM-IV) when given 
for a short period of 4 weeks (McClure et al. 2010). This cognitive benefit was also 
associated with symptomatic improvement. 
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3.4.6. Future directions 
 
One of the clear priorities of future research is the development of non-dopaminergic 
agents that are effective in treating the cognitive and psychotic features of 
schizophrenia. As argued previously the proposed biomarkers can assist in this 
endeavour by allowing early proof of concept studies in surrogate populations. 
However, as the spectrum of clinical efficacy of such compounds emerges they will 
help to validate biomarkers for drugs targeting different aspects of schizophrenia.  
 
There is a clear need for more data on the reliability of the measures especially for the 
non-MATRICS biomarkers and for data about drug actions on the novel biomarkers 
(SDT, SAT) and the EEG measures. Further, standardised procedures need to be 
agreed on and established in each task. These are all key prerequisites in order for 
large, multi-site screening of novel compounds to take place. 
 
Further validation of biomarkers can be achieved through prospective clinical trials in 
target groups such as unaffected relatives and high schizotypes. The example of the 
study by McClure et al. show that such design can give a more clinically relevant 
picture of the properties of the drug and the biomarker than the trials where acute drug 
administration takes place (McClure et al. 2010).  
 
From the basic science point of view, more research is needed into the 
pathophysiological mechanism of the cognitive mechanisms that underlie the 
biomarkers. Dissecting the neurophysiological and molecular basis of the different 
components of complex functions such as working memory could reveal a number of 
prospective targets for drug development. Such informed approach to research and 
development will benefit from the possibility for quick validation of the resulting 
compound with the biomarker that they were derived from (in this case working 
memory).  
 
Finally, imaging techniques such as fMRI and PET are an exciting field for cognitive 
biomarker research. More research however is needed in identifying reliable and 
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pathophysiologically relevant outcome measures that will be useful in the settings of a 
clinical trial. 
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Abstract 
 
A number of compounds aimed at improving cognition in schizophrenia have failed to 
demonstrate efficacy in Phase 2 and 3 clinical trials. Translational studies using 
biomarkers in surrogate populations, such as schizotypy, could be used to assess the 
efficacy of novel compounds. In this study, we aimed to validate the sensitivity and 
inter-site reliability of cognitive biomarkers (working memory (N-back), spatial 
working memory (SWM) and verbal fluency (VF) tasks) to detect the schizotypy 
phenotype and its reversal by psychotropic drugs. Healthy volunteers scoring high or 
average on a schizotypal personality measure (122 in each group) were randomized to 
receive a single dose of risperidone, amisulpride, nicotine or placebo in a double-blind 
randomized design. We found evidence for worse performance on N-back and VF 
tasks in the high schizotypy group, replicating previous research. This effect was 
counteracted by amisulpride on N-back: it improved the high schizotypy group but 
impaired the average schizotypy controls. A similar pattern was observed in the SWM 
and VF tasks. We interpret this finding in the light of the dopamine enhancing action 
of low dose amisulpride. In contrast, risperidone impaired both groups and nicotine 
had a beneficial effect for the low baseline performers only. These effects were 
consistent across sites. These data demonstrates the utility of biomarkers in detecting 
the effect of schizotypy and its reversal by drugs that enhance dopamine and 
cholinergic function. Studies using similar design could help the early assessment of 
potential of compounds designed to improve cognition in schizophrenia. 
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4.1. Introduction 
 
Cognitive deficits are a core feature of schizophrenia (Green 2006) that predict 
functional outcome (Green et al. 2000; Hofer et al. 2005; Milev et al. 2005) and 
treatment adherence (Burton 2005). Currently available therapies offer marginal 
improvement at best (Heinrichs 2005) and development of novel agents aimed 
specifically at ameliorating cognitive deficits in schizophrenia is a recognized unmet 
need (Nuechterlein et al. 2008). 
 
In the last two decades technological advances, notably genome sequencing, 
combinatorial chemistry and high-throughput screening, led to rapid expansion of 
potential drug targets for cognition. As a result, a number of theoretically sound 
compounds have emerged from animal models as safe and effective. However, the 
clinical success rate has been dwindling, as most novel compounds fail at the initial 
tests of efficacy in human disease, phase 2 clinical trials (Hurko 2010). This trend has 
exposed drawbacks of animal models of mental illness: despite capturing certain 
aspects of the condition, they do not predict efficacy. In addition, the noisiness of the 
traditional clinical end-points in psychiatry may have contributed to the rejection of 
otherwise promising compounds. 
 
The use of biomarkers and surrogate end points to detect efficacy early in 
development has been proposed as a way of reducing the risk of failure in clinical 
development (Hurko 2009). The aim is to give a compound every chance to succeed, 
for example by selecting only a subgroup of patients that is more likely to respond or 
by recruiting groups of individuals that have limited symptom profile but lack the 
confounds associated with patient research (surrogate populations). These proof of 
concept studies precede the costly Phase 2 clinical trials which use more rigid 
diagnostic criteria, heterogeneous populations and traditional clinical end-points. 
Their principal goal is to single out the compounds that are unlikely to be effective in 
humans and thus inform internal decision making.  
 
In the case of schizophrenia, such early assessment of drug efficacy could be 
accomplished using cognitive biomarkers validated in schizophrenia (for example the 
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ones developed by the MATRICS initiative (Nuechterlein et al. 2008; Keefe et al. 
2010)) in surrogate populations such as high schizotypes. These individuals have 
personality traits corresponding to psychopathological manifestations of 
schizophrenia and also exhibit a profile of attenuated cognitive deficits (Raine 2006). 
This overlapping symptom profile, as well as evidence highlighting the common 
genetic and neurobiological basis of schizophrenia and schizotypy (Siever et al. 2002) 
support theories that see the two conditions as the two extreme ends of a spectrum of 
disorders (Meehl 1989; Tsuang et al. 2002; Lenzenweger 2006). Despite these 
similarities, schizotypal individuals are most commonly spared psychotic episodes, 
repeated hospitalizations and chronic antipsychotic treatment (Raine et al. 1995). 
Importantly for cognition research, IQ levels and education levels are largely normal 
(Raine 2006) and their cooperation with study procedures is not hampered by 
profound psychotic and negative symptoms. In contrast, a large proportion of 
schizophrenia patients have decreased IQ levels which predict negative symptoms and 
cognitive impairment (Leeson et al. 2009) thus possibly confounding the core 
cognitive deficit. 
 
In this experiment, we aimed to validate the use of cognitive biomarkers for the 
detection of cognition enhancing drug action in schizotypy samples. We used an 
online schizotypy questionnaire (Schizotypal Personality Questionnaire, (Raine 
1991)) to screen a large number of healthy volunteers and identify volunteers with 
elevated schizotypal traits. Our choice of recruitment method was based on: i) studies 
showing that SPQ scores are elevated in relatives of schizophrenia patients (Kremen 
et al. 1998; Yaralian et al. 2000; Vollema et al. 2002); ii) data demonstrating that the 
SPQ identifies reliably a sample with a high prevalence of schizotypal personality 
disorder (SPD) (Raine 1991; Kremen et al. 1998); iii) extensive literature on cognitive 
abnormalities in high SPQ scorers, for example two large studies have found that high 
scorers have eye movement abnormalities similar to the clinically diagnosed SPD and 
schizophrenia (Smyrnis et al. 2003; Smyrnis et al. 2007).  
 
Three centers in the UK administered three cognitive tasks (two probing working 
memory and one testing verbal fluency) to volunteers with high and average SPQ 
scores and challenged their performance with three psychopharmacological agents in 
a double-blind randomized design. The agents were amisulpride (partial dopamine D2 
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antagonist), risperidone (full dopamine D2 antagonist), as well as a patch of nicotine 
(cholinergic agonist). We laid out the following criteria for successful validation:  
1. The biomarkers detect cognitive deficits in the schizotypy group 
2. The effect of schizotypy is reversed by antipsychotic and/or nicotine administration 
3. The observed effects are reliable across several sites 
 
Page |   
 
100 
4.2. Methods 
 
4.2.1. Subjects and study criteria 
 
Subjects were recruited from three sites in the United Kingdom: Manchester, London 
and Cardiff via an online questionnaire measuring schizotypy (Schizotypal 
Personality Questionnaire in its short (SPQ-B, (Raine et al. 1995)) and full version 
(SPQ, (Raine 1991))). Participants were screened via telephone interview to exclude 
relevant mental health and medical conditions. Volunteers that passed the telephone 
screening were invited for a screening appointment. At screening, participants 
provided written consent and completed the full version of the SPQ again. Volunteers 
with scores in the range of 21-36 formed the control average schizotypy group (AS) 
and those with scores of 41 or above formed the high schizotypy group (HS). Male 
and female participants, aged 18-45 years, fluent English speakers and physically 
healthy (BMI, blood pressure, ECG, blood biochemistry and ECG all within normal 
range) were included in the sample. The lack of relevant medical history was 
confirmed by letter from GP. The Mini-International Neuropsychiatric Interview 
(MINI; Sheehan et al., 1998) was used to screen for psychiatric disorders. On both 
screening and randomization days participants had to test negative for alcohol 
(alcohol breath test), illicit drug use (urine dipstick) and pregnancy (urine dipstick). 
Other exclusion criteria were: known/suspected intolerance or allergy to the study 
drugs, smoking more than 5 cigarettes per day, consumption of more than 8 standard 
caffeinated drinks per day, history of migraines, significant visual or hearing 
impairment, participation in any other drug trial in the 84 days before the 
randomization visit, prescribed medication 14 days prior to or over the counter 
medicine 48 hours before the randomization. Additionally participants were asked not 
to consume caffeinated drinks on the randomization day. 
 
13,275 people completed the full version of the online SPQ and a further 9,098 filled 
out the short version, SPQ-B (SPQ mean: 22.2, SD: 13.8; SPQB mean: 8.6, SD: 4.8). 
945 individuals underwent telephone screening and 451 were excluded at this stage. 
Of the 494 people that attended a screening appointment, 250 were excluded. Data on 
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the reasons for exclusions at each stage are presented in Figure 4.1. The randomized 
sample consisted of 244 participants.   
 
4.2.2. Randomization day procedures 
 
High and average schizotypy individuals were separately randomized to one of four 
treatment arms: nicotine (7 mg nicotine patch and placebo capsule), amisulpride 
(placebo patch and 400 mg amisulpride capsule), risperidone (placebo patch and 2 mg 
risperidone capsule) or placebo arm (placebo patch and placebo capsule). The patch 
(nicotine or placebo) was applied first and the capsule (amisulpride, risperidone or 
placebo) was administered 3 hours later. The treatments were randomized by an 
independent pharmacy and both the research and the medical staff were blind to drug 
status. 
 
A set of neuropsychological tests was completed 4.5 hours after application of the 
patch and 1.5 hours after administration of the drug capsule. The timing was chosen to 
allow the drugs to reach peak plasma concentrations by the time of cognitive testing. 
This paper presents the results of tests probing working memory (N-back and Spatial 
Working Memory, SWM) and verbal fluency (VF).  The order of the tasks was 
randomized for each participant. Vital signs were assessed regularly to check for 
adverse reactions to the treatments. 
 
244 participants attended the randomization visits at the three sites (97 in Manchester, 
83 in London and 64 in Cardiff).  There was no main effect of site on the SPQ scores 
of the final high and average schizotypy groups. The high and average schizotypy 
groups consisted of 122 participants each. 59 were randomized on placebo, 62 on 
amisulpride, 62 on nicotine and 61 on risperidone (Figure 4.1). The demographic data 
of randomized participants is presented in Table 4.1.  
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Figure 4.1. Flow-chart of participants screened, excluded and randomized as part of 
the study procedures. Abbreviations: HS – high schizotypes; AS – average 
schizotypes. 
 
Table 4.1. Demographics of randomized study participants 
Demographics Average 
schizotypy 
group (mean ± 
SD) 
High 
schizotypy 
group (mean 
± SD) 
Significance 
Age 23.5 ± 5.6 23.7 ± 5.3 p = .698 
NART 113.6 ± 4.9 113.6 ± 5.2 p = .964 
Years of education 15.5 ± 2.0 16.1 ± 2.2 p = .047 
Sex 61  62 female χ2 = .898 
SPQ total score 28.7 ± 4.5 50.0 ± 5.8 p < .001 
Cognitive-perceptual SPQ subscale 10.6 ± 5.0 20.4 ± 4.7 p < .001 
Interpersonal SPQ subscale 13.3 ± 5.0 22.4 ± 5.0 p < .001 
Disorganized SPQ subscale 8.1 ± 3.4 13.5 ± 2.4 p < .001 
 
13 275 
SPQ 
responders
9 098
SPQ-B
responders
140 Medical 
history
86 Mental 
health history
140 Smoking
25 Illicit drug
abuse
19 Not 
registered 
with a GP
135 Other
125 SPQ out 
of range
53 Medical 
reasons
32 Mental 
health 
reasons
13 Drug or 
alcohol abuse
12 Unable to 
schedule
59 Placebo
62 
Amisulpride
61 
Risperidone
62 Nicotine
135 Other
27 HS
32 AS
30 HS
32 AS
33 HS
29 AS
31 HS
30 AS
22 373 Online SPQ 
and SPQ-B 
responders 
945 Telephone 
screenings:
451 excluded
494 Screening 
appointments:
250 excluded
244 Randomisations
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4.2.3. Task description 
 
Working memory (N-back) task 
A series of alphabet letters were presented one at a time on a color monitor.  
Participants were instructed not to respond until they saw the same letter twice 
following one another. The task had three levels of difficulty according to the number 
of letters in between the two matching letters. In the 1-back condition the two letters 
followed each other immediately. In the 2-back condition the target letters were 
separated by one letter and in the three back two letters separated the target letters. 
Thus participants had to hold in mind one, two or three letters. Consequently, the 1-
back condition exerted the lowest load on working memory and the 3-back condition 
the highest. There was also a baseline condition to control for attending to the task 
where participants simply needed to respond when they saw the letter ‘X’. The 
participants completed 3 blocks of each condition presented in a pseudorandom order.  
 
Spatial working memory (SWM) task 
Treasure chests were presented on a computer screen. The participants were instructed 
to search for coins in the treasure chests. Only one of the chests contained a coin at 
any one time and once it had been found it moved to a treasure chest that it had not 
been present in during the trial. The participants completed trials with 4, 6 and 8 
chests and 4 repetitions of each level of the task. A practice trial with only 3 treasure 
chests was completed to ensure the understanding of the task.  
 
Verbal fluency (VF) task 
Letter and category VF and word production were assessed during a succession of one 
minute periods. For the letter VF test participants were asked to verbally report as 
many words as they could beginning with the letters F, A and S (FAS condition). The 
experimenter wrote down the words produced. In the category VF test the categories 
used were vegetables and animals (category naming condition).  Participants were 
then asked to switch between two categories (fruit and furniture) during the same one 
minute period (category swap condition). 
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Intelligence quotient (IQ) 
IQ was determined using the National Adult Reading Test (Nelson et al. 1991), a 
reading-based estimate of premorbid intelligence. We collected this data to check that 
the groups have comparable IQ and as a potential covariate of performance. The 
participant was asked to pronounce irregularly spelt words from a standardized 
written list. The scores were determined on the basis of the number of correctly 
pronounced words.  
 
4.2.4. Statistical analysis 
 
Outcome variables 
The dependent variables in the N-back task were percentage correct, errors of 
commission and the reaction times of correct and incorrect responses for each of the 
four conditions of the task (attention, 1-back, 2-back, 3-back). In the SWM task, 4 
outcome measures were extracted for each of the three task levels: time to complete, 
mean number of choices, mean number of within and between search errors. For all 
conditions of the VF task the following measures were calculated: mean number of 
correct words, set and repetition errors.  
 
Statistical analysis 
Before analysis, the data was checked for outliers. For the N-back task, the criterion 
for outlier was performance at the attention and 3-back conditions that fell outside the 
95% confidence interval. Participants that had below 20% accuracy on the 3-back 
condition were also excluded from the analysis. For the VF task, participants were 
classed as outliers if their number of either set or repetition errors on the FAS 
condition were outside the 95% confidence interval. For the SWM task, outliers were 
identified by visual inspection of boxplots and the extreme values tables produced 
from SPSS. The dependent variables were entered into a repeated-measures ANOVA 
(with the exception of set and repetition errors of the VF task which were entered into 
univariate ANOVAs) with between-subject factors of group, drug, sex and site. The 
within-subjects factor was condition of the task (level of difficulty for the N-back and 
SWM task; condition (FAS, category naming and category swap) for the VF task). 
Covariates added into the model were IQ, age and time since dosing. Covariates that 
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were found to be non-significant were removed from the model for each variable. In 
case of a main effect of level of difficulty, polynomial contrasts were run to determine 
the character of the relationship. Significant effects of drug were investigated by a 
post-hoc simple contrast of the study drugs versus placebo. The effect of schizotypy 
was examined both in the ANOVAs and in the placebo-treated groups. Schizotypy 
group by drug interactions were explored by three way interactions between 
schizotypy, drug and level of difficulty of the task. Significant interactions were 
reported with Huyhn-Feldt correction for sphericity and were followed by univariate 
ANOVAs on the identified level of difficulty in the two schizotypy groups separately. 
In case of significant main effect of drug in these analyses, post-hoc comparisons of 
the study drugs versus placebo were then used to explore the effect of each drug in the 
two schizotypy groups. Also, to test the hypothesis that amisulpride affected the two 
schizotypy groups differentially, we performed ANOVA analyses on the level of the 
task where the interaction between group, drug and task level occurred including the 
amisulpride and placebo treatment arms only. Since this is an exploratory study with 
multiple endpoints, no correction for multiple testing was made on any of the 
analyses.  
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4.3. Results  
 
4.3.1. N-back  
 
Subjects  
For 2 participants there was no data on the N-back test available (1 AS on amisulpride 
and 1 HS on amisulpride). 2 participants (1 HS (risperidone) and 1 AS (nicotine)) 
were excluded based on the criteria for outliers. The final sample consisted of 240 
participants, 120 high and 120 average schizotypes. The two schizotypy groups used 
in the N-back analysis did not differ in terms of age, IQ and sex. The HS group had 
significantly more years of education however (p= .042). 
 
Main effects  
Performance in both schizotypy groups decreased with increasing task difficulty 
(F(3,573) = 6 383, p < .001) in a linear fashion (F(1,191) = 7.527, p < .01). The main 
effect of schizotypy was significant in the errors of commission model with the HS 
group making more errors than the AS group (F(1,46) = 6.628, p = .013). The main 
effect of drug was significant for errors of commission (F(3, 191) = 4.010, p < .01), an 
effect that was due to risperidone worsening performance in comparison with placebo 
(p = .06). Risperidone also increased the latency of correct responses (F(3, 189) = 
7.804, p <.001) and the latency of errors of commission (F3, 190) = 8.428, p <.001).  
 
Interactions 
A significant drug, schizotypy and WM load interaction was evident in the errors of 
commission model (F(9, 573) = 2.489, p = .019). The 3-back condition was confirmed 
as the level of this interaction by visual inspection of the histograms (Figure 4.2). 
Univariate ANOVA with a dependent variable of errors of commission at 3-back was 
performed separately for each schizotypy group to explore this effect. Simple 
contrasts in the HS group demonstrated that amisulpride and nicotine improved 
performance against placebo, the latter significantly (p = .024), the former at a trend 
for significance (p = .055). In the AS group risperidone and amisulpride both 
worsened performance, p = .041 and p = .076 respectively (Figure 4.2). 
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To confirm the differential effect of amisulpride on the two groups, we performed a 
post-hoc test, where only the placebo and amisulpride treated groups were retained in 
the univariate ANOVA. The outcome measure was errors of commission at the 3-
back level. The interaction between group and drug was highly significant in this 
analysis (F(1, 96) = 7.827, p < .01). 
 
Effects of covariates and site 
IQ was a significant factor in the errors of commission (F(1,191) = 5.717, p = .018) 
but not the percentage correct model. IQ and time since dosing were significant 
covariates in regards to the latency of correct responses, (F(1, 189) = 5.189, p = .024 
and F(1, 189) = 8.645, p <.01. respectively). There were no significant effects of site 
in the N-back analyses. 
 
  
 
 
 
 
 
 
 
 
Figure 4.2. Effect of study drugs on the mean number of errors of commission in the 
N-back task. Task load on the horizontal axis, mean number of errors of commission 
on the vertical axis. High schizotypy group on the left-hand side, average schizotypy 
on the right-hand side. Symbols: * = p ≤. 05; † = .05 <  p  < .10. 
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4.3.2. Spatial working memory 
 
Subjects 
For 7 subjects, no data on SWM was available (3 HS (1 on nicotine and 2 on 
risperidone) and 4 AS (2 on placebo, 1 on nicotine and 1 on risperidone). The final 
sample consisted of 237 subjects, 118 HS and 119 AS. The two schizotypy groups 
were well matched in terms of age, IQ and sex, but the HS group had significantly 
more years of education (p= .031). 
 
Main effects 
The performance on the task as measured by the number of between search errors 
decreased with difficulty (F(2, 376) = 4.527, p = 0.011) and the relationship was 
linear (F(1, 186) = 5.4909, p = .020). There were no main effects of schizotypy across 
drug conditions for any of the outcome variables (time to complete, number of 
choices per trial, within search errors or between search errors). There was no main 
effect of schizotypy in the placebo group either. There were no main effects of drug in 
any of the SWM models.  
 
Interactions 
The interaction between drug, schizotypy and task difficulty was significant in the 
between search errors model (F(6,376) = 4.257, p < .01). Inspection of the histograms 
(Figure 4.3) confirmed that this interaction was at level 3 of the task. To explore this 
effect we performed univariate ANOVAs within each schizotypy group. In the HS 
group, risperidone worsened the performance significantly in comparison with 
placebo (p = .05, Figure 4.3). No difference was found between the treatment arms in 
the AS group. To test the hypothesized differential effect of amisulpride, we repeated 
the same univariate ANOVA analyses in the groups treated with placebo and 
amisulpride only. The interaction between drug and schizotypy did not reach 
significance. 
 
Effect of covariates and site 
IQ was a significant factor in the between search errors model (F(1,188) = 6.860, p = 
.010).  Age was a significant factor in the time to complete model (F(1, 185) = 5.893, 
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p = .016). The factor of site approached significance in the between search errors 
model (F(2, 188) = 2.712, p = .069). This was due to the participants in Cardiff 
performing the task better than the ones in Manchester (p = .078) and London (p= 
.025)  
 
 
 
 
 
 
 
 
Figure 4.3. Effect of study drugs on the mean between search errors on the SWM task. 
Task load on the horizontal axis, mean number of between search errors on the 
vertical axis. High schizotypy group on the left-hand side, average schizotypy on the 
right-hand side. Symbol: * = p ≤  .05. 
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4.3.3. Verbal fluency task 
 
Subjects 
5 participants were excluded from the analysis due to being outliers on the number of 
errors on the FAS task (4 HS (3 on nicotine, 1 on amisulpride) and 1 AS (nicotine)). 
The final sample consisted of 117 HS and 120 AS participants. The two groups did 
not differ in terms of age and IQ. The HS group had higher number of years of full-
time education at a trend for significance (p = .082). 
 
Main effects 
The main effect of schizotypy approached overall significance in respect to the correct 
words model, the high schizotypes performing worse than the controls (F(1, 188) = 
3.673, p = .057).This trend was sustained in the placebo-treated groups where the 
effect was significant (F(1,46) = 6.063, p = .018). There was a trend for significance 
for the factor of drug in respect to the number of correct words (F (3,188) = 2.371, p = 
.072). Simple contrasts showed that the effect was due to risperidone decreasing the 
mean number of correct words produced in comparison with placebo, p = .01 (Figure 
4.4).  
 
Interactions 
The correct words model revealed an interaction between drug, schizotypy and 
condition that approached significance (F(6, 376) = 2.023, p =.062). Visual inspection 
of the histograms presented in Figure 4.4 indicated that the level of the interaction is 
the category swap condition. A univariate ANOVA on this level was performed for 
the two schizotypy groups separately. In the controls, all study drugs led to worsening 
of performance (p = .012, p = .038 and p < .01 for amisulpride, nicotine and 
risperidone respectively). No such effects were observed in the HS group.  
 
To test the hypothesized differential effect of amisulpride on the two schizotypy 
groups, we performed the univariate ANOVA in the category swap condition for the 
placebo and amisulpride treated groups only. This analysis revealed a significant drug 
and schizotypy interaction (F(1, 95) = 4.574, p = .035), indicating that while 
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amisulpride improved performance in the HS group, it had the opposite effect in the 
AS controls (Figure 4.4).   
 
Effect of covariates and site 
IQ was a significant covariate for the correct words model (F(1,186) = 19.441, p 
<.001). There were no significant effects of site in the VF models.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Effect of study drugs on the mean number of correct words on the VF task. 
The two schizotypy groups on the horizontal axis, mean number of correct words on 
the vertical axis. Symbols: * = p ≤ .05. 
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4.4 Discussion 
 
In this double-blind placebo-controlled study we aimed to validate the use of 
cognitive biomarkers to detect drug action in schizotypy. We laid out three validation 
criteria: the biomarkers should be sensitive to the schizotypy phenotype; this effect of 
schizotypy should be reversed by some or all of the drug challenges; the first two 
criteria should be consistent across different sites. In this section we will discuss the 
results of the study in respect to each of those in turn.  
 
4.4.1. Criterion 1: Sensitivity of the biomarkers to the schizotypy 
phenotype 
 
Two of the tasks satisfied this requirement. On the N-back task, the HS group 
performed worse than the controls in respect to the 3-back errors of commission 
measure, consistent with a subtle working memory deficit. This is in line with the 
results from a recently published study on a subgroup of the same sample where we 
again found evidence of behavioural and neurophysiological abnormalities during a 
working memory task (Chapter 6). Such working memory deficits are one of the most 
widely replicated findings in both schizotypy and schizophrenia and are considered a 
neurocognitive hallmark of the schizophrenia spectrum (Lee et al. 2005; Raine 2006). 
The performance in high schizotypes tends to be intermediate between that of healthy 
controls and schizophrenia patients (Trestman et al. 1995). On the VF task, the HS 
group produced significantly lower number of words on the category swap condition, 
but not on FAS or category naming conditions. This indicates that the detected 
abnormality may not due to verbal fluency impairment per se, but rather a central 
executive mechanism related to working memory (mental manipulation and inhibition 
of irrelevant cues). Hence, both biomarkers appear to be sensitive to the effect of 
schizotypy on executive function in its working memory and inhibitory domains.  
 
The findings of deficits on the N-back but not the SWM task could be attributed to the 
key differences that exist between the two working memory tasks. In the former the 
presentation of each stimulus was very brief (1 second) while in the latter it was 
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unlimited. Previous research has indicated that schizophrenia patients require longer 
stimulus presentations to achieve stable working memory representations (Hartman et 
al. 2003; Fuller et al. 2005; Fuller et al. 2009). There is also evidence for 
abnormalities in the earliest stages of information processing driving higher-order 
cognitive impairment (Butler et al. 2007; Haenschel et al. 2007). In addition, 
cognitive performance in patients can sometimes be improved by increasing the 
duration of the encoding phase of the tasks (Tek et al. 2002; Lencz et al. 2003). In the 
previously mentioned study on a sub-sample of the HS, we found that they showed 
abnormal WM performance on a working memory task that allowed only brief 
encoding but intact performance in cognitive tasks with unlimited stimulus 
presentation (Chapter 6). This data indicates that early information processing is a key 
component in the pathogenesis of schizophrenia spectrum cognitive abnormalities. 
The practical implication is that these abnormalities will be more easily demonstrable 
using tasks that allow only brief stimulus encoding.  
 
4.4.2. Criterion 2: Reversal of the effect of schizotypy by drug 
challenge 
 
All drug challenges induced effects that were detectable using the proposed 
biomarkers, but amisulpride provided the clearest evidence for reversal of the 
schizotypy effect on cognition. In the HS group it reduced the number of errors of 
commission on the N-back task but worsened the performance in the AS group 
(Figure 2). In the SWM task the same effect was evident in respect to the between-
search errors model, but this effect did not reach significance (Figure 3). In VF the AS 
produced significantly more words than the HS in the category switch task when 
placebo treated. AS participants treated with amisulpride produced significantly fewer 
correct words whereas performance improved non-significantly in the HS (Figure 4). 
A direct comparison between the amisulpride and placebo treated groups revealed that 
amisulpride had differential effect on the two schizotypy groups. These effects of 
amisulpride could be explained by data showing that when given in low doses (less 
than 10 mg/kg) it blocks the presynaptic dopamine receptors and enhances dopamine 
neurotransmission (Schoemaker et al. 1997). This is compatible with the results from 
a study that found improvement of working memory performance in schizotypal 
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personality disorder (SPD) after acute amphetamine administration (Kirrane et al. 
2000). The benefit of dopamine enhancing agents in schizotypy is not limited to acute 
challenges, as a recently published study also found improvement in the cognitive 
function of SPD patients after 4-week treatment with pergolide, a combined D1 and 
D2 receptor agonist (McClure et al. 2010). Further, dopamine agonist challenges in 
humans and primates improve cognition, but only in those with low baseline 
performance (Barch 2004). These findings fit in well with the idea that the 
relationship between dopamine and executive function is best described by a U-
shaped curve (Barch 2004). According to this theory, hypodopaminergic states of the 
prefrontal cortex (e.g. schizophrenia spectrum disorders) improve with enhancement 
of dopamine function, while people that have optimal dopamine function are 
worsened by these challenges.   
 
In contrast to amisulpride, risperidone worsened spatial working memory in HS and 
verbal fluency performance of the AS group or did not otherwise benefit the 
performance. These findings are consistent with reports that administration of acute 
high potency D2 antagonists to healthy volunteers induces cognitive impairment 
(Luciana et al. 1998; Honey et al. 1999; Mehta et al. 1999). The observed effect of 
risperidone in our study could have also at least partly been due to its sedative effects 
(Miller 2004). In support of this interpretation, the latency of N-back responses was 
increased in the risperidone treatment arm. These sedative effects have been attributed 
to risperidone’s H1-receptor affinity (Richelson et al. 2000).  
 
Nicotine had mixed effects on cognition. However, it showed an overall tendency to 
improve the HS group but impair the AS one. In N-back it reduced the number of 
errors of commission in the HS group but had no effect on AS performance. In VF 
however, nicotine did not improve performance in the HS group but impaired the AS 
control group. This suggests that the two tasks engage different cognitive 
mechanisms. The beneficial effect of nicotine on N-back could reflect its well-known 
ability to improve attention (Newhouse et al. 2004). This may have interfered with the 
requirement for inhibition in the category swap condition of VF.  
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4.4.3. Criterion 3: Site-independence of criteria 1 and 2 
 
There were no differences between the sites in respect to the main effect of 
schizotypy, drug or their interaction. The only interaction between schizotypy group 
and site that approached significance was found in between search errors model of the 
SWM. As this effect was not sustained in other measures of the SWM test or indeed 
one of the other two tasks, we consider this to be a random finding. 
 
4.4.4. Limitations  
 
Several limitations of this study exist. First and foremost, an inherent problem with 
validating biomarkers is the lack of drugs known to reliably improve cognition in 
schizophrenia. Consequently there is currently no criterion treatment against which 
biomarkers, surrogate populations and novel treatments can be validated.  
 
Another consideration is that our choice of schizotypy groups could have lessened the 
main effect of schizotypy. Firstly, we used a self-reported schizotypy measure (Raine 
1991; Raine et al. 1994) which may have missed certain domains of schizotypal 
psychopathology (such as circumstantial thinking and speech, constricted affect, odd 
behaviour and appearance). These may be evident in a clinical interview but often 
remain unrecognized by the schizotypal individuals (Compton et al. 2008). As a 
result, it may be that the HS group did not fully capture the extreme of the schizotypy 
spectrum. Another observation that supports this conclusion is that a large part of the 
total psychopathology score in the HS group (50.0 ± 5.8) was accounted for by the 
cognitive-perceptual subscale (20.4 ± 4.7). This may be significant in the light of 
theories that distinguish between neuro- and pseudo-schizotypy (Raine 2006). The 
former is argued to be genetically akin to schizophrenia and is characterized by 
interpersonal, disorganized and cognitive symptoms while the latter is related to 
psychosocial factors and features cognitive-perceptual psychopathology and intact 
cognition. It is therefore possible that a significant proportion of the HS sample was 
made up of pseudo-schizotypy individuals which lessened the overall degree of 
cognitive impairment in the group. Secondly, the HS group included only individuals 
who were non- or light-smokers (less than 5 cigarettes per day) and had no history or 
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presence of substance abuse. Given the link between schizotypy and increased 
incidence of substance abuse and smoking (Esterberg et al. 2007; Barkus et al. 2010) 
it could be argued that our high schizotypy sample may be particularly high 
functioning. On a similar note, the HS group had more years of education relative to 
the AS control group. Thirdly, we also excluded people with concurrent past or 
present Axis I disorders, including depression. Since depression is common in 
schizotypal personality the high schizotypy sample may not have been representative. 
However, we wished to avoid the effects of current or past symptoms of depression 
on performance. Finally, the use of an average scoring schizotypy control group rather 
than low scoring one could also have led to lessening of the effect of schizotypy. 
Despite these considerations regarding our choice of schizotypy groups, two of the 
tasks demonstrated the anticipated effect of schizotypy. We interpret this as further 
evidence for the validity of these cognitive biomarkers. 
 
Since the statistically significant effects were not corrected for multiple comparisons 
and the control group was average rather than low scorers, further studies are required 
to validate these biomarkers in high schizotypy against a low scoring control sample.  
 
4.4.5. Conclusion 
 
In summary this double-blind three-centre study showed that biomarker measures of 
WM can reliably detect the schizotypy phenotype and are also sensitive to the action 
of psychopharmacological agents, such as amisulpride, risperidone and nicotine. The 
experiment’s large sample size and the consistency of effects across sites strengthen 
the validity and reliability of these conclusions. The reversal of the schizotypy effect 
by amisulpride adds further weight to claims that suboptimal prefrontal cortex 
dopamine neurotransmission is at the core of the schizophrenia spectrum disorders. 
These results support the use of cognitive biomarkers and surrogate populations such 
as schizotypy in translational studies aimed at early assessment of efficacy of 
cognition enhancing agents in schizophrenia.  
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CHAPTER 5 
 
Preparing for proof of concept studies of  
novel cognitive enhancing agents in schizotypy:  
Who is a control? 
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Contribution of the thesis author: The study was designed by the author with the 
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average and high schizotypy samples of the Manchester site of the Schiz01 study; he 
analyzed the presented study data, wrote the first draft of the article that is featured in 
this thesis and is currently coordinating the input from the co-authors.    
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Abstract 
 
Increasing number of compounds aimed at improving cognition in schizophrenia fail 
to demonstrate efficacy at clinical stages of drug development. Translational studies 
using cognitive biomarkers in surrogate populations of schizophrenia could help 
identify the compounds destined to fail early in their development. Using measures to 
define high schizotypy psychometrically may be a particularly useful approach to 
identify populations featuring moderate schizophrenia spectrum-related cognitive 
impairment. However there is still no agreement regarding the optimal control group 
for cognitive studies in schizotypy, as both average and low scoring individuals have 
been used. In addition, more work is needed to define the boundaries of cognitive 
impairment in schizotypy. In this study we aimed to investigate these two questions 
by comparing the cognitive performance of low, average and high scoring schizotypes 
on a range of cognitive biomarker and eye-tracking tasks. We found a linear 
relationship between schizotypy and performance on two working memory tasks and 
the error rate on the antisaccade eye-tracking task.  In contrast, average schizotypy 
was marginally superior to low schizotypy in respect to only one task that detected the 
schizotypy effect (verbal fluency). In addition, two other tasks (salience attribution 
and smooth pursuit eye movement tasks) did not distinguish between the three groups. 
These results suggest that maximum schizotypy effect in regards to working memory 
and inhibition-related cognitive performance can be obtained in low vs. high 
schizotypy design. This conclusion fits with the full dimensional model of schizotypy, 
which sees liability to schizophrenia and its associated cognitive impairment as a 
continuously distributed trait in the population. In addition, we demonstrated that 
some areas of cognitive impairment in schizophrenia (such as salience attribution) are 
probably related to state-specific processes (such as psychotic symptoms) and may 
not yield meaningful results in proof of concept studies in schizotypy.  
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5.1. Introduction  
 
Cognition is a core symptom domain in schizophrenia that predicts functional 
outcome (Green et al. 2000; Hofer et al. 2005; Milev et al. 2005) and treatment 
adherence (Burton 2005). However, it is left largely unaffected by currently available 
medication (Heinrichs 2005) and the development of agents to affect the cognitive 
deficits in schizophrenia is a recognized unmet need (Nuechterlein et al. 2008). 
 
A key reason for the lack of effective cognitive enhancing therapy in schizophrenia is 
the high attrition rate of novel agents, especially in phase 2 and 3 clinical trials (Hurko 
2010). Compounds fail mostly because of lack of clinical efficacy, a trend that reveals 
critical missing links between the animal and clinical stages of drug development. 
One way of addressing this issue is to single out agents that are likely to fail in small 
Phase 1 clinical studies (Hurko 2009). The aim is to give a compound every chance to 
succeed, for example by selecting only a subgroup of patients that is more likely to 
respond or by recruiting groups of individuals that have only limited symptom profile 
but lack the confounds associated with patient research (surrogate populations). Such 
proof of concept studies precede the costly Phase 2 clinical trials and use biomarkers 
to assess efficacy instead of the traditional clinical end-points.  
 
In the case of schizophrenia, such early assessment of cognitive enhancers could be 
accomplished using cognitive biomarkers in surrogate populations such as high 
schizotypes. These individuals have personality traits corresponding to the 
schizophrenia psychopathology and also exhibit a profile of attenuated cognitive 
deficits (Raine 2006). This overlapping symptom profile, as well as evidence 
highlighting the common genetic and neurobiological basis of schizophrenia and 
schizotypy (Siever et al. 2002) support theories that see the two conditions as the two 
extreme ends of a spectrum of disorders (Meehl 1989; Tsuang et al. 2002; 
Lenzenweger 2006). Despite these similarities, schizotypal individuals are most 
commonly spared psychotic episodes, repeated hospitalizations and chronic 
antipsychotic treatment (Raine et al. 1995). Importantly for cognition research, IQ 
levels and education levels are largely normal (Raine 2006) and their cooperation with 
study procedures is not hampered by psychotic and negative symptoms.  
Page |   
 
120 
 
Defining schizotypy psychometrically is an effective way of identifying populations 
with schizophrenia-like cognitive impairment (Smyrnis et al. 2003; Smyrnis et al. 
2007) and may be a useful approach in proof of concept studies. However it is still 
unclear whether individuals scoring in the average or low ranges on questionnaires 
measuring schizotypal personality traits (such as the Schizotypal Personality 
Questionnaire, SPQ (Raine 1991)) should form the comparator group used against 
high scorers. This controversy reflects the existence of two theoretical frameworks to 
describe the relationship between schizotypy and schizophrenia. The first framework 
proposes that only a small percentage of people have a key disturbance, the results of 
a dominant combination of schizophrenia risk genes, that is manifested by the 
development of schizophrenia or extreme schizotypal symptoms and neurocognitive 
deficits (Matthysse et al. 1986; Meehl 1989). According to this threshold model, there 
should not be any difference in the neurocognitive performance of healthy volunteers 
with anything but the most extreme schizotypal symptoms (i.e. average and low 
scoring schizotypes should have the same cognitive performance). The second 
theoretical framework postulates that the schizotypal personality traits are a 
continuum from health to schizophrenia (‘full dimensional model’). These authors 
argue that there is no need to introduce arbitrary cut-off points above which 
schizotypy lies (Eyseneck et al. 1976; Claridge 1994). Instead, the vulnerability to 
schizophrenia is represented by correlated schizotypal and neurocognitive symptoms 
that have a continuous distribution in the population. According to this model, the 
most appropriate control group would be low scoring schizotypes, as they should have 
the most intact cognitive performance.  
 
In addition to defining the optimum control group, more work is needed to identify 
the boundaries of cognitive impairment in schizotypy. It is probable that while some 
cognitive deficits are associated with the core schizophrenia spectrum deficit, other 
cognitive domain abnormalities are driven primarily by the psychotic process and are 
therefore not reliable measures of the schizotypy phenotype. For example, we found 
recently that high schizotypy scorers have impaired working memory performance 
relative to low schizotypy scorers in tasks that require swift information processing 
but have normal executive function in paradigms with longer encoding periods 
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(Chapter 6). This suggests that speed of information processing is a more reliable 
biomarker of the schizophrenia spectrum phenotype than executive function.  
 
In this study we aimed to investigate these two questions by comparing the cognitive 
performance of low, average and high scoring schizotypes on a range of cognitive 
biomarker tasks. We included general cognitive tasks (tests of working memory and 
verbal fluency), as well as measures probing salience attribution and eye-tracking 
abilities. Our first hypothesis was that some but not all tasks will detect the schizotypy 
phenotype. Our second hypothesis was that the pattern of cognitive performance in 
the two control groups will favour the full dimensional model e.g. average 
schizotypes will have an intermediate performance between that of the low and high 
schizotypes.    
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5.2. Methods 
 
5.2.1. Subjects, study criteria and design 
 
Average and high scoring schizotypes were recruited from three sites in the United 
Kingdom (Manchester, London and Cardiff) via an online version of the Schizotypal 
Personality Questionnaire in its short (Raine et al. 1995) and full version (Raine 
1991). Participants were screened using telephone interview to exclude mental health 
and medical history. The included participants were invited to a screening 
appointment at which consent was obtained and the full SPQ was completed again. 
Volunteers that had a score in the 21-36 range were assigned to the average 
schizotypy (AS) group and those scoring 41 or above formed the high schizotypy 
(HS) group. Other inclusion criteria at the screening visit were age between 18 and 45 
years, fluency in the English language, no medical history and body mass index in the 
range of 18-30. Exclusion criteria were history or presence of mental health disorders 
(screened for using the Mini-International Neuropsychiatric Interview (MINI; 
Sheehan et al., 1998)), daily consumption of more than 5 cigarettes or more than 8 
standard caffeinated drinks, history of migraines, significant visual or hearing 
impairment,  
 
The included participants were invited a day of testing. On the day participants were 
allowed to take part if the criteria for the study had not been violated and if there had 
been no prescribed medication in the 14 days prior before or over-the-counter 
medicine in the 2 days before. At the onset of the experiment, a nicotine (7 mg) or 
placebo patch was applied. Three hours later a capsule of either amisulpride (400 mg), 
risperidone (2 mg) or placebo was administered. Various neuropsychological tests 
were completed 1.5 hours after the capsule administration. In the current analysis, 
only participants that had received placebo patch and placebo capsule were included 
in the analysis (27 HS and 31 AS).  
 
A group of low scoring schizotypes (LS) was recruited in Manchester only. The 
participants attended a single appointment where the schizotypy status was confirmed 
(SPQ score of 9 or less) and the same inclusion and exclusion criteria as the ones 
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described earlier were applied. The included LS participants completed the same 
battery of neuropsychological tests as the AS and HS but received no treatment. 35 
participants were recruited of which 4 were excluded due to SPQ scores out of range 
and 1 due to medical history.  
 
The demographics of the participants included in the study are presented in table 5.1.  
 
Table 5.1. Demographics of the three study groups 
Demographics High 
schizotypy 
group: 
mean ±SD 
Average 
schizotypy 
group: 
mean ±SD 
Low 
schizotypy 
group: 
mean ±SD 
Significance 
values 
SPQ 50.1 ± 6.1 27.8 ± 4 3.8 ± 3.1 p < .001 
Age 25.3 ± 5.0 23.8 ± 4.6 25.4 ± 5.8 p = .239 
IQ 114.2 ± 6.2 114.2 ± 4.9 113.8 ± 6.0 p = .958 
Years of education  16.3 ± 2.2 15.5 ± 1.7 17.4 ± 2.6 p = .004 
Sex 13 f 14 m 16 f 15 m 15 f 15 m χ2= .125 
 
 
5.2.2. Task description 
 
Working memory (N-back) task 
A series of alphabet letters were presented one at a time on a color monitor.  
Participants were instructed not to respond until they saw the same letter twice 
following one another. The task had three levels of difficulty according to the number 
of letters in between the two matching letters. In the 1-back condition the two letters 
followed each other immediately. In the 2-back condition the target letters were 
separated by one letter and in the three back two letters separated the target letters. 
Thus participants had to hold in mind one, two or three letters. Consequently, the 1-
back condition exerted the lowest load on working memory and the 3-back condition 
the highest. There was also a baseline condition to control for attending to the task 
where participants simply needed to respond when they saw the letter ‘X’. The 
participants completed 3 blocks of each condition presented in a pseudorandom order.  
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Spatial working memory (SWM) task 
Treasure chests were presented on a computer screen. The participants were instructed 
to search for coins in the treasure chests. Only one of the chests contained a coin at 
any one time and once it had been found it moved to a treasure chest that it had not 
been present in during the trial. The participants completed trials with 4, 6 and 8 
chests and 4 repetitions of each level of the task. A practice trial with only 3 treasure 
chests was completed to ensure the understanding of the task.  
 
Verbal fluency (VF) task 
Letter and category VF and word production were assessed during a succession of one 
minute periods. For the letter VF test participants were asked to verbally report as 
many words as they could beginning with the letters F, A and S (FAS condition). The 
experimenter wrote down the words produced. In the category VF test the categories 
used were vegetables and animals (category naming condition).  Participants were 
then asked to switch between two categories (fruit and furniture) during the same one 
minute period (category swap condition). 
 
Salience Attribution Test (SAT)  
On this task participants responded quickly to a probe (a black square) in order to win 
money (possible earnings for the whole task ranging between £5-20). Coloured 
images of household objects or animals were presented immediately before the probe. 
One stimulus dimension (e.g. red vs. blue – relevant dimension) very reliably 
predicted the availability or non-availability of money while the other (e.g. animals 
vs. household objects – irrelevant dimension) was not a reliable predictor. The 
rewarded stimulus feature (e.g. blue) generally comes to speed responding for reward 
relative to the unrewarded one (e.g. red), providing a measure of implicit adaptive (i.e. 
appropriate) salience; participants are usually also able to report this association 
overtly using visual analogue scales (explicit adaptive salience). If faster 
responding/greater reward rating occurs to one of the irrelevant features over the other 
(e.g. animals faster over household objects), this indicates aberrant salience. 
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Eye-tracking (ET) task  
Eye-tracking is a technique that allows the recording of the pattern of eye movements 
in response to task conditions. In the prosaccade task a novel visual target appeared in 
the periphery and participants had to direct their gaze at it. In the antisaccade task 
participants had to inhibit the prosaccadic response to a new stimulus and instead look 
at its mirror image location on the opposite side of the screen. In the Smooth Pursuit 
Eye Movement (SPEM) paradigm, participants were required to follow a small visual 
target moving at a constant velocity without moving their head. The participants 
completed the SPEM task at three target speeds.  
 
Intelligence quotient (IQ) 
IQ was determined using the National Adult Reading Test (Nelson et al. 1991), a 
reading-based estimate of premorbid intelligence. We collected this data to check that 
the groups have comparable IQ and as a potential covariate of performance. The 
participant was asked to pronounce irregularly spelt words from a standardized 
written list. The scores were determined on the basis of the number of correctly 
pronounced words.  
 
5.2.3. Statistical analysis 
 
Outcome variables 
The dependent variables in the N-back task were percentage correct, errors of 
commission and the reaction times of correct and incorrect responses for each of the 
four conditions of the task (attention, 1-back, 2-back, 3-back). In the SWM task, 4 
outcome measures were extracted for each of the three task levels: time to complete, 
mean number of choices, mean number of within and between search errors. For all 
conditions of the VF task the following measures were calculated: mean number of 
correct words, set and repetition errors, mean number of correct transitions on the 
category swap condition.  The dependent variables in the SAT were reaction time, 
adaptive and aberrant salience based on reaction time, omission errors and premature 
responses. In the prosaccade and antisaccade conditions of the ET task, the following 
variables were calculated: frequency of saccade errors, percentage of corrections after 
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error, as well as latency, gain and peak velocity of the correct saccades. For SPEM, 
the saccadic frequency during pursuit was calculated for each target speed.  
 
General description of pre-planned statistical analysis 
Before analysis, the data was checked for outliers. For N-back, the criterion for outlier 
was performance at both the attention and 3-back condition outside the 95% 
confidence interval. Participants that had below 20% accuracy on the 3-back 
condition were also excluded from the analysis. For the VF task, participants were 
classed as outliers if their number of either set or repetition errors on the FAS 
condition were outside the 95% confidence interval. For the SWM task, outliers were 
identified by visual inspection of boxplots and the extreme values tables produced 
from SPSS. The dependent variables were entered into a repeated-measures ANOVA 
(with the exception three VF variables (set errors, repetition errors and mean number 
of correct transitions) which were entered into univariate ANOVAs) with between-
subject factors of group, sex and site. The within-subjects factor was level of 
difficulty or condition of the task. IQ, age and years of education were added as 
covariates to the model and were retained if statistically significant. In case of a main 
effect of level of difficulty, polynomial contrasts were run to determine the character 
of the relationship. In the case of a main effect of group of schizotypy, polynomial 
and LSD comparisons were performed to compare the three groups). In case of a 
group and level interaction, simple contrasts between the different task levels were 
performed to determine the level of the interaction.    
 
For the SAT only, we performed correlations between the variables and the four 
subscales of the OLIFE questionnaire. This was based on a previously published data 
showing a correlation between aberrant salience and the Introvertive Anhedonia 
subscale. 
 
5.2.4. Ethical Approval 
 
The study has been approved by The University of Manchester Ethics committee 
(reference number 08176) and has been carried out in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki. 
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5.3. Results 
 
5.3.1. N-back task  
 
Task difficulty 
On the measure of percentage correct the main effect of level of difficulty was highly 
significant (F(3, 222) = 55.058, p < .001) due to worsening of performance with 
increasing task difficulty (F(1, 74) = 119.789, p <.001). The main effects of task 
difficult in the latency of correct responses and error of commission models were 
significant (F(3, 222) = 101.507, p<.001 and F(3, 222) = 30.322, p<.001 
respectively), due to a linear increase in reaction times with higher task difficulty 
(F(1, 74) = 224.494, p<.001 and F(1, 74) = 41.590, p<.001 ). 
 
Main effect of schizotypy 
The main effect of schizotypy group was not significant in the percentage correct 
model, but its interaction with task difficulty approached significance (F(6,222) = 
1.936, p = .076). The most difficult condition, 3-back, was identified as the level of 
the interaction through contrasting the different task conditions. The univariate 
ANOVA with a dependent variable of percentage correct at 3-back revealed a 
significant main effect of schizotypy (F(2,74), = 3.165, p = .048). The polynomial 
contrast confirmed that a linear relationship exists between this variable and the extent 
of schizotypy (T = 2.41, p = .024, Figure 5.1). In the contrasts between the groups, LS 
but not AS was significantly different from the HS (T = 2.51, p = .014 and T = 1.034, 
p = .304 respectively).  
 
In the errors of commission model the main effect of schizotypy group was significant 
(F(2,84) = 3.908, p = .001). This was due to HS making more errors of commission 
than AS and LS (T = 2.770, p =.007 and T = 2.387, p = .020 respectively). Schizotypy 
group also interacted with level of difficulty (F(6, 219) = 6.095, p < .001). 3-back was 
indentified as the level of the interaction by contrasting the different conditions and 
we performed am univariate ANOVA with errors of commission at 3-back as a 
dependent variable. The polynomial contrast revealed that the relationship between 
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the number of errors of commission and schizotypy was linear (T = 3.720, p < .001, 
Figure 5.1). The main effect of schizotypy group was highly significant (F(2,88), = 
3.628, p < .001), due to worse performance in HS relative to AS (T = 2.642, p =.010) 
and LS (T = 2.862, p =.005).  
 
The factor of schizotypy group had no main effect on the latencies of correct 
responses and errors of commission. It also did not interact with task difficulty in 
these two models.   
 
Covariates 
The covariate of IQ approached significance in the errors of commission model (F(1, 
73) = 3.040, p = .085). 
 
 
 
 
 
 
 
 
Figure 5.1. Main effect of schizotypy group on the N-back task measures.  
Symbols: * = p ≤ .05 for comparison versus the high schizotypy group.  
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5.3.2. Spatial working memory 
 
Task difficulty 
The main effect of task difficulty was significant in all four SWM models: F(2, 140) = 
446.625, p < .001 for number of choices; F(2, 140) = 10.804, p < .001 for within 
search errors; F(2, 140) = 41.592, p < .001 for between search errors; F(2, 140) = 
753,563, p < .001 for time needed for completion of each level. The polynomial 
contrasts revealed that the effect was due to linearly decreasing performance and 
increasing time needed to complete with increasing task difficulty.  
 
Schizotypy effect 
The main effect of schizotypy approached significance in the between search error 
model (F2, 71) = 2.649, p = 0.78). This effect was due to LS making lower number of 
between search errors at trend for significance relative to HS (T = 1.847, p = .069) 
and AS (T = 1.925, p = .058). Schizotypy group also interacted with task difficulty in 
respect to the total number of choices (F(4, 140) = 2.933, p = .023), and between 
search errors (F(4, 142) = 4.068, p = .004). Contrasting the different task indicated 
that the interaction occurred at level 3 (8 chests). A univariate ANOVA at level 3 with 
a within-subject factor of total number of choices revealed a significant main effect of 
schizotypy group (F(2, 70) = 3.267, p = .044, Figure 5.2). The relationship between 
schizotypy and total number of choices was linear (T = 2.413, p = .018) even though 
the there was no statistically significant difference between LS and the other two 
groups in LSD comparisons (T = 1.063, p = .292 and T = 1.310, p = .195 for 
comparisons vs. AS and HS respectively). The factor of schizotypy group also had a 
significant main effect on the univariate ANOVA at level 3 using a within-subject 
factor of between search errors (F(2, 71) = 4.204, p = .019, Figure 5.2). The 
relationship between schizotypy group and between search errors was linear (T = 
3.701, p<.001) and this was reflected in better performance in LS relative to AS (T = 
2.400, p =.019) and HS (T = 2.458, p =.016).   
 
Covariates 
There were no significant covariates in the SWM models. 
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Figure 5.2. Effect of schizotypy group on the SWM task. Symbol: * = p ≤ .05 for 
comparisons versus the high and average schizotypy groups. 
Low schizotypy group
Average schizotypy group
High schizotypy group
Main effect of schizotypy group on the 
mean number of choices at level 3 of SWM
13.0
13.5
14.0
14.5
15.0
15.5
16.0
16.5
17.0
M
ea
n
 
n
u
m
be
r 
o
f c
ho
ic
es
Schizotypy group
M
ea
n
 
n
u
m
be
r 
o
f c
ho
ic
es
Main effect of schizotypy group on the 
between search errors at level 3 of SWM 
.0
.5
1.0
1.5
2.0
2.5
3.0
M
ea
n
 
n
u
m
be
r 
o
f b
et
w
ee
n
 
se
ar
ch
 
er
ro
rs
Schizotypy group
*
M
ea
n
 
n
u
m
be
r 
o
f b
et
w
ee
n
 
se
ar
ch
 
er
ro
rs
Page |   
 
131 
5.3.3. Verbal fluency task 
 
Schizotypy effect 
The main effect of schizotypy group reached significance in the correct words model 
(F(2, 74) = 3.216, p = .046, Figure 5.3). This was due to HS having producing 
significantly lower number of correct words relative to both AS (T = 2.524, p = .014) 
and LS (T = 2.055, p = .043). The relationship between schizotypy and performance 
in this analysis was quadratic at trend for significance (T = 1.815, p = .076), 
indicating that AS had marginal superiority over LS. The main effect of schizotypy 
group was also significant in respect to the number of correct transitions on the 
category swap VF task (F(2, 74) = 4.308, p = .017, Figure 5.3). Pairwise comparisons 
demonstrated that HS had made significantly lower number of correct transitions 
compared to both AS (T = 2.572, p = .012) and LS (T = 2.067, p = .042). The 
relationship between schizotypy and transitions was confirmed to be quadratic by 
polynomial contrasts (T = 2.12, p = 0.037). The factor of schizotypy group had no 
main effect on the set and repetition error models.  
 
Covariates 
IQ was a highly significant covariate in the correct words model (F(1,74) = 18.723, p 
<.001) and the number of successful transitions model (F(1,74) = 10.587, p =.002). 
 
 
 
 
 
 
 
 
Figure 5.3. Effect of schizotypy group on the VF task. Symbols: * = p ≤ .05 for 
comparisons versus the high schizotypy group.  
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5.3.4. Salience Attribution Test 
 
Schizotypy effect 
Schizotypy was not a significant factor in any of the seven SAT models (reaction 
time, implicit and explicit adaptive salience, implicit and explicit aberrant salience, 
number of omissions and premature responses).  
 
Covariates 
IQ was a significant factor in the reaction time (F(1,82) = 4.291, p = .041), adaptive 
explicit salience measure (F(1,81) = 9.724, p = .003) and number of omissions 
(F(1,83) = 6.263, p = .014) models. Age was a significant covariate in respect to 
reaction time (F(1,82) = 7.823, p = .006). 
 
OLIFE questionnaire correlation 
The four OLIFE subscales did not correlate significantly with any of the seven SAT 
variables.  
 
5.3.5. Prosaccade and antisaccade eye-tracking task 
 
Schizotypy effect: prosaccade task 
In the prosaccade condition there was no main effect of schizotypy in any of the four 
prosaccade models (number of errors, latency, gain and velocity of the saccades).  
 
Schizotypy effect: antisaccade task 
In the antisaccade condition schizotypy was a significant factor in regards to the 
number of antisaccade errors model (F(2, 73) = 8.219, p = .001, Figure 5.4). The 
polynomial contrast showed that this relationship between schizotypy and antisaccade 
errors is linear (p < .001). The pairwise comparisons revealed that HS made 
significantly higher number of antisaccade errors compared to both AS (T = 2.871, p 
= .005) and LS (T = 4.109, p < .001). There was no main factor of schizotypy in the 
analysis of the percentage of corrective saccades after an error as well as in the 
latency, gain or velocity of the saccades models.  
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Covariates 
The only significant covariate in these models was age in respect to the percentage of 
corrective saccades model in the antisaccade task (F(1,84) = 5.291, p =.025). 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Effect of schizotypy group on the antisaccade error rate. * = p ≤ .05 for 
comparisons versus the high schizotypy group.  
 
 
5.3.6. Smooth pursuit eye movement task 
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5.4. Discussion 
 
In this report we aimed to clarify the relationship between schizotypy and 
neurocognition by comparing the performance in three healthy volunteers groups 
defined by their scores on the Schizotypal Personality Questionnaire (low, average 
and high schizotypy scorers). We tested whether all the tasks from our battery detect 
the schizotypy effect and whether low or average scorers are the optimal controls for 
cognitive comparison versus high schizotypy scorers.  
 
5.4.1 Tasks sensitivity to the schizotypy phenotype: working memory, 
antisaccade and verbal fluency  
 
Outcome variables of four tasks detected the schizotypy phenotype (N-back, spatial 
working memory, verbal fluency and antisaccade eye-movement tests) while two 
other tests did not distinguish between the groups (salience attribution and smooth 
pursuit eye-movement tasks).  
 
The effect of schizotypy on the two working memory tasks in the battery (N-back and 
SWM) is in line with previous research. Individuals with high levels of schizotypal 
personality traits tend to have intermediate working memory performance between 
(Siever et al. 2002; Raine 2006). It has been hypothesized that working memory 
impairment might be a critical component that forms several more complex cognitive 
deficits in the schizophrenia spectrum disorders (Roitman et al. 2000). In 
demonstration of this, performance on working memory tasks has been shown to be 
the single most important neurocognitive factor accounting for the differences 
between schizotypal individuals and controls (Mitropoulou et al. 2005; McClure et al. 
2007). The evidence for working memory deficits being core abnormalities in the 
schizophrenia spectrum has prompted Raine at al. to propose that a dopamine-
mediated prefrontal cortex disruption might be part of the schizotypy phenotype 
(Raine et al. 1992). This is compatible with data showing that worse working memory 
performance in schizotypal personality is associated with smaller volume of the 
ventro-lateral prefrontal cortex. The relation of this frontal deficit to dopamine has 
been demonstrated by studies showing the working memory performance in 
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schizotypal individuals can be improved by acute (Kirrane et al. 2000) and chronic 
(McClure et al. 2010) administration of agents enhancing dopamine 
neurotransmission. Similarly, the analysis of the larger dataset that this study is part of 
revealed that enhancement of dopamine function (through low-dose amisulpride 
challenge) improved the working memory performance of high but not average 
schizotypes (Chapter 4). These data support the notion that dopamine dysfunction is 
related to working memory impairment in schizotypy. Additionally, this deficit is 
responsive to drug challenges and is a promising target for proof of concept studies on 
novel cognition enhancing medication.  
 
The fact that the abnormality was detected reliably only in the most difficult 
conditions of the task argues that the psychometrically defined schizotypy group is a 
high functioning population. On a similar note, in a study on a subsample of the same 
population we found that the working memory deficit in high schizotypy was 
demonstrable on a challenging working memory task that required quick stimulus 
encoding but not on a different one where encoding was longer (Chapter 6).Therefore 
differences in task difficulty may explain why some previous studies did not find 
executive function deficits in high SPQ scorers (Jahshan et al. 2007). Proof of concept 
studies featuring high functioning risk groups may thus benefit from employing more 
difficult cognitive tasks that the ones demonstrating deficit in schizophrenia. 
 
5.4.2. Optimal schizotypy control group: Working memory tasks  
 
The finding that working memory performance of the average schizotypy group is 
intermediate between that of low and high schizotypy group suggests are in line with 
the predictions derived from the Eysenck theoretical framework of schizotypy 
(Eyseneck et al. 1976). According to this ‘full dimensional’ model, as Claridge coins 
it, ‘traits that describe deviance – in this case schizophrenia – are represented in 
personality as healthy diversity’ (Claridge 1994). In contrast, the threshold model, 
predicted from the theory of Meehl sees deviant traits as confined to the disease 
domain (Claridge 1994). The latter model would expect all non-high scorers (low and 
average schizotypes) to have the same, superior to high schizotypy, working memory 
performance. Our results thus favour the full-dimensional over the threshold model 
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and indicate that working memory comparisons in schizotypy populations would 
benefit by selecting a low vs. high schizotypy design. This has been the preferred 
approach in some (Gooding et al. 1999) but not all (Tallent et al. 1999) studies in 
schizotypy.  
 
A few studies have investigated the correlation between schizotypy scores and 
executive function in a healthy population. Some (Park et al. 1997; Gooding et al. 
2006; Matheson et al. 2008) but not all (Jahshan et al. 2007; Noguchi et al. 2008) 
have found an inverse relationship between schizotypy scores and neurocognitive 
performance. One of the studies that did not find such a correlation also failed to 
detect impairment of executive function in the high scorers (Jahshan et al. 2007). It 
could be hypothesized therefore that the tasks in the negative studies were not 
sufficiently difficult to demonstrate the subtle schizotypy deficit. 
 
5.4.3. Optimal schizotypy control group: Antisaccade task 
 
The finding of increased antisaccade error rate but normal spatial accuracy and 
latency of pro- and antisaccades in the high schizotypy group also replicates previous 
findings (Siever et al. 1990; Siever et al. 1994; Clementz et al. 1995; Thaker et al. 
1996; O'Driscoll et al. 1998). This shared abnormality between schizotypy individuals 
and schizophrenia patients has been shown to be due to underlying abnormality in the 
frontal cortex (Ettinger et al. 2004) and the striatum (Raemaekers et al. 2002). The 
antisaccade error rate also correlates with measures of executive function in 
schizophrenia patients (Hutton et al. 2004) while acute enhancement of dopamine 
neurotransmission has been reported to improve antisaccade performance (Klein et al. 
2002; O'Driscoll et al. 2005; Wonodi et al. 2006). This indicates that antisaccade error 
performance may share some of the neural mechanisms that underpin working 
memory.  
 
The relationship between schizotypy and antisaccade performance was linear, similar 
to the pattern obtained for the working memory tasks. This result also favours the full-
dimensional model of schizotypy and the use of low schizotypes as controls in 
comparisons with high schizotypes. One study has so far investigated the relationship 
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between antisaccade error rate and SPQ scores (Smyrnis et al. 2003). Although the 
authors found that the error rate in the population had a similar distribution to the SPQ 
scores (skewed normal distribution), there was no correlation between the two 
variables. Instead, the authors found that only the extremely high scorers had 
increased antisaccade error rates, favouring the threshold approach to schizotypy. The 
discrepancy between these two sets of results could be due to problems with the 
validity of the SPQ scores in the Smyrnis et al. (2003) study given their translation in 
Greek for the first time, as acknowledged by the authors. Differences in the phrasing 
of the questions could have led to mixing of the low and average scoring groups, 
masking the linear relationship between schizotypy and antisaccade error rate. In 
addition, the authors reported that anxiety and depression scores were correlated with 
both the antisaccade error rate and schizotypy. It is therefore possible that the lack of 
correlation between SPQ scores and antisaccade error rate was due to the inclusion of 
anxiety and depressive disorders in the group. In our study, we excluded participants 
with such disorders which might have led to a more confound-free comparison of 
schizotypy and SPQ interaction.   
 
5.4.4. Optimal schizotypy control group: Verbal fluency task 
 
The findings from the verbal fluency task appear to favour the threshold approach: the 
average schizotypy comparison yielded higher effect size than the low schizotypy 
one. This could however also be due to the specific profile of verbal fluency in 
schizotypy: one study reported that positive schizotypy is associated with normal 
verbal fluency performance but increased usage of rare words (Duchene et al. 1998). 
The authors interpreted this as an indication that magical ideation is linked to the 
ability to form broad associative connections which foster or mask deficits in verbal 
fluency (Raine 2006). It is thus possible that the small advantage of the average 
schizotypy over the low schizotypy group could have been due to their high positive 
schizotypy scores. In comparison, our high schizotypy group however had high scores 
on the negative and disorganized scores which could explain their inferior verbal 
fluency performance.  
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5.4.5. No effect of schizotypy: Smooth pursuit eye movement task  
 
We also found that the saccade rate and gain during smooth pursuit eye-movements 
failed to distinguish between the schizotypy groups. So far the reports using these 
SPEM measures in schizotypy have been mixed. One study reported no difference in 
pursuit gain and saccade rate (Siever et al. 1994), while another found reduced gain 
but normal saccade rate (Gooding et al. 2000).  In addition, Smyrnis et al. found no 
relation of these variables with SPQ scores, but reported disrupted performance in the 
high scorers on the SPQ disorganization factor. These mixed results could be 
interpreted in the light of Thaker et al.’s studies on schizotypy individuals with and 
without family risk of schizophrenia (Thaker et al. 1996). They showed that the 
SPEM abnormality is found only in schizotypal individuals who have family history 
of schizophrenia and argued that the SPEM deficit is specifically associated with the 
familial risk for schizophrenia. Smyrnis et al. (2007) did not report the rate of 
schizophrenia family history in their sample but it is possible that the SPEM 
abnormality in the high disorganization scorers was due to higher genetic loading 
(Smyrnis et al. 2007). In our sample, only a small proportion reported being first-
degree relatives of schizophrenia patients. We therefore consider our negative SPEM 
finding to support the view proposed by Thaker et al. that SPEM abnormality is 
primarily linked to the genetic risk of schizophrenia (Thaker et al. 1996).  
 
5.4.6. No effect of schizotypy: Salience Attribution Test 
 
The negative findings regarding the SAT indicate that psychometrically defined 
schizotypy is probably not associated with deficits in salience attribution. We also 
failed to replicate an earlier report linking the negative schizotypy symptom of 
introvertive anhedonia to aberrant salience (Roiser et al. 2009). This suggests that 
salience attribution measures might be more relevant as state-dependent biomarkers. 
In support of this, several studies have shown that the salience attribution 
abnormalities in schizophrenia patients are correlated with psychotic symptoms and 
the negative symptoms secondary to the psychotic state (Roiser et al. 2009; Ziauddeen 
et al. 2010). Additionally, treatment with atypical antipsychotics has been 
demonstrated to normalise salience attribution in patients (Juckel et al. 2006).  
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5.4.7. Limitations 
 
The results of this explorative analysis should be treated with caution as several 
important limitations exist. First and foremost the average and high schizotypy groups 
were recruited as part of a larger placebo-controlled study which investigated the 
effects of acute administration of risperidone, amisulpride, nicotine on cognition. The 
two samples were required to attend two appointments (data recruited on the second, 
full-day appointment), were placebo-treated and were recruited from three sites in the 
UK. In contrast, the low schizotypy group attended a single 3 hour appointment in 
which the data was recorded, did not receive placebo medication and was recruited in 
Manchester only. We therefore cannot rule out the possibility that the superior 
performance in the low schizotypy group was due to these protocol differences. It is 
feasible that fatigue or placebo effects could have led to the reduced performance in 
AS relative to LS, a scenario that favours the threshold model of schizotypy.  
 
Two lines of evidence suggest that fatigue or placebo effects might not have fully 
accounted for the superior low schizotypy effect. Firstly, there was no group 
difference in respect to the reaction times and latencies on the SWM, N-back and 
antisaccade tasks, measures that one would expect to be affected by placebo or fatigue 
effects. Secondly, the superior performance of the low schizotypy group was confined 
solely to measures where a difference between the placebo-treated average and high 
schizotypy was already evident. The lack of schizotypy effect on the other tasks 
argues against a generalized placebo or fatigue effects-driven cognitive superiority in 
the low schizotypy group.  
 
The finding of higher years of full-time education in the low schizotypy group also 
seems unlikely to have influenced the results significantly due to the same arguments 
as the ones that concern the placebo-effect. In addition, this variable was an 
insignificant confound in all models. This echoes previous findings of lack of 
correlation between years of education and neurocognitive performance, such as in 
the large sample eye-tracking studies by Smyrnis et al. (Smyrnis et al. 2003; Smyrnis 
et al. 2007).    
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5.4.7. Conclusion 
 
In summary, this study explored the neurocognitive correlates of low, average and 
high psychophysically defined schizotypy. The results on the working memory and 
antisaccade tasks showed the performance of average schizotypes was intermediate 
between that of low and high schizotypes. These results argue in favour of the full 
dimensional view of schizotypy and suggest that low schizotypy might be the most 
appropriate control group in proof of concept studies of cognitive enhancing agents in 
high schizotypy.  
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CHAPTER 6 
 
Visual information processing deficits as 
biomarkers of vulnerability  
to schizophrenia:  
An event-related potential study in schizotypy* 
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Abstract 
 
We aimed to clarify the importance of early visual processing deficits for the 
formation of cognitive deficits in the schizophrenia spectrum. We carried out an 
event-related potential (ERP) study using a computerised delayed matching to sample 
working memory (WM) task on a sample of volunteers with high and low scores on 
the Schizotypal Personality Questionnaire (SPQ). The amplitudes of the visual ERPs 
to the encoding and retrieval stimuli in the task were measured using the BESA 
software. The hypothesis was that high schizotypes would have deficits in early visual 
processing (reduced P1 amplitude) and working memory similar to those observed in 
schizophrenia. The high schizotypy group identified fewer previously encoded target 
cues than the low schizotypy group in the WM task and their mean cue-evoked P1 
amplitudes were significantly reduced, both in the encoding and the retrieval phases 
of the task. Accuracy on the WM task correlated with the P1 amplitude. None of the 
later components (N1, P2) were significantly different between the groups, nor were 
there differences in performance on the CANTAB tests. The results are compatible 
with the hypothesis that trait vulnerability to schizophrenia is associated with 
impaired early visual processing which may contribute to impaired cognitive memory 
performance. However, the high schizotypes are apparently able to compensate for 
the visual processing deficits and perform normally when stimuli are presented for 
longer as in the CANTAB tasks. This study adds to growing evidence that the 
schizophrenia spectrum is characterized by early sensory abnormalities.  
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6.1. Introduction 
 
Visual processing abnormalities have been consistently reported in schizophrenia. 
Studies using psychophysical methods have found deficits in motion (Stuve et al. 
1997; Chen et al. 1999; Brenner et al. 2003; Chen et al. 2003) and contrast sensitivity 
(Slaghuis 1998; Keri et al. 2002; Butler et al. 2005), perceptual organization 
(Silverstein et al. 1996; Silverstein et al. 2005), spatial discrimination (O'Donnell et 
al. 1996; Tek et al. 2002; Keri et al. 2004) and the ability to detect targets masked 
after short intervals (Butler et al. 1996; Cadenhead et al. 1998; Green et al. 1999; 
Schechter et al. 2003).  
 
The perceptual findings are supported by the available neurophysiological evidence. 
Studies in patients using event-related potential (ERP) electroencephalographic (EEG) 
techniques have found a reduction in the amplitude of P1 (Foxe et al. 2001; Doniger 
et al. 2002; Schechter et al. 2005; Yeap et al. 2006; Haenschel et al. 2007; Yeap et al. 
2008), a positive ERP component peaking at 100 ms post-stimulus. This component 
has a characteristic distribution over the lateral occipital scalp regions and reflects 
early activation of the visual cortex (Ellemberg et al. 2001; Di Russo et al. 2002; Di 
Russo et al. 2003). The P1 reduction has been linked to impairment in the 
magnocellular visual pathway (Foxe et al. 2001; Butler et al. 2007) and data from 
psychophysical studies support this association (Keri et al. 1998; Slaghuis 1998; 
Schwartz et al. 2001; Keri et al. 2002; Keri et al. 2005). The magnocellular pathway is 
the part of the visual pathway that rapidly transmits low-resolution information and 
projects primarily to the dorsal visual stream in the cortex. The function of this 
pathway has been proposed to be spatial orientation, motion detection and overall 
stimulus perception (Steinman et al. 1997; Vidyasagar 1999; Norman 2002). In 
contrast, the slower parvocellular (ventral) visual pathway (transmitting high 
definition, color information) appears to be functioning normally in schizophrenia, as 
electrophysiological studies have shown that if parvocellular-biased stimuli are used, 
no deficits in the early visual processing are evident (Butler et al. 2007; Lalor et al. 
2008). Also, the evoked potential N1 that follows P1 is of normal characteristics, 
which has been attributed to intact early ventral/parvocellular input (Foxe et al. 2005). 
This pattern of preferential magnocellular abnormalities in schizophrenia might have 
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functional implications, as early stimulus recognition is dependent on the efficient 
interplay between the magno- and parvocellular pathways (Kveraga et al. 2007). The 
existing evidence supports this: an electrophysiological study showed reduced activity 
from the visual cortex once the information from the two streams is integrated 
(Doniger et al. 2002).  
 
It has been suggested that these early sensory impairments contribute to higher order 
cognitive (Bruder et al. 1998; Brenner et al. 2002) and social (Sergi et al. 2003) 
impairments, which in turn affect outcome (Green et al. 2000). A recent study 
addressed this issue by testing working memory in adolescent schizophrenics versus 
control using ERPs. It showed that the P1 amplitude predicted WM performance in 
controls, but was reduced in patients (Haenschel et al. 2007). Another study in 
schizophrenia patients found that contrast sensitivity deficits correlated with reduced 
ability to recognize facial emotions (Butler et al. 2009), the abnormality being most 
pronounced with magnocellular-biased stimuli. 
 
Despite the growing evidence for early sensory abnormalities driving higher order 
cognitive deficits, studies on schizophrenia patients suffer from several 
methodological weaknesses which may be particularly relevant when exploring subtle 
cognitive processes. Firstly, most of the studies exploring cognition in schizophrenia 
are conducted in chronically ill patients, where the effects of neuroleptics and 
continuous hospitalizations introduce significant confounds to the data interpretation 
(Raine et al. 1995). Negative symptoms, such as lack of motivation and apathy, might 
also reduce the engagement and compliance with the study procedures (Raine et al. 
1995). Studies on first-episode patients provide a good alternative and two such 
studies have confirmed the presence of P1 visual deficits (Haenschel et al. 2007; Yeap 
et al. 2008). In this type of studies however, confounds are still possible, as florid 
psychotic symptoms could blur the subtle cognitive abnormalities. Lastly, 
schizophrenia is associated with restricted educational opportunity (Gambini et al. 
1992) and IQ levels (Reichenberg et al. 2007). This can cause problems in matching a 
control group and in interpreting group differences.  
 
A different approach to the pathophysiology of schizophrenia is offered by studies in 
subjects with schizotypal personality traits. This is based on the idea that 
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schizophrenia lies on the extreme of a spectrum of disorders with a common 
phenomenological, genetic and neurobiological basis (Kendler et al. 1993; Siever et 
al. 2002; Siever et al. 2004). In support of this, it has been shown that schizotypal 
personality individuals experience schizophrenia-like symptoms: cognitive-
perceptual, deficit-like and disorganized psychopathology (Kendler et al. 1993; Raine 
et al. 1994; Raine et al. 1995; Bergman et al. 1996; Bergman et al. 2000). In 
demonstration of the common genetic basis of the two conditions, family studies have 
found that relatives of schizophrenia probands have higher incidence of schizotypal 
personality disorder (Siever et al. 1990; Kendler et al. 1993) and vice versa (Battaglia 
et al. 1995; Bergman et al. 2000). Lastly, subjects with schizotypal personality traits 
have been shown to have structural brain abnormalities (Buchsbaum et al. 1997; 
Silverman et al. 1998; Dickey et al. 1999) and neuropsychological deficits (Siever et 
al. 2002) similar to schizophrenia, albeit of lesser severity. Despite the similarities 
that subjects with schizotypal personality traits share with schizophrenia, they are 
nonetheless spared repeated hospitalizations, chronic antipsychotic therapy, severe 
neuropsyhological dysfunction and symptoms and most have normal educational and 
IQ levels. This makes them particularly suited for studies aiming to distinguish 
neurophysiological abnormalities associated with vulnerability to schizophrenia from 
those that are the consequence of its overt symptoms, treatment and course. Applying 
this approach to the P1 visual deficit appears particularly appropriate, as it has been 
demonstrated both in unaffected relatives (Yeap et al. 2006) and bipolar patients(Yeap 
et al. 2009), which suggests that it is more likely to reflect general vulnerability to 
psychosis. In further support of this no correlation has been found between the P1 
reduction and disease chronicity or medication dose in patients (Yeap et al. 2008).  
 
In this study we aimed to test whether the findings of early visual processing deficits 
reported in schizophrenia can be extended to healthy volunteers with elevated 
schizotypal personality traits (high schizotypy) using event-related potentials. As we 
also intended to explore the relevance of visual processing for the formation of 
higher-order cognitive deficits, we employed a delayed matching-to-sample task used 
in schizophrenia patients (Haenschel et al. 2007). We hypothesized that vulnerability 
to schizophrenia, as indexed by high scores on schizotypal questionnaires, will be 
characterized by a reduction of the P1 visual potential, but normal later ERP 
components (N1, P2). We also predicted that P1 amplitude will correlate with the 
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performance on the task. In addition we wished to determine whether the effect of 
impaired early visual processing deficits on WM generalized to effects on two other 
cognitive functions (central executive and spatial memory), as measured by two tasks 
from the CANTAB neuropsychological battery.  
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6.2. Materials and methods  
 
6.2.1 Subjects 
 
45 healthy volunteers were recruited via the University of Manchester research 
volunteering e-mail list, posters and flyers and selected according to their online 
responses on the short version of the Schizotypal Personality Questionnaire (SPQ-B, 
(Raine 1991)). All participants signed a consent form prior to any experiment 
procedures, completed the full version of the SPQ (74 questions) (Raine 1991) and 
were screened for current and past mental health disorders (using Mini-International 
Neuropsychiatric Interview), neurological conditions and significant visual 
impairment.  The inclusion criteria was a score of 43 or more on the SPQ for the high 
schizotypy group and 9 or below for the control group respectively, as well as no 
history of psychiatric or neurological conditions, no prescribed medication and no 
significant visual impairment. The SPQ cut-off scores were based on results from a 
previous study using SPQ in 760 students from the Manchester University (Barkus et 
al. 2008) and the SPQ manual 
(http://www-rcf.usc.edu/~raine/spqrel.html). During the screening stage 5 participants 
were excluded (3 participants due to SPQ score out of range, 1 - history of depression 
and 1 - severe astigmatism). Once included, the subjects also underwent a semi-
structured personality interview based on the Structured Clinical Interview for DSM-
IV Axis II Disorders (SCID-II) instrument. All interviews were carried out by one 
medically trained researcher, Ivan Koychev, who had been trained in using the 
instrument.  
 
After processing of the data, 1 participant was excluded due to unidentifiable P1 
component (merging of the P1 and P2 components) and 1 due to abnormal 
distribution of the P1 component (midline instead of bilateral distribution of the P1 
peak). The final groups used in the analysis were 18 high schizotypes and 20 controls. 
The two groups were well-matched for age and IQ. The demographic, SPQ and 
family mental health history data is presented in table 6.1. The results from the SCID-
II interview in the high schizotypy group revealed that 12 participants met the criteria 
for a personality disorder (5 paranoid, 3 paranoid and schizotypal, 2 schizotypal, 1 
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schizoid and 1 depressive), 5 were subtreshold (2 paranoid, 2 schizotypal and 1 
schizoid) and 1 did not meet any criteria for a personality disorder. No participants 
from the control group fulfilled the SCID-II criteria for personality disorders.  
 
Table 6.1. Demographic and mental health family history data of schizotypal 
individuals and controls 
 High schizotypes Controls P value 
Age 23.1 ± 4.1 23.5  ± 3.4 .7 
Sex    
Male 12 13  
Female 6 7  
Handedness    
Right 18 17  
Left 0 3  
IQ (NART) 114.3 ± 4.8 114.9 ± 4.8 .7 
SPQ score    
SPQ total score 49.4 ± 5.3 3.1 ± 2.3 <.001 
Cognitive-perceptual 
SPQ score 
19.5 ± 5 .7 ± .9  
Negative SPQ score 19.5 ± 5 1.6 ± 1.6  
Disorganized SPQ 13.1 ± 2.6 1.0 ± 1.1  
Family history of 
schizophrenia 
   
First-degree 1 0  
Second-degree 4 3  
No history 13 17  
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6.2.2 Stimuli and task – ERP experiment 
 
A delayed discrimination task (minor modifications from a previously published study 
(Haenschel et al. 2007)) that probes the effect of working memory load on visual 
information processing was presented on a personal computer using E-Prime software 
(Psychology Software Tools, Inc., Pittsburgh, the USA) (Figure 6.1). Thirty-six non-
natural objects were presented in the center of a black screen (0.6 x 0.6 visual angles). 
The participants were instructed to encode one, two or three subsequently presented 
images into WM. After the delay (maintenance) period a target probe appeared on the 
screen and the participants had to indicate whether it was part of the initial sample set 
by pressing a button. Each block consisted of 60 trials, 20 of each working memory 
load. The trials were intermixed pseudorandomly. All subjects completed 4 blocks.  
 
 
 
Figure 6.1. Working memory event-related potential task. During encoding one, two 
or three images were presented for 400 ms seconds each separated by an 
interstimulus interval of 600 ms. A delay period of 6 seconds ensued (maintenance 
phase). A target image then appeared and remained on the screen for 3 seconds and 
the participants were required to indicate by pressing a button whether it was shown 
during the encoding phase or not (retrieval phase). An interstimulus interval of 1 
second separated the trials. 
 
   
Encoding  
phase 
Maintenance  
phase 
Retrieval and 
response 
phase 
600 ms 400 ms 600 ms 400 ms 600 ms 400 ms 6 sec 3 sec 1 sec 
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6.2.3. Stimuli and task – neuropsychological experiment 
 
Two tasks from the CANTAB neuropsychological battery were used (Cambridge 
cognition, http://www.cantab.com/science/default.asp). The first one, Paired 
Associates Learning (PAL), focuses on the visual memory abilities. Boxes were 
displayed on the screen and opened in a randomized order. One or more of them 
contained a pattern. The patterns were then displayed in the middle of the screen, one 
at a time, and the participant was required to touch the box where the pattern was 
originally located. If the participant made an error, the patterns were re-presented to 
remind the participant of their locations. The difficulty level increased through the 
test. The second task (Intra-Extra Dimensional Set Shift (IEDSS)) probes the ability 
for rule acquisition and adaptation to rule reversal, functions attributed to the central 
executive. Two artificial dimensions were used in the test: color-filled shapes and 
white lines. Simple stimuli were made up of just one of these dimensions, whereas 
compound stimuli were made up of both, namely white lines overlying color-filled 
shapes. The subject started the task by seeing two simple color-filled shapes, and was 
required to learn which one is correct by touching it. Feedback taught the subject 
which stimulus was correct, and after six correct responses the stimuli and/or rules 
were changed. These shifts were initially intra-dimensional (e.g. color filled shapes 
remain the only relevant dimension), then later extra-dimensional (white lines become 
the only relevant dimension). 
 
6.2.4. ERP data acquisition, processing and analysis 
 
Continuous EEG recording was obtained using ActiveTwo BioSemi electrode system 
(BioSemi, Amsterdam, the Netherlands) from 72 electrodes digitized at 512 Hz with 
an open passband from DC to 150 Hz. In the BioSemi system, the classical ‘ground’ 
electrodes are replaced with two separate ones: Common Mode Sense (CMS) active 
electrode and Driven Right Leg (DRL) passive electrode. These 2 electrodes form a 
feedback loop, which drives the average potential of the subject (the Common Mode 
voltage) as close as possible to the ADC reference voltage in the AD-box (the ADC 
reference can be considered as the amplifier ‘zero’). A detailed description of the 
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BioSemi electrode referencing and grounding convention can be found at 
http://www.biosemi.com/faq/cms&drl.htm.  
 
Data were analyzed using BESA version 5.2 (Brain Electric Source Analysis, 
Gräfelfing, Germany). For the purpose of the analysis an averaged reference was 
employed. Only trials where the participants responded correctly were included in the 
analysis. The epoch within each trial was defined as the period starting at 400 ms 
prestimulus and ending at 1000 ms poststimulus. For the encoding phase, the stimulus 
was defined as the last object to appear within the encoding series (object 1 in load 1, 
object 2 in load 2 and object 3 in load 3). For the retrieval phase, the stimulus was the 
target image. Baseline was defined as the period between -100 and 0 ms. An 
automatic predefined source model was used for artifact correction in the period from 
400 ms prestimulus to 1000 ms poststimulus (Ille et al. 2002). The model included 
topographies for horizontal, vertical eye movements and blinks. These standard 
templates were used to apply weighted corrections to all channels in trials in which 
the signal amplitude in the horizontal or vertical channels oculomotor channels 
exceeded ±250 µV and ±150 µV respectively. The continuous data was then 
examined for outstanding blink artifacts and those were removed manually. The trials 
that survived artifact correction were averaged together with a high-pass filter of 
forward phase shift of 0.3 Hz (6 dB/octave) applied before the procedure.  A low-pass 
filter of 0-phase shift of 30 Hz (24 dB/octave) was used on the data after averaging.  
The mean percentage acceptance rate and the standard deviation for the two groups is 
as follows: high schizotypes - encoding 87 ± 2 % and retrieval 89 ± 2%, controls - 
encoding 89 ± 2 % and retrieval 91 ± 2%. 
 
Because the task was designed to probe the early visual components (P1, N1, P2), 
data from three pairs of occipital electrodes were used in the analysis (PO4/PO3, 
PO8/PO7, O2/O1). Utilizing the fact that the P1 and N1 visual potentials are well 
characterized (Di Russo et al. 2002), global field power was employed to identify P1 
and N1 as the first two major consecutively occurring peaks of respectively positive 
and negative voltage in the 50-200 ms post-stimulus period. Their latencies were 
defined as the time points of maximum amplitude in the respective peaks. The P1 
amplitude was defined as the mean amplitude of the 20 ms window around the P1 
peak (local mean amplitude) (Luck 2005). The same approach was used for N1, 
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whereby mean amplitude was calculated for a 30 ms centered on the N1 peak. The 
mean amplitude for P2 was defined as the 60 ms period beginning 50 ms after the N1 
peak.  
 
6.2.5. Statistical analysis 
 
ERP data  
Repeated measures ANOVA with a within-subjects factor of working memory load 
and between-subjects factor of group was performed on the mean amplitudes and 
latencies of the components of interest. Repeated measures 3x2x3 ANOVAs using 
within-subject factors of working memory load (1, 2, 3), hemisphere (left and right) 
and electrode (PO4/PO3, PO8/PO7, O2/O1) and a between-subject factor of group 
was calculated for the mean amplitude of each component. We used polynomial 
contrasts to determine whether the increase in WM load resulted in a linear or 
quadratic increase in the component amplitude. To test for correlation between P1 
amplitude and task performance, we averaged the values of the amplitude for the three 
electrode pairs (PO4/PO3, PO8/PO7, O2/O1) over the three WM loads for retrieval 
and encoding separately and ran Pearson’s correlation between the resulting values 
and the overall accuracy on the WM task.    
 
CANTAB data 
For both PAL and IEDSS the total number of errors and trials were calculated. For 
PAL we also extracted the number of mean errors to success and the number of stages 
completed on the first try. In the IEDSS analysis of we calculated the number of 
errors before and after the dimensional shift.  The two groups were then compared on 
each of these measures using t-tests. 
 
6.2.6. Ethical approval 
 
The study has been approved by The University of Manchester Ethics committee 
(reference number 08175) and has been carried out in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki. 
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6.3. Results  
 
6.3.1. Behavioural data 
 
Figure 6.2 demonstrates the mean reaction time to the correct trials and mean 
percentage correct for the two schizotypy groups.  
 
 
 
 
 
 
 
 
Figure 6.2. Reaction times (A) and percentage correct (B) for high schizotypes (light 
grey) and controls (dark grey). Reaction times in milliseconds on the vertical axis and 
working memory load on the horizontal axis (A). Percentage correct on the vertical 
axis and working memory load on the horizontal axis (B). 
 
The two groups did not differ in terms of their reaction times. In both groups the 
reaction times increased with WM load (F(2,72) = 108.327, p < .001). The monotonic 
increase was confirmed by the linear contrast (F(1,36)168.077, p < .001). Analysis of 
the reaction times to the incorrect trials also revealed non-significant difference 
between the groups, but there was a significant increase in the reaction times to the 
incorrect trials when compared to the correct ones (F(1,30) = 41.962, p < .001). 
 
Overall accuracy was significantly lower in the high schizotypy group compared to 
controls (F(1,36) = 4.841, p = .034). The accuracy in both groups decreased with WM 
load (F(2,72) = 15.282, p < .001). This relationship was found to be linear using a 
polynomial contrast (F(1,36) = 34.387, p < .001).  
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6.3.2. ERP data: Encoding  
 
P1 component 
The grand mean ERP to all encoding conditions for the two groups are presented in 
Figure 6.3.  P1 during encoding peaked at a latency of 148 ± 2.3 ms and 148 ± 2.2 ms 
for the high schizotypy and control groups, respectively. There was no effect of group 
or WM load on latency.  
 
P1 amplitude was significantly reduced in the high schizotypy group compared with 
the control group (F(1,36) = 5.026, p = . 034, Figure 6.4A). The effect size of this 
factor was moderate, r = .350. The main effect of WM load was statistically 
significant (F(2,72) = 3.907, p = .024, Figures 6.4A and 6.5). The polynomial contrast 
revealed that the mode of increase was quadratic (F(1,36) = 5.579, p = .024), the P1 
increasing in amplitude from load 1 to load 2 and then decreasing from load 2 to load 
3 (Figure 6.4A). There was no interaction between the factors of group and WM load 
(Figure 6.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Grand averaged waveforms for the encoding conditions in high 
schizotypes (black solid line) and controls (black lines and dots). Plot is the average 
for electrodes  PO7, PO8, PO3, PO4, O1 and O2. Amplitude in microvolts on the 
vertical axis and time in milliseconds on the horizontal axis.   
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Figure 6.4. Averaged waveform for the encoding phase of working memory loads 1 
(black solid line), 2 (black lines) and 3 (black dots) in high schizotypes (A) and 
control (B). Plot is the average for electrodes PO7, PO8, PO3, PO4, O1 and O2. 
Amplitude in microvolts on the vertical axis and time in milliseconds on the horizontal 
axis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Grand averaged waveforms for the retrieval conditions in high 
schizotypes (black solid line) and controls (black lines and dots). Plot is the average 
for electrodes PO7, PO8, PO3, PO4, O1 and O2. Amplitude in microvolts on the 
vertical axis and time in milliseconds on the horizontal axis.  
 
The topography of the P1 peak in response to encoding stimuli in both groups is 
presented in Figure 6.6. 
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Figure 6.6. Topographical representation of the P1 peak in high schizotypy (left-hand 
side) and control (right-hand side) groups in current source density (µV/cm2). 
 
N1 component 
The N1 component peaked at 208 ± 4 ms and 208 ± 3 ms for the high schizotypy and 
control groups, respectively. There was no significant latency difference between the 
schizotypy groups and WM loads. The two schizotypy groups did not differ also in 
terms of their N1 amplitudes. However there was a significant main effect of WM 
load (F(2,72) = 10.435, p < .001), the polynomial contrast revealing a linear increase 
of N1 amplitude with WM load (F(1,36) = 14.279, p = .001).  
 
P2 component 
The encoding stimuli evoked a P2 component with a mean latency of 281 ± 3 ms in 
the high schizotypes and 274 ± 3 ms in controls and this difference approached 
significance (F(1,36) = 3.176, p = .083). The main effect of WM load on latency was 
statistically significant (F(2,72) = 3.915, p = .024), the effect due to linear latency 
decrease with increasing WM load (F(1,36) = 5.625, p = .023). The factors of 
schizotypy and WM load did not interact. P2 component amplitude was not 
significantly different between schizotypy groups, but increased with load (F(2,72) = 
7.009, p = .002) in a linear fashion (F(1,36) = 59.613, p = .004).  There was no 
interaction between group and WM load in the P2 amplitude model. . 
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The amplitude and latencies of P1, N1 and P2 components in response to encoding 
stimuli are presented in table 6.2.  
 
Table 6.2. Amplitudes and latencies during encoding 
 Mean (95% CI; SE) Amplitude, µV Mean (SE) Latency, ms 
Encoding WM Load 1 WM Load 2 WM Load 3 WM 
Load 1 
WM 
Load 2 
WM 
Load 3 
P1 
Controls 4.7  
(3.7-5.8; .5) 
5.3  
(4.2-6.4; .5) 
5.0  
(4.0-5.8; .4) 
149 (3) 149 (3) 147 (3) 
High schizotypes 3.2  
(2.1-4.2;.5) 
3.7  
(2.5-4.8; .5) 
3.6  
(2.6-4.5; .5) 
148 (3) 147 (3) 148 (3) 
N1 
Controls -0.1  
(-1.2-0.9; .5) 
1.0 
 (0-2.0; 0.5) 
1.3  
(0.4-2.2; .4) 
208 (3) 204 (3) 202 (4) 
High schizotypes -1.0 
 (-1.2-0.9; .5) 
0.4  
(-0.6-1.4; .5) 
0.6 ( 
-0.4-1.5; .5) 
209 (4) 209 (3) 207 (4) 
P2 
Controls 3.5  
(2.6-4.5; .5) 
4.5 
 (3.4-5.5; .5) 
4.5  
(3.5-5.6; .5) 
276 (4) 272 (4) 274 (3) 
High schizotypes 3.5  
(2.5-4.5; .5) 
4.0  
(2.9-4.1; .5) 
3.9  
(2.9-5.0; .5) 
286 (4) 280 (4) 277 (3) 
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6.3.3. ERP data: Retrieval  
 
P1 component 
The grand mean ERP to all retrieval conditions for the two schizotypy groups are 
presented in Figure 6.7.  The latency of P1 in response to retrieval stimuli was 141 ± 2 
ms for the high schizotypy group and 139 ± 2 ms for the controls.  There were no 
significant main effects of group or WM load on P1 latency. 
 
The P1 amplitude was significantly lower in the high schizotypy group compared with 
the controls (F(1,36) = 5.140, p = .029, Figure 6.4B), effect size of r = .354. There 
was no main effect of WM load (Figure 6.4B) nor did WM load interact with 
schizotypy group. 
 
N1 component  
The N1 component in the retrieval phase peaked at 205 ± 2 ms in the high schizotypy 
group and at 201 ± 2 ms in the controls. The main effects of schizotypy group and 
WM level did not reach statistical significance nor did they interact in respect to N1 
amplitude and latency,  
 
P2 component 
The P2 component peaked at 285 ± 4 ms in the high schizotypes and at 275 ± 4 ms in 
the controls. In respect to latency, the difference between the schizotypy groups 
approached significance (F (1,36) = 3.946, p = .055), while the main effect of WM 
load was not significant. The main effects of schizotypy group and WM load were not 
significant in respect to P2 amplitude. Schizotypy and WM load did not interact in the 
retrieval P2 models.  
 
. 
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Figure 6.7. Amplitude of the P1 in response to the encoding (A) and retrieval (B) 
stimuli for high schizotypes (light grey) and controls (dark grey). Amplitude in 
microvolts on the vertical scales and working memory load on the horizontal scales. 
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The amplitude and latencies of P1, N1 and P2 components in response to retrieval 
stimuli are presented in table 6.3.  
 
Table 6.3. Amplitudes and latencies during retrieval 
 Mean (90% CI; SE) Amplitude, µV Mean (SE) Latency, ms 
Encoding WM Load 1 WM Load 2 WM Load 3 WM Load 
1 
WM Load 
2 
WM Load 
3 
P1 
Controls 4.7 
(3.6-5.7; .5) 
4.7  
(3.7-5.6; .5) 
5.1  
(4.0-6.1; .5) 
141 (3) 137 (3) 138 (3) 
High schizotypes 3.2  
(2.1-4.3; .5) 
3.2  
(2.2-4.2; .5) 
3.3  
(2.2-4.4; .5) 
141 (2) 142 (2) 141 (3) 
N1 
Controls 0.2  
(-1.0-1.2; .5) 
0.0  
(-1.1-1.2; .6) 
0.4  
(-.7-1.4; .5) 
202 (3) 201 (3) 201 (3) 
High schizotypes 0.0  
(-1.2-1.1; .6) 
- 0.1 
 (-1.3-1.1; .6) 
- 0.4  
(-1.4-.7;.5) 
205 (3) 204 (3) 206 (4) 
P2 
Controls 4.4  
(3.2-5.4; .5) 
4.2  
(3.2-5.2; .5) 
4.2  
(3.1-5.3; .6) 
273 (3) 275 (4) 277 (4) 
High schizotypes 3.6  
(2.4-4.7; .6) 
3.7  
(2.6-4.7; .5) 
3.8  
(2.7-5.0; .6) 
287 (4) 282 (6) 286 (4) 
 
6.3.4. Effect of genetic loading 
 
Given the presence of family history of schizophrenia in the groups, it could have 
been argued that the difference in P1 amplitude was driven by a few familial cases. To 
resolve this we removed the first-degree relative from the high schizotypy group from 
the analysis. The significant difference was retained both in terms of the encoding and 
retrieval P1 amplitudes, F (1,35) = 4.437, p = .042 and F (1,35) = 4.64, p = .038, 
respectively. Similarly, after removing the second degree relatives from both groups 
(4 and 3 for the high schizotypy and control groups, respectively) the P1 difference 
between the two groups remained significant both for the encoding and retrieval 
conditions (F (1,28) = 6.145, p = .019 and F (1,28) = 6.174, p = .019, respectively).  
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6.3.5. Correlation between P1 amplitude and performance 
 
Pearson’s correlation coefficients were calculated to assess the relationship between 
P1 amplitude and accuracy on the WM paradigm. A significant positive correlation 
was found between the P1 amplitude of the response to encoding stimuli and accuracy 
on the task, R = .307, p = .030. The P1 amplitude during the retrieval phase was also 
positively correlated with performance, R = .279, p = .045.  
 
6.3.6. Results cognitive battery 
 
Paired Associate Learning 
There was no main effect of schizotypy group in respect to any of the PAL outcome 
measures.   
 
Intra- and Extra-Dimensional Set Shift 
There was also no statistically significant difference between the two groups in the 
IEDSS models. The high schizotypy group made more errors than controls at the 
extra-dimensional set shift (4.9 ± 6.3 and 2.7 ± 0.9, respectively), but this effect did 
not reach statistical significance (t(36) = 1.607, p = .117). 
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6.4. Discussion 
 
The present study on healthy volunteers scoring high and low on the SPQ (Raine 
1991) adds to the growing body of evidence suggesting that the schizophrenia 
spectrum disorders are characterized by early sensory processing deficits. 
Specifically, we found that the high schizotypy group exhibited reduced P1 visual 
evoked responses, but intact later peaks (N1 and P2). We also found evidence of 
correlation between the size of the P1 amplitude and the performance on the delayed 
matching-to-sample task. In accordance with this the high schizotypy group made 
significantly more errors on this WM task, but interestingly no differences were 
evident between the groups when tested with two CANTAB paradigms. We will 
discuss each of these findings in turn in the following section. 
 
6.4.1. Group difference in amplitude 
 
The major finding of this study is that the P1 amplitude reduction that is consistently 
reported in schizophrenia is also evident in high schizotypy. The effect sizes we 
obtained were of moderate degree (.353 and .351 for the encoding and retrieval 
conditions, respectively). In comparison, the study by Haenschel et al. that used the 
same paradigm in adolescent schizophrenia patients reported effect sizes of .63 and 
.67 for the P1 reduction for encoding and retrieval, respectively. This suggests that the 
severity of the early visual processing abnormality in high schizotypes lies between 
the schizophrenia patients and controls. This finding is in agreement with previous 
studies that found moderate degree of neuropsychological disturbance in schizotypal 
personality when compared with patients (Siever et al. 2002). On this basis, one 
conclusion that can be drawn from the currently reported results is that the P1 
abnormality observed in schizophrenia is not the result of florid positive or severe 
negative symptoms, repeated hospitalization or medication. On the same note, a 
recently published study found that the P1 deficit in schizophrenia patients is 
unrelated to disease duration, medication dose or age (Yeap et al. 2008). Instead the 
abnormality is probably related to mechanisms that predispose to schizophrenia, as 
suggested by a study that found reduced P1 amplitude in unaffected relatives of 
schizophrenia patients (Yeap et al. 2006). However, our sample had minimum family 
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history for schizophrenia and removing the family history cases did not affect the 
difference between the groups in terms of P1. This suggests that the early visual 
processing deficits are probably related to the general psychopathology that is 
characteristic for the schizophrenia spectrum. As such the P1 deficit is probably a 
more reliable index of overall susceptibility to schizophrenia and not only genetic 
susceptibility. It is plausible that early sensory abnormalities appear after the genetic 
and environmental factors have combined to produce the risk state. 
 
6.4.2. Relevance of the P1 abnormalities to higher-order cognitive 
deficits 
 
Another important finding of this study is that the P1 amplitude in response to both 
the encoding and retrieval stimuli correlated positively with task performance. We 
interpret these findings as an indication that the efficient perception of both the 
encoding and retrieval stimuli is crucial for later cognitive operations and 
abnormalities at this stage contribute to cognitive impairment. The current finding is 
supported by a study that used the same delayed matching-to-sample paradigm in 
schizophrenia patients and found that higher P1 amplitude to both encoding and 
retrieval stimuli predicted better accuracy in controls on the task (Haenschel et al. 
2007). One other study has reported an association between P1 amplitude reduction 
and cognitive impairment. It demonstrated that impaired emotion recognition 
correlated with visual sensory dysfunction (Butler et al. 2009). These findings add to 
a growing body of evidence that primary abnormality in encoding exists in 
schizophrenia and that it affects cognitive processes by not allowing the effective 
transformation of the perceived stimulus into an internal representation. Direct 
psychophysical evidence supports this conclusion, as patients have been demonstrated 
to need longer periods of uninterrupted encoding to achieve stable working memory 
representations (Hartman et al. 2003; Fuller et al. 2005; Fuller et al. 2009). Also, the 
encoding abnormality can sometimes be reduced by increasing the duration of the 
stimulus presentations (Tek et al. 2002; Lencz et al. 2003; Fuller et al. 2009). In 
demonstration of this, we found abnormal performance on the WM ERP task with 
short stimulus presentation in the encoding phase but no difference on the PAL and 
IEDSS tasks that allowed longer encoding (encoding stimulus presentation times: 400 
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ms in WM ERP task, 2000 ms in PAL and unlimited in IEDSS). The relevance of 
encoding abnormalities for the formation of higher order cognitive deficits was 
underlined by a meta-analysis showing that the cognitive deficits in schizophrenia are 
not due to dysfunction in information storage, as greater maintenance periods in 
working memory paradigms do not worsen the deficit (Lee et al. 2005).   
 
6.4.3. Magnocellular involvement in the P1 deficit 
 
The pathophysiological mechanism behind the early visual processing abnormalities 
has consistently been linked to the magnocellular visual pathway. Evidence from 
psychophysical studies show that patients are particularly impaired in perceiving 
stimuli that are biased to activate the M-pathway (Keri et al. 1998; Slaghuis 1998; 
Schwartz et al. 2001; Keri et al. 2002; Keri et al. 2005). Similarly, 
electrophysiological studies have found a preferential disturbance in the P1, but not 
the N1 potentials, suggesting impaired early dorsal, but not ventral stream dysfunction 
(Doniger et al. 2002; Foxe et al. 2005; Butler et al. 2007). The results from our study 
show that the same pattern is observable in high schizotypy. The relevance of the 
magnocellular/dorsal disturbance lies with the specific functions it serves in the 
human brain. Transmission of information is significantly faster within this pathway 
and it has been proposed that this data is used to create a low-resolution template in 
the extrastriate areas. This template facilitates the processing of the high-resolution 
input from the ventral stream (Kveraga et al. 2007). Consequently, any dysfunction of 
the dorsal visual stream could disturb this early template generation and compromise 
the formation of stable representations of the perceived image. This interpretation is 
supported by data showing normal initial ventral stream input, but abnormal activity 
once the two streams are integrated (Ncl component in negativity closure studies) 
(Doniger et al. 2002).  
 
The neurochemical basis for the magnocellular and related encoding dysfunction has 
been proposed to be due to an abnormality within the glutamatergic neurotransmitter 
system (Javitt 2009). Glutamate has been implicated in schizophrenia on the basis of 
studies showing that pharmacologically induced glutamate hypofunction (using 
ketamine, NMDA-antagonist) in healthy volunteers produces psychopathological and 
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cognitive disturbances similar to the ones in schizophrenia, e.g. (Krystal et al. 1999). 
Evidence for the importance of glutamate in early visual processing deficits was 
provided by a study that linked P1 reductions in schizophrenia patients to a specific 
haplotype of the dysbindin-1 gene (DTNBP1) (Donohoe et al. 2008). The product of 
this gene has been implicated in the NMDA/glutamate neurotransmission and the 
DTNBP1 variant has been associated with an increased risk for schizophrenia 
(Numakawa et al. 2004). One theory regarding the early visual processing 
abnormalities suggests that a basic NMDA abnormality in the visual system does not 
allow effective transmission of data (Javitt 2009). Another possibility is that the P1 
reduction is the result of ineffective top-down regulation of the visual cortex by 
higher order structures. The existence of such a relationship in the brain is 
demonstrated by data showing unilateral P1 reduction with ipsilateral prefrontal 
cortex lesions (Barcelo et al. 2000). However both bottom-up and top-down processes 
might be simultaneously implicated, as recent evidence has shown that top-down 
facilitation of recognition is dependent on the fast magnocellular projections (Kveraga 
et al. 2007).   
 
 
6.4.4. Relationship between WM load and P1 amplitude 
 
The study also found that in both groups P1 amplitude increased with WM load 
during encoding, but not retrieval. This finding replicates the pattern observed in 
controls from the previously reported study using the same paradigm (Haenschel et al. 
2007). In the original study however, this relationship was not true for the 
schizophrenia sample, as the encoding P1 amplitude did not increase with demand. 
The fact that the normal pattern of activation is sustained in high schizotypes could be 
interpreted in the following way: reduced P1 amplitude is an index of vulnerability to 
schizophrenia, but in non-clinical cases the visual cortex is more efficiently regulated 
by higher-order brain areas, resulting in activation with increased demand. In the 
developed condition this relationship decompensates and the top-down projections 
cannot modulate as effectively the primary sensory areas.  
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6.4.5. Limitations 
 
Several important limitations in regards to the currently reported finding of early 
visual deficits in schizotypy need to be addressed. Firstly, based on findings that P1 
amplitude is dependent on spatial attention (Mangun et al. 1998), it is often argued 
that the observed P1 reduction could be due to differences in the level of arousal or 
engagement with the task. Our data argue against such criticism. Firstly, it is now well 
established that both P1 and N1 amplitudes are modulated by attention (Mangun et al. 
1991; Luck et al. 1993; Eimer et al. 1998; Mangun et al. 1998) and in our study there 
was an effect of group only on the P1 but not N1. Secondly, we only analyzed the 
amplitude to images from successful trials. This ensured that the reported results were 
only from instances when the participants were actively engaged with the task. 
Thirdly, the two groups did not differ in their reaction times to the task where the 
deficit was observed. Lastly, the two groups did not differ in their performance on the 
two CANTAB tasks, which both require considerable and sustained attention. Given 
these arguments, we believe that the effects cannot be attributed solely to difference in 
engagement and attention. Recent data from schizophrenia patients also argues 
against an effect of attention or arousal in the P1 deficit. A study using a technique 
that allows the selective activation of the parvocellular pathway discovered normal P1 
amplitude in patients but reduced P1 component in standard visual evoked potential 
technique (Lalor et al. 2008). The authors argued that it would be very unlikely that 
an arousal mechanism should affect only one of the two visual pathways.  
 
A second limitation is that a recently published study did not find significant 
difference between controls and patients with schizotypal personality disorder (SPD) 
in terms of P1 amplitude (Vohs et al. 2008). The P1 amplitude in the SPD group was 
lower in comparison with the controls and higher than the one in a sample of 
schizophrenia patients. This pattern coincides with the results emerging from our data 
but the effect was not found to be significant. One possible explanation of this 
discrepancy is that the SPD sample recruited for the Vohs et al. study had lower 
overall SPQ score compared to our sample (42.6 ± 6 vs. 49.4 ± 5) (Vohs et al. 2008). 
Also, the SPQ score in the Vohs et al. study was elevated mainly due to the cognitive-
perceptual score (20.9±7 cognitive-perceptual; 13.0 ±7 interpersonal and 8.7 ± 5 
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disorganized), while the participants in our sample had more pronounced 
interpersonal and disorganized traits (19.5 ± 5 cognitive-perceptual; 19.5 ±5 
interpersonal and 13.1 ± 2.6 disorganized). Previous studies have shown that negative 
and disorganized schizotypy tends to have greater cognitive similarities with 
schizophrenia (Kendler et al. 1991). In schizophrenia itself, negative and disorganized 
symptoms correlate stronger with cognitive impairment than positive symptoms 
(O'Leary et al. 2000; Rocca et al. 2005). Also, negative schizotypy is higher among 
relatives of schizophrenia patients (Tsuang et al. 2002). This has led some authors to 
hypothesize that negative schizotypy is the one that is more closely linked to 
schizophrenia (Tsuang et al. 2002). As a result the observed difference between the 
two studies could be regarded as further evidence for the claim that the P1 amplitude 
is a biomarker that reflects the level and type of psychopathology and is demonstrable 
in subjects with higher symptom severity.  
 
Thirdly, it should be noted that we did not correct our results for multiple 
comparisons. Therefore our results regarding P1 in schizotypy should be treated with 
caution and may necessitate further studies to replicate the findings. Also, the study 
has limited power to exclude abnormalities in the N1 and P2 components despite the 
confidence intervals supporting the conclusions drawn on the basis of the significance 
values (Tables 6.2 and 6.3).  
 
Finally, although we have used a standard approach to ERP identification, it is 
nonetheless possible that slow drifts or low frequency oscillations components might 
have been mistaken for the peaks of interest. However, given the short duration of the 
peaks of interest (20 and 30 ms for P1 and N1 respectively), their well-defined 
characteristics and the application of 0.3 Hz high-pass and 30 Hz low-pass filters, it is 
very unlikely that signal drifts or noise would have systematically obscured the ERPs 
of interest.  
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6.4.6. Conclusion 
 
The findings of a significantly reduced P1 amplitude in this group of healthy 
volunteers with elevated schizotypal traits support claims that the schizophrenia 
spectrum is characterized by an early sensory deficit. The abnormality also appears to 
contribute to higher order cognitive deficits, particularly in cases when only short 
stimulus encoding is possible. This provides evidence that the P1 deficit is a trait 
marker for the disease that could partly underlie the cognitive impairment in 
schizophrenia. 
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CHAPTER 7 
 
Abnormal neural oscillations in schizotypy 
during a visual working memory task:  
Support for a deficient top-down network?* 
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Abstract 
 
Neural oscillatory deficits may to be core features of schizophrenia spectrum 
disorders. In this study we aimed to test this hypothesis by examining early evoked 
oscillatory patterns in the EEG theta, beta and gamma bands of individuals with high 
schizotypal personality trait scores. We carried out an event-related experiment using 
a computerised delayed matching to sample working memory (WM) task on a sample 
of volunteers scoring high or low on the Schizotypal Personality Questionnaire (SPQ).  
Phase-locking factor (PLF), a measure of network synchronisation, was reduced in the 
beta and gamma bands in two distinct topographical regions (fronto-central and 
central-occipital).  In addition, signal power in the beta band was decreased in the 
high schizotypy group in the same fronto-occipital network. These findings suggest 
that abnormalities in functional connectivity, already described in schizophrenia, 
extend to schizotypy.  Further, the pattern and latency of altered neural oscillations in 
the high schizotypy group suggests a deficient modulation of sensory processing by 
higher-order structures. Such top-down deficits have been reported in schizophrenia 
and this data supports the idea that top-down dysfunction is a vulnerability trait that is 
independent of disease course, medication or symptom severity. 
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7.1. Introduction 
 
There is increasing evidence that the psychotic and cognitive manifestations of 
schizophrenia involve a distributed abnormality affecting multiple regions and their 
coordination (Andreasen 1999; Friston 2005). fMRI studies find evidence of a 
‘dysconnectivity’ syndrome affecting the efficiency of distributed dynamic 
coordination of neural activity (Liang et al. 2006; Liu et al. 2006). 
 
EEG and MEG have also been used extensively to study coherent neural activity in 
schizophrenia by analysing the patterns of spontaneous and evoked neural oscillations 
(Uhlhaas et al. 2008). These oscillations have been identified as the key mechanism 
that allows coordination of local and global neuronal populations (Singer 1999; Fries 
2009). Studies in animals and humans have shown that during cognitive acts neurons 
align the rhythm (phase) of their oscillations to achieve highly precise 
synchronization of their action potential discharges. The temporal correlation between 
the emergence of synchronized oscillations and various cognitive acts, such as 
perception, working memory and consciousness, supports the functional relevance of 
this mechanism (Varela et al. 2001). Also, oscillatory activity in different frequency 
bands has been implicated in coordinating separate cognitive processes. Oscillations 
in beta and gamma bands (13-30 and 30-200 Hz respectively) are implicated in the 
synchronization of local cortical networks and maintenance of the current cognitive 
set respectively (Engel et al.; Gray et al. 1989), while theta and alpha bands (4-7 and 
8-12 Hz) have been proposed to underlie long-distance coordination of local higher 
frequency activity (von Stein et al. 2000).  
 
Two main parameters are used to measure oscillatory activity: signal power and 
phase-locking factor (PLF). While the first measure provides information regarding 
the signal magnitude, the latter indicates the degree of synchronization of neural 
oscillations to the stimulus presentation, irrespective of power (Roach et al. 2008). 
PLF measures the consistency of this synchronization across trials, such that a PLF of 
zero indicates random phase distribution, while a maximum of one reflects exact 
alignment of phase. It provides information regarding the variability of neural 
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response and reductions in PLF have been interpreted as an indication of increased 
‘cortical noise’ (Winterer et al. 2000; Winterer et al. 2004).  
 
Many studies have reported oscillatory abnormalities in schizophrenia, some of the 
most common findings being decreased power and PLF of evoked oscillations 
(Uhlhaas et al. 2010). These are oscillations that are tightly time and phase-locked to 
the stimulus onset and have been linked to early encoding processes. Disruption in 
this activity has been associated with both perceptual and higher-order cognitive 
deficits (Hirano et al. 2008; Johannesen et al. 2008; Spencer et al. 2008; Haenschel et 
al. 2009; Uhlhaas et al. 2010). For example, studies in schizophrenia patients showed 
that the degree of evoked oscillatory abnormality predicts impairment on a working 
memory task (Haenschel et al. 2009; Haenschel et al. 2010). The relevance of 
oscillatory disturbance is not limited to cognition, as several studies have shown that 
the severity of psychotic, disorganized and negative symptoms is correlated with the 
extent of evoked oscillatory abnormality (Lee et al. 2003; Spencer et al. 2004; 
Spencer et al. 2008; Spencer et al. 2009). The implication of these findings is that 
disturbed oscillatory activity is a core mechanism of the disease that underpins diverse 
cognitive deficits and psychopathological symptoms.   
 
Studies in schizophrenia patients however suffer from several methodological 
weaknesses that may be particularly relevant when interpreting these subtle 
neurophysiological signals. In most cases the patients have had the disease for many 
years and chronic polypharmacy is common (Raine et al. 1995). Furthermore, 
behavioural and perceptive disturbances may reduce the number of accepted trials in a 
cognitive experiment. This in turn affects the reliability of key oscillatory parameters 
such as the phase-locking factor (Roach et al. 2008). In addition schizophrenia is 
associated with restricted educational opportunities (Gambini et al. 1992) and reduced 
IQ levels (Reichenberg et al. 2007) which could lead to problems in recruiting an 
appropriate control group.     
 
One way of tackling the confounding factors of chronicity, drug treatment, florid 
symptoms and low IQ is to recruit individuals with schizophrenia-like personality 
traits. This is based on theories that see schizophrenia and schizotypal personality as 
the two extremes in a spectrum of disorders (Meehl 1962). Extensive data has 
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supported this by demonstrating that the two conditions share a common 
psychopathological, genetic and neurobiological basis (Kendler et al. 1993; Siever et 
al. 2002; Siever et al. 2004). Despite these similarities schizotypal individuals are 
most commonly spared antipsychotic treatment, repeated hospitalizations or florid 
symptoms. In addition, the majority attain normal educational and IQ levels. 
 
The currently available data regarding evoked oscillatory activity in schizotypy comes 
from auditory steady-state studies (experimental settings in which the sensory system 
is entrained by stimuli of particular frequency). The results are mixed with two studies 
reporting abnormalities (Hong et al. 2004; Skosnik et al. 2006) and another one that 
did not find evidence of disturbance (Brenner et al. 2003).  
 
In this study we tested the hypothesis that schizotypy is associated with oscillatory 
abnormalities by studying the transient evoked-responses of a sample of non-
medicated high schizotypal individuals using a visual working memory (WM) 
paradigm. We chose this paradigm as previous studies have shown that the efficiency 
of the early information processing predicts the performance on the task (Haenschel et 
al. 2007; Haenschel et al. 2009; Haenschel et al. 2010). In accordance with this we 
have already reported findings of early event related potential  abnormalities that were 
related to WM deficits in the same sample and the current report is an analysis of the 
evoked time-frequency oscillations in the same dataset (Koychev et al. 2010). The 
hypothesis was that the high schizotypy group would exhibit abnormal oscillatory 
patterns in the earliest stages of information processing that are similar to those 
observed in schizophrenia patients.  
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7.2. Materials and methods  
 
7.2.1. Subjects 
 
University of Manchester research volunteering e-mail, posters and flyers list were 
used to recruit 45 healthy participants according to their online responses on the short 
version of the Schizotypal Personality Questionnaire (SPQ-B, (Raine 1991)). At the 
appointment, participants signed a consent form, completed the full version of the 
SPQ (Raine 1991) and were included if there was no current or past history of mental 
health disorders (established by using the Mini-International Neuropsychiatric 
Interview), neurological conditions, no uncorrected visual impairment and no 
prescribed medication. Based on the SPQ scores the participants were entered into 
two groups: high schizotypy one (HS) for those with scores of 43 or more and low 
schizotypy one (LS) for scores of 9 or below. The SPQ cut-off scores were based on 
the results from a previous study using SPQ in 760 students from the Manchester 
University (Barkus et al. 2008) and the SPQ manual  
(http://www-rcf.usc.edu/~raine/spqrel.html). 5 participants were excluded from the 
study at this stage (3 participants due to SPQ score out of range, 1 - history of 
depression and 1 – severe astigmatism). The participants that successfully passed the 
screening procedures completed the ERP experiment, as well as a semi-structured 
personality interview based on the Structured Clinical Interview for DSM-IV Axis II 
Disorders instrument. 
 
The presence of an identifiable and typically distributed P1 event-related component 
was selected as a criterion for including the data into further analysis. The data from 
two participants were excluded at this stage in accordance with this criterion (1 due to 
unidentifiable P1 and 1 due to midline instead of bilateral distribution of the P1). The 
final groups used in the analysis were 18 high schizotypes and 20 controls and they 
were well-matched for age and IQ. The demographic, SPQ and family mental health 
history data is presented in table 7.1. The results from the SCID-II interview in the 
high schizotypy group revealed that 12 participants met the criteria for a personality 
disorder (5 paranoid, 3 paranoid and schizotypal, 2 schizotypal, 1 schizoid and 1 
depressive), 5 were subtreshold (2 paranoid, 2 schizotypal and 1 schizoid) and 1 did 
Page |   
 
175 
not meet any criteria for a personality disorder. No participants from the control group 
fulfilled the SCID-II criteria for personality disorders.  
 
Table 6.1. Demographic and mental health family history data of schizotypal 
individuals and controls 
 High schizotypes Controls P value 
Age 23.1 ± 4.1 23.5  ± 3.4 .7 
Sex    
Male 12 13  
Female 6 7  
Handedness    
Right 18 17  
Left 0 3  
IQ (NART) 114.3 ± 4.8 114.9 ± 4.8 .7 
SPQ score    
SPQ total score 49.4 ± 5.3 3.1 ± 2.3 <.001 
Cognitive-perceptual 
SPQ score 
19.5 ± 5 .7 ± .9  
Negative SPQ score 19.5 ± 5 1.6 ± 1.6  
Disorganized SPQ 13.1 ± 2.6 1.0 ± 1.1  
Family history of 
schizophrenia 
   
First-degree 1 0  
Second-degree 4 3  
No history 13 17  
 
 
7.2.2. Stimuli and task – ERP experiment 
 
A Sternberg-type delayed discrimination task (minor modifications from a previously 
published study (Haenschel et al. 2007)) was presented on a personal computer using 
E-Prime software (Psychology Software Tools, Inc., Pittsburgh, the USA) (Figure 
7.1). For details see (Koychev et al. 2010).  
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Figure 7.1.  Working memory event-related potential task. During encoding one, two 
or three images were presented for 400 ms seconds each separated by an 
interstimulus interval of 600 ms. A delay period of 6 seconds ensued (maintenance 
phase). A target image then appeared and remained on the screen for 3 seconds and 
the participants were required to indicate by pressing a button whether it was shown 
during the encoding phase or not (retrieval phase). An interstimulus interval of 1 
second separated the trials. 
 
7.2.3. Data acquisition, processing and analysis 
 
Continuous EEG recording was obtained using ActiveTwo BioSemi electrode system 
(BioSemi, Amsterdam, the Netherlands) from 72 electrodes digitized at 512 Hz with 
an open passband from DC to 150 Hz. Data were analyzed using BESA version 5.2 
(Brain Electric Source Analysis, Gräfelfing, Germany). Only trials where the 
participants responded correctly were included in the analysis. The epoch within each 
trial was defined as the period starting at 400 ms prestimulus and ending at 1000 ms 
poststimulus. For the encoding phase, the stimulus was defined as the last object to 
appear within the encoding series (object 1 in load 1, object 2 in load 2 and object 3 in 
load 3). For the retrieval phase, the stimulus was the target image. An automatic 
predefined source model was used for artifact correction in the period from 400 ms 
prestimulus to 1000 ms poststimulus (Ille et al. 2002). The model included 
topographies for horizontal, vertical eye movements and blinks. These standard 
templates were used to apply weighted corrections to all channels in trials in which 
   
Encoding  
phase 
Maintenance  
phase 
Retrieval and 
response 
phase 
600 ms 400 ms 600 ms 400 ms 600 ms 400 ms 6 sec 3 sec 1 sec 
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the signal amplitude in the horizontal or vertical channels oculomotor channels 
exceeded ±250 µV and ±150 µV respectively. The mean percentage acceptance rate 
and the standard deviation for the two groups is as follows: high schizotypes - 
encoding 87 ± 2 % and retrieval 89 ± 2%, controls - encoding 89 ± 2 % and retrieval 
91 ± 2%. For full details on data acquisition and analysis, see (Chapter 6).  
 
The retained trials were subjected to a complex Morlet wavelet transformation and 
signal power and phase-locking factor values were calculated for each time point 
according to Tallon-Baudry et al. in frequency steps of 1Hz (Tallon-Baudry et al. 
1997). The wavelet transformation results in complex coefficients of the 
decomposition of EEG signal as a weighted sum of the wavelet functions. It can be 
seen as a convolution of signal with wavelet functions: windowed, complex sinusoids, 
with the distinctive property that the width of the Gaussian window is coupled to the 
sinusoid frequency. Therefore as the frequency increases the time resolution 
increases, whereas the frequency resolution decreases (Tallon-Baudry et al. 1997). 
Signal power is a measure of the magnitude, i.e. the absolute value of the wavelet 
coefficients. The phase-locking factor (PLF) is a quantitative approach for measuring 
the phase synchronization that tests the consistency of phases across trials in the EEG 
spectrum at particular frequencies. The PLF at frequency f and time point t is defined 
as  
  
Where  is the phase of the complex wavelet coefficients  and L is the number 
of trials. This corresponds to projecting of wavelet coefficients onto a unit circle in 
the complex plane, and therefore is independent of the signal power. 
 
PLF is a measure of the phase variability across trials within each electrode. It 
provides information regarding the degree of synchronization between the oscillations 
and the event onset, separate from its signal power. PLF ranges between 0 and 1, 0 
indicating completely random phase distribution across trials and 1 perfectly 
synchronized phase angles across trials (Roach et al. 2008). The measures were 
calculated for three frequency bands (4-14, 14-30 and 30-80 Hz). Peaks of activity 
were identified in each of the three bands by inspecting the time-frequency plots of 
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each group in the encoding condition. Topography plots were generated for the time 
and frequency ranges of these peaks and on the basis of their inspection electrodes of 
interest were selected. The values of the power and PLF of these groups of electrodes 
were extracted for each level of the task for encoding and retrieval separately.  
 
Repeated measures ANOVA with a within-subjects factor of working memory load 
and between-subjects factor of group was performed on the signal power and PLF 
values. An additional within-subject factor of region was entered in the cases where 
activity was present in two separate topographical regions in the selected time and 
frequency windows. Two-tailed Pearson’s correlations between the two regions were 
also ran in each WM load. In the case of a significant factor of WM load, polynomial 
contrast was used to determine the characteristics of the effect.  
 
7.2.4. Ethical Approval 
 
The study has been approved by The University of Manchester Ethics committee 
(reference number 08175) and has been carried out in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki. 
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7.3. Results 
 
7.3.1. Behavioural data 
 
No difference between the two groups was found in terms of their reaction times. The 
HS group however had a significantly lower accuracy (p = .034). In both groups 
accuracy decreased with WM load (p < .001) and this relationship was linear (p < 
.001).  
 
7.3.2. Time-frequency analysis data 
 
7.3.2.1 Alpha and theta band range 
 
There was a peak of activity in both participant groups at 150–250 ms in the 5-8 Hz 
band. This effect was due to a bilateral occipital increase in power (electrodes P5, P6, 
P7, P8, PO8, PO7, PO4, PO3, O2 and O1). The values of these electrodes were 
averaged into one dependent variable and entered into a repeated ANOVA with WM 
load as the within-subject factor and schizotypy as the between-subject factor. 
 
5-8 Hz at 150-250 ms: Signal power  
In encoding, the main effect of schizotypy was not significant. There was a main 
effect of WM load (F(2, 72) = 5.672, p = .01) due to its positive linear correlation 
with theta power (F(1, 36) = 7.332, p = .01). This effect was significantly more 
pronounced in LS than in HS, producing a significant WM load and schizotypy 
interaction (F(2, 72) = 4.743, p = .01). Post-hoc contrasts showed that the interaction 
was due to the two groups being statistically different at WM loads 2 and 3 in 
comparison with load 1 (F(1, 36) = 5.388, p = .026 and F(1, 36) = 6.006, p = .019). 
 
In retrieval, the main effects of WM load, schizotypy and their interaction were not 
statistically significant. 
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5-8 Hz at 150-250 ms: Phase-locking factor  
In encoding, there was no main effect of schizotypy or WM load. The interaction 
between the two factors however was of borderline statistical significance (F(2,72) = 
2.432, p = .09). Polynomial contrast revealed that the relationship was linear, but in 
opposite direction in the two groups (F(1,36) = 5.284, p = .03). Inspection of the 
marginal means showed that while PLF increased with WM load in LS it decreased in 
HS. Post-hoc comparisons between the WM loads revealed that the group and WM 
load interaction was significant for WM load 3 relative to WM 1 (F(1, 36) = 5.284, p 
= .027). 
 
In retrieval the main effects of WM load, schizotypy and their interaction were not 
statistically significant. 
 
7.3.2.2 Beta band range 
 
Inspection of the time-frequency plots revealed that there was a peak of activity in the 
14-28 Hz band at the 50-150 ms period post-stimulus (Figure 7.2A). The topography 
plots (Figure 7.2B) suggested that the activation was due to two groups of electrodes: 
fronto-central (FCz, FC1 and FC2) and central-occipital (POz and Pz). Therefore in 
addition to the factors of WM load and schizotypy we added a within-subject factor of 
region (fronto-central and central-occipital). 
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Figure 7.2. Oscillatory activity in the -200 to 800 ms period and 14-30 Hz range 
during encoding stage of the WM paradigm. Signal power on the left-hand side and 
phase-locking factor on the right-hand side. A peak of activity is identified at 50-200 
ms in the 14-28 Hz band range (A). Its values for power and PLF are plotted 
topographically in the two schizotypy groups (B). Two groups of electrodes were 
selected for statistical analysis (FC1, FC2 and FCZ vs. Pz and POz). Abbreviations: 
LS group – low schizotypy group; HS group – high schizotypy group.   
 
14-28 Hz at 50-150 ms: Signal Power 
During encoding, the main effect of schizotypy did not reach significance (F(1,36) = 
2.522, p = .12, Figure 7.2). There was no main effect of WM load or region and WM 
load and schizotypy did not interact.  
 
During retrieval, LS showed significantly greater beta band activity compared to HS 
(F(1,36) = 4.932, p = .03). The main effect of WM load approached significance 
(F(1,36) = 2.562, p = .08), but it did not interact with schizotypy. Also, in both groups 
the activation in the occipital electrodes was greater in comparison to the fronto-
central electrodes (F(1,36) = 8.451, p = .01). 
 
14-28 Hz, 50-150 ms: Phase-locking factor 
During encoding the LS group had significantly greater PLF values compared to HS 
(F(1,36) = 17.119, p < .001, Figure 7.2). There was no main effect of WM load nor 
did it interact with schizotypy. PLF was significantly greater in the occipital 
electrodes in comparison with the fronto-central electrodes in both groups (F(1,36) = 
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27.240, p < .001). However, the two sets of electrodes were significantly correlated in 
load 1 (r = .541, p <.001), load 3 (r = .426, p <.001) and in trend in load 2 (r = .317, p 
=.05).  
 
In retrieval, LS had significantly greater degree of PLF in comparison to HS (F(1,36) 
= 20.063, p<.001). There was no main effect of WM load, but it interacted with 
schizotypy at trend level for significance (F(2,72) = 2.510 p = .09). As in encoding, 
the effect of region was highly significant (F(1,36) = 45.252, p < .001). This was due 
to the occipital set of electrodes having significantly greater PLF values in 
comparison with the fronto-central electrodes. The PLF values in the two regions 
were again correlated, load 1 (r = .35, p = .03), load 2 (r = .54, p < .001), and in trend 
at load 3 (r = .30, p = .06). 
 
7.3.2.3. Gamma band range 
 
A peak of activity in the 30-50 Hz band at 50-200 ms was identified (Figure 7.3). The 
activity was evident in two regions: fronto-central (FCz, FC1 and FC2) and central-
occipital (Oz and POz). The ANOVA included a between-subject factor of 
schizotypy, as well as within-subject factors of WM load and region (fronto-central 
and central-occipital).  
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Figure 7.3. Oscillatory activity in the -200 to 800 ms period and 30-80 Hz range 
during encoding stage of the WM paradigm. Signal power on the left-hand side and 
phase-locking factor on the right-hand side. A peak of activity is identified at 50-200 
ms in the 30-50 Hz band (A). Its values for power and PLF are plotted 
topographically in the two schizotypy groups (B). Two groups of electrodes were 
selected for statistical analysis (FC1, FC2 and FCZ vs. Pz and POz). Abbreviations: 
LS group – low schizotypy group; HS group – high schizotypy group   
 
30-50 Hz at 50-200 ms: Signal Power 
In the encoding condition, the power of gamma activity in HS was significantly 
greater in comparison with LS (F(1,36) = 5.327, p = .03, Figure 7.3). There were no 
significant main effects or interactions involving WM load, schizotypy or region. The 
fronto-central and occipital sets of electrodes were correlated in loads 2 and 3 
(respectively r = .31, p =.06 and r = .58, p < .001).  
 
During retrieval, there were no main effects of schizotypy, WM load, region and the 
interaction between load and group was non-statistically significant. The two sets of 
electrodes were significantly correlated in load 2 (r = .52, p < .01) and at trend for 
significance in load 3 (r = .30, p = .07).  
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30-50 Hz at 50–200 ms: Phase-locking factor 
During encoding, the factor of schizotypy was statistically significant (F(1,36) = 
4.320, p = .04, Figure 7.3). Gamma PLF was significantly higher in LS compared to 
HS. There were no main effects of WM load, region and the interaction of WM load 
and schizotypy was not statistically significant. The fronto-central and occipital 
regions were correlated in loads 1 and 3 (r = .47, p < .01 and r = .43, p = .01, 
respectively). 
 
In the retrieval condition, the main effect of schizotypy was again significant, the LS 
group having greater PLF values compared to HS (F(1,36) = 4.38, p = .04). There was 
no main effect of WM load or region. WM load and schizotypy however interacted 
(F(2,72) = 7.34, p < .01). The contrasts revealed that this was due to a linear increase 
of gamma PLF with WM load in HS, but linear decrease in LS. 
 
The significance values for the main effects and schizotypy-by-WM load interaction 
during encoding and retrieval are presented in tables 7.2 and 7.3 respectively. 
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Table 7.2. Significance values of the ANOVA factors and the interaction between WM 
load and schizotypy during encoding in the theta, beta and gamma bands  
Theta band Beta band Gamma band 
 
Power PLF Power PLF Power PLF 
Schizotypy NS NS NS p < .001 p = .03 p = .04 
WM load p = .01 NS NS NS NS NS 
Region NA NA NS p < .001 NS NS 
Schizotypy 
and WM load 
interaction 
p = .01 p = .09 NS NS NS NS 
 
Table 7.3. Significance values of the ANOVA factors and the interaction between WM 
load and schizotypy during retrieval in the theta, beta and gamma bands 
Alpha band Beta band Gamma band  
Power PLF Power PLF Power PLF 
Schizotypy NS NS p = .03 p < .001 NS p = .04 
WM load NS NS p = .08 NS NS NS 
Region NA NA p = .01 p < .001 NS NS 
Schizotypy 
and WM load 
interaction 
NS NS NS p = .09 NS p = .01 
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7.4. Discussion 
 
In this study we compared the signal power and PLF of evoked oscillations during a 
working memory task in a sample of non-medicated high schizotypy participants 
compared to a low schizotypy control group. The HS group was characterized by 
reduced phase-locking factor values of evoked oscillations in the beta and gamma 
bands in two correlated sets of electrodes (fronto-central and central-occipital). 
Interestingly, the gamma band signal power in the same set of electrodes was 
significantly increased in the HS group relative to the LS controls.  
 
7.4.1. Phase-locking factor reductions and top-down abnormality in 
the schizophrenia spectrum disorders 
 
PLF is a measure of stimulus-induced phase locking of background EEG activity and 
it indicates the degree of variability of neuronal responses to sensory stimuli. The beta 
and gamma band PLF reductions in the HS group may indicate that HS did not exhibit 
the same degree of synchronized and coordinated neural activity as controls. Instead 
of building up coherent signal, HS appears to be characterized by increased ‘cortical 
noise’. This term was suggested by Winterer et al. to explain the common finding of 
decreased PLF in schizophrenia patients (Winterer et al. 2000; Winterer et al. 2004). 
The findings of PLF reduction in schizotypy are therefore compatible with 
suggestions that dysconnectivity is a core mechanism in the pathophysiology of the 
schizophrenia spectrum disorders.  
 
While the PLF reduction in the occipital electrodes could indicate impaired local 
integration, correlated abnormalities were also seen in a set of fronto-central 
electrodes. We interpret this correlation as evidence for synchronized activity between 
the two topographical regions in the 100-250 ms period after stimulus presentation. 
One mechanism to explain the abnormality in this synchronized network may involve 
disturbed small-scale organization at the level of the occipital cortex driving higher-
order cortical abnormalities, as already proposed by Butler et al. (Butler et al. 2007). 
Another is that the occipital abnormality is imposed by dysfunctional top-down 
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processes. Studies in perception support the existence of top-down factors that bias 
incoming signals and modulate the sensory cortex to respond more efficiently to 
behaviourally salient stimuli (Engel et al. 2001). Such contextual modulation of 
perception allows swift integration of new information with previous experience and 
ongoing action planning. Several research groups have already reported diminished 
top-down modulation of perception in schizophrenia. For example Ford et al. have 
demonstrated that patients lack a corollary discharge from motor to temporal cortex 
that normally occurs during speech initiation (Ford et al. 2004; Ford et al. 2007). As a 
result the dysregulated temporal cortex reacts with the same magnitude to both self- 
and non self-initiated speech. Decreased coupling during visual perception between 
frontal and visual cortex has also been reported (Harvey et al. 2011). Experiments by 
Dima et al. have indicated that the equilibrium between bottom-up and top-down 
processes in perception might be disturbed in schizophrenia. Using dynamic structural 
modelling (DCM) they reported that patients are less able to employ conceptually-
driven top-down strategies during perception and instead rely on bottom-up processes 
(Dima et al. 2009; Dima et al. 2010). On a similar line, an eye-tracking fMRI study 
showed that during smooth pursuit patients have higher BOLD signal in occipital 
retinal motion regions, but diminished activity in extra-striatal regions in the frontal 
and temporal cortex (Hong et al. 2005). Therefore, mounting evidence suggests that 
perception in schizophrenia has diminished access to top-down factors and instead 
relies primarily on bottom-up processes to form internal representation. Our results 
suggest that the same might be true for milder forms of the schizophrenia spectrum, 
such as schizotypy. 
 
The potential top-down abnormality in the schizophrenia spectrum has wide ranging 
implication. Diminished top down influences on sensory processing can help explain 
the increasing evidence of misattribution of salience in schizophrenia  (Roiser et al. 
2009). Inefficient priming of the sensory cortex by higher order structures could also 
account for the reports of primary perceptual deficits (Chen et al. 1999; Keri et al. 
2002; Keri et al. 2004; Green et al. 2006) and decreased sensory cortex responses to 
stimuli (Haenschel et al. 2007; Martinez et al. 2008) in schizophrenia patients. The 
timing of events from our study supports this possibility: the peak in activity of the 
frontal-occipital network occurred earlier than the visual P1 potential (peak of activity 
at 110 ms and 148 ms respectively) allowing a possible causal relationship.  
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The pathophysiology of the proposed top-down abnormality could be driven by a 
localized and/or a distributed deficit. A localized deficit might be due to an 
abnormality specific to higher-order structures such as the prefrontal cortex. This 
possibility is supported in principle by a prefrontal cortex lesion study showing that 
unilateral prefrontal cortex lesions are associated with ipsilateral visual P1 ERP 
amplitude reduction (Barcelo et al. 2000). This interpretation would be in line with 
the literature showing prefrontal cortex abnormalities in schizophrenia and might 
complement the dopamine theory of schizophrenia, as it can help explain the 
existence of abnormalities in areas outside of the dopamine-mediated striatum and 
prefrontal cortex. However, a distributed abnormality, such as general neuronal 
dysconnectivity (Andreasen 1999), might also be responsible for the emergence of 
top-down dysfunction. Such a deficit would affect the integrity of long-range 
projections that underpin top-down modulation. In the current study we observed a 
pattern of inconsistent phase of oscillations in the fronto-central and occipital regions 
in the HS group. These results argue that the primary dysfunction is one of functional 
decoupling of brain regions rather than a genuine effect of higher-order structure 
driving lower-order deficits and therefore probably favour the dysconnectivity 
hypothesis. 
 
Regardless of the underlying pathophysiology, the current results and previously 
published research argue that the top-down abnormality is a trait that reflects the 
vulnerability to schizophrenia. In an auditory MEG study that compared 
schizophrenia patients, ultra-high risk individuals and controls, Koh et al. found 
decreased alpha band PLF and power in a parieto-occipital network in both patients 
and at-risk individuals when compared with controls (Koh et al. 2010). The degree of 
PLF abnormality was higher in patients than in the ultra-high-risk group. The authors 
interpreted this as an indication that the extent of top-down dysfunction reflects the 
vulnerability to schizophrenia. Our results extend these findings by demonstrating a 
down-regulation of a similar neural network in schizotypy during visual perception. 
These results argue that the top-down modulation abnormality is a key feature of the 
schizophrenia spectrum and is not attributable to disease chronicity, medication or 
florid symptoms of schizophrenia.  
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7.4.2. Beta band signal power in schizotypy 
 
We also found that in the LS group the increase in evoked PLF in the fronto-central 
and occipital electrodes was associated with a burst of beta power activity. One of the 
recent hypotheses states that activity in this band signals the conformity of incoming 
sensory information with the current endogenous cognitive set (Engel et al. 2010). 
This is based on observations that paradigms that promote expectancy and 
endogenous top-down modulation, such as the one used in our experiment, evoke 
activity in the beta band (Okazaki et al. 2008; Iversen et al. 2009). In this context the 
finding of beta band augmentation in the LS group suggests that they treated the 
incoming stimuli as expected. Conversely, the beta PLF and power reduction in the 
HS group may indicate that their degree of expectancy regarding the sensory input 
was reduced. This could be attributed to the impaired top-down modulation proposed 
earlier.  
 
Beta band oscillatory abnormalities in schizotypy have been reported using steady-
state paradigm, in which brain oscillations are entrained in the frequency of repetitive 
sensory stimuli. The authors reported a negative correlation between the power of 
beta oscillations and SPQ scores in a sample of heavy cannabis users (Skosnik et al. 
2006). The present results extend the evidence for beta band abnormalities in 
schizotypy to non-substance abusing individuals and to settings where conventional 
transient evoked response paradigms are used.  
 
7.4.3. Gamma band signal power in schizotypy 
 
The finding of greater fronto-central and occipital evoked gamma oscillations in the 
HS group was unexpected. Nonetheless, this could again mean that the sensory input 
in the HS participants was treated as novel. Such interpretation is based on studies 
showing that conditions where responses are primarily stimulus-driven (e.g. free 
choice versus instruction driven tasks) cause a decrease in beta and increase in gamma 
band activity (Pesaran et al. 2008). It should be noted however that our finding of 
increased gamma power is at odds with the results from another steady-state study in 
schizotypy which reported a decrease in the power of gamma oscillations (Hong et al. 
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2004). This discrepancy could be attributed to the methodological differences that 
exist between steady-state and transient paradigms. The former demonstrates explores 
the ability to sustain prolonged activity in a particular frequency band, while the latter 
provides information regarding the unfolding of perceptual processes under natural 
conditions. Therefore, reduced ability to sustain gamma oscillations in a steady-state 
paradigm does not automatically mean that gamma oscillations have lost their 
function (e.g. discriminating between stimulus and top-down driven responses).  
 
7.4.4. Relationship between theta band oscillations and WM demand 
 
Finally, we also observed an abnormal pattern of occipital theta band activity in 
response to working memory demand in the HS group. In the LS group, the power 
and PLF of the oscillations in the 5-8 Hz range increased with task difficulty. In 
contrast to controls, in HS the power of the theta oscillations remained constant and 
theta PLF decreased with the increase of task difficulty. Such modulation by demand 
was also noted in respect to the P1 ERP amplitude in the initial analysis of this dataset 
(Koychev et al. 2010). We therefore consider the theta-band results to be at least 
partially the oscillatory correlate of the P1 abnormality that we reported earlier. Also, 
in a study using the same working memory task a correlation was found between P1 
amplitude and evoked theta but not alpha or beta band occipital activity (Haenschel et 
al. 2009). This is inline with extensive evidence showing that evoked theta 
oscillations underlie the formation of the P1 potential while alpha oscillations 
generate the N1 peak (Klimesch et al. 2004; Gruber et al. 2005). The finding of lesser 
modulation of theta oscillations by demand in the HS group relative to the LS controls 
can be interpreted as another manifestation of the proposed diminished top-down 
control in schizotypy.  
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7.4.5. Limitations  
 
A potential limitation of this analysis is the method of window of interest selection for 
the time-frequency analysis. In a slight modification from Tallon-Baudry et al. 
(Tallon-Baudry et al. 1997) we defined the windows of interest based on the activity 
in the control group on the basis of their stronger signal. I recognize this method as a 
potential bias towards the TF activity in the control groups. However examination of 
the time-frequency plots of the high schizotypy sample did indicate the presence of 
activities unique to them that might have been omitted from the analysis.  
 
It could be also argued that the effects we observe in the beta and gamma bands also 
represent primarily the activity that generates the P1 potential. However several lines 
of evidence argue against this point. Firstly, the available evidence indicates that 
synchronization in the theta and alpha, but not higher frequencies produce the signal 
that constitutes the visual P1 and N1 ERPs (Klimesch et al. 2004; Gruber et al. 2005). 
In accordance, the peaks in beta and gamma band activity in our study differed 
temporally and topographically from the P1 potential and the theta band oscillations. 
Specifically, the peaks in beta and gamma power and PLF began earlier 
(approximately 50 ms post-stimulus) than the P1 (approximately 110 ms) and peaked 
earlier (110 ms for gamma/beta and 148 ms for P1) than the P1. Also, while the P1 
potential and its respective theta band oscillations had a bilateral occipital 
topographical distribution (e.g. see Figure 6.6 in Chapter 6), the evoked beta and 
gamma oscillations had a fronto-central and central-occipital distribution (Figures 7.2 
and 7.3). We therefore conclude that the beta and gamma band results are a novel 
finding that is unaccounted for by the already published ERP analysis (Koychev et al., 
2010).    
 
It should also be noted that despite the considerable evidence suggesting an early 
dysfunctional top-down network in the schizophrenia spectrum, our finding of 
correlated fronto-central occipital activity could equally represent the same response 
that is volume conducted rather that the activation of separate neural populations. This 
limitation is inherent to voltage data subjected to laplacian transformation. 
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7.4.6. Conclusion 
 
In summary, the results of this study indicate that neural oscillatory abnormalities are 
a key feature of the schizophrenia spectrum disorders. The specific pattern of the 
disruption indicated the existence of dysfunctional top-down modulation of 
perception in schizotypy. As similar top-down deficits have already been reported in 
schizophrenia, this data supports the idea that top-down dysfunction is a vulnerability 
trait for the condition that is independent of disease course, medication or symptom 
severity 
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Abstract 
 
Cognition is a core symptom domain in schizophrenia that has been proposed to be 
due to a distributed abnormality in neural connectivity. The development of objective 
laboratory measures (biomarkers) to detect dysconnectivity is therefore a promising 
lead in defining schizophrenia etiologically. Experiments in patients using 
electrophysiological methods have demonstrated abnormal information processing 
and activation of distributed cortical networks during simple cognitive tasks. We have 
shown similar patterns in individuals with high schizotypal personality traits, with 
evidence of a down-regulated fronto-occipital network in the earliest stages of visual 
information processing during a working memory task. In the current study we used 
the same experimental paradigm to test if this dysfunctional fronto-occipital network 
is a manifestation of a core schizophrenia deficit. Electrophysiological recordings 
were acquired from twenty chronically ill, medicated patients diagnosed with either 
schizophrenia or schizo-affective disorder and 20 healthy volunteers while they 
conducted a working memory task. The patient group had significantly lower 
accuracy on the working memory task and a trend for slower responses. Early visual 
evoked potential P1 was reduced in patients. Analysis of the EEG oscillations showed 
decreased phase-locking factor (in the theta, beta and gamma bands) and signal power 
(theta frequency band). The beta and gamma oscillatory abnormalities were confined 
to two sets of correlated fronto and occipital electrodes. The findings of ERP and 
oscillatory abnormalities in patients with schizophrenia and schizoaffective disorder 
confirm the sensitivity of early visual information processing measures to the 
schizophrenia phenotype. The fronto-occipital distribution of the oscillatory 
abnormalities replicates our findings from a schizotypal sample and implicates a 
possible top-down dysfunction as a trait for the vulnerability to schizophrenia.  
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8.1. Introduction 
 
Schizophrenia is currently diagnosed on the basis of psychotic symptoms (e.g. 
hallucinations and delusions) present for most of the time in a 4-week period along 
with functional impairment. The lack of specificity and longitudinal stability of 
psychotic features (Jansson et al. 2007) leads to operational criteria accepting the risk 
that etiologically, prognostically and clinically heterogeneous disorders may be 
lumped together in one condition (Stober et al. 2009). This complicates within- and 
inter-sample analysis and limits the relevance of fundamental research. In respect to 
genetic studies for example, none of the identified risk genes are specific to 
schizophrenia but rather indicate a general vulnerability to mental health disorders or 
personality psychopathology (Allan et al. 2008). 
 
One way of decreasing the extreme clinical and probably etiological heterogeneity of 
the DSM-IV defined schizophrenia is to decompose its manifestations into distinct 
clinical dimensions (e.g. positive, negative, cognitive, disorganization, mood, motor 
symptom domains) (Tandon et al. 2009). These dimensions have been broadly 
replicated (Tandon et al. 2009) and discriminate with regard to treatment response and 
course (Davidson et al. 1997; Dikeos et al. 2006; Harvey et al. 2006). The dimensions 
may in turn reflect separate etio-pathogenic processes that are associated with 
measureable biological correlates (biomarkers or intermediate phenotypes) (Preston et 
al. 2005; Owen et al. 2007; Braff et al. 2008). The successful development of such 
biomarkers would validate the dimensions etiologically and may ultimately be better 
at defining specific drug targets (Thaker 2007).    
 
A dimension that may be particularly relevant to the vulnerability to schizophrenia 
and therefore its core pathophysiology is the cognitive symptom domain. Cognitive 
dysfunction is highly prevalent in schizophrenia (Saykin et al. 1991; Keefe et al. 
2005) and at-risk populations (Siever et al. 2004; Raine 2006), is present in the 
premorbid stages (Woodberry et al. 2008) and persists longitudinally (Rund 1998; 
Hoff et al. 2005). It has been hypothesized that this symptom domain may be at least 
partially due to impairments in the coordination of neural activity (coined 
‘dysconnectivity’) (Andreasen 1999; Friston 2005). Therefore, one prominent 
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direction of biomarker development is to objectively define the dysconnectivity 
phenotype associated with cognitive dysfunction.  
 
Defining neural connectivity patterns in schizophrenia has classically been undertaken 
while patients perform working memory tasks, a function considered to be a cardinal 
neuropsychological feature of the disease (Silver et al. 2003; Gooding et al. 2004). It 
is proposed to be subserved by the prefrontal cortex (Goldman-Rakic 1994) and 
research into connectivity using event-related fMRI e.g. (Thermenos et al. 2005) or 
electroencephalography e.g. (Barr et al. 2010) has therefore focused on activity within 
this region. Recent evidence has however indicated that WM deficit may at least 
partly be accounted for by early sensory deficits that disrupt information encoding 
(Javitt 2009). Specifically, an early event-related potential (P1) that is reduced in 
amplitude in patients and at-risk individuals (Butler et al. 2005; Yeap et al. 2006; 
Haenschel et al. 2007; Lalor et al. 2008; Yeap et al. 2008) has been shown to predict 
WM performance (Haenschel et al. 2007) and other executive functions (Butler et al. 
2009; Dias et al. 2011). In addition, the magnitude and inter-trial consistency of 
evoked neural oscillations that make up the early visual ERPs are also abnormal in 
schizophrenia (Hong et al. 2004; Uhlhaas et al. 2006; Uhlhaas et al. 2008; Haenschel 
et al. 2009; Haenschel et al. 2010; Koh et al. 2010) and this oscillatory aberration has 
also been shown to predict cognitive performance (Haenschel et al. 2009; Haenschel 
et al. 2010). Therefore, P1 and evoked oscillations could represent biomarkers of a 
dysconnectivity process that has a causative role in the cognitive domain of 
schizophrenia and may act as ‘footholds’ linking the cognitive dysfunction to its 
aetiology.  
 
One key limitation of using information processing biomarkers to aid the diagnostics 
of schizophrenia is their lack of specificity. Both P1 and evoked oscillation 
abnormalities have been reported in bipolar disorder (Ozerdem et al. 2008; Ozerdem 
et al. 2008; Yeap et al. 2009) and disorders that involve sensory or higher order 
cortical damage (Grayson et al. 1995; Barcelo et al. 2000; Grice et al. 2001; 
Weinstock-Guttman et al. 2003). A possible way to deal with this is to further 
characterize the temporal and spatial characteristics of early information processing in 
schizophrenia in view of producing a pattern that is relatively specific to the disorder. 
For example, the evoked oscillatory abnormalities in schizophrenia patients and at-
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risk individuals have been reported to affect distributed networks linking sensory 
cortex with higher order structures during auditory stimulation (Koh et al. 2010). This 
finding fits in the suggestion that the naturally occurring  top-down modulation of 
perception (Engel et al. 2001) may be disrupted in schizophrenia (Dima et al. 2009; 
Dima et al. 2010). Biomarkers of early top-down dysfunction could therefore be more 
specific to the schizophrenia phenotype and perhaps more informative of the 
pathophysiology of the cognitive deficits.  
 
In this study we aimed to test this hypothesis by examining the early information 
processing patterns using EEG in a sample of medicated schizophrenia patients. In 
order to ensure the presence of a prominent top-down component in perception we 
administered a working memory paradigm which was already demonstrated to elicit 
the effects of cognitive demand on perception (Haenschel et al. 2007). We expected to 
find that the evoked oscillatory abnormalities are confined to regions of correlated 
activity (sensory and higher order structure topographies). Our expectation was 
guided by findings from a previous study by our group, in which early information 
processing abnormality in schizotypal personality individuals (See Chapter 6) was 
associated with a down-regulation of an oscillatory network linking frontal and 
occipital topographical regions (See Chapter 7).  We therefore hypothesized that top-
down dysfunction is a trait marker of the vulnerability to schizophrenia and therefore 
should be demonstrable in patients with schizophrenia.   
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8.2. Materials and methods  
 
8.2.1. Subjects 
 
Twenty eight patients diagnosed according to DSM-IV with schizophrenia or 
schizoaffective disorder were recruited from mental health care teams and clozapine 
clinics in Greater Manchester and Merseyside areas in the United Kingdom. Patients 
were included if they: i) had been diagnosed at least 1 year prior to the appointment; 
ii) had been clinically stable for at least 6 months prior to the appointment;  iii) did 
not suffer from any neurological disorders; iv) had normal or corrected-to-normal 
vision. 7 patients were excluded due to poor performance on the working memory 
task: 3 patients did not complete it while 4 other patients had a below chance 
performance (less than 50 % correct responses). Also, the data from 1 patient was not 
included in the final analysis due to unacceptable signal-to-noise ratio.  
 
26 controls were recruited from a database of responders to an online version of the 
Schizotypal Personality Questionnaire (SPQ) (Raine 1991). Participants who scored 
in the average SPQ range (9-36) were invited for an appointment where they 
completed the questionnaire again and were included in the study if the score 
remained in the 9-36 range. The SPQ cut-off scores were based on the results from a 
previous study using the SPQ on the same population (See Chapter 4) and the SPQ 
manual (http://www.rcf.usc.edu/raine/spqrel.html). All controls were free from 
prescribed medication (apart from the contraceptive pill) and had no history of mental 
health disorders as confirmed by the Mini-International Neuropsychiatric Interview. 
All controls reported normal or corrected-to-normal vision and had no history of 
neurological conditions. 6 controls were excluded before any data was recorded due 
to SPQ scores out of the 9-36 range.  
 
The final groups used in the analysis consisted of 20 (5 female) patients and 20 (7 
female) controls. They were well matched in terms of age, but the controls had a 
significantly higher IQ (p <. 001). All included patients were taking antipsychotic 
medication (13 clozapine only, 1 clozapine and flupentixol, 1 clozapine and 
quetiapine, 1 clozapine and amisulpride, 2 risperidone depot, 1 risperidone depot and 
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aripiprazole and 1 on aripiprazole only). 9 of the patients were also taking selective 
serotonin reuptake inhibitors (SSRIs) for mood and anxiety symptoms. The 
demographic data of the included sample, the mean SPQ of the controls, as well as the 
mean duration of disease, BPRS and daily dosage (DDD) of the patient group are 
presented in table 8.1.  
 
Table 8.1. Subject characteristics 
 
Schizophrenia 
patients 
Controls 
Significance 
value 
Age 36.4 ± 9.0 34.7  ± 7.8 p = .54 
Sex 5 female 7 female x2 = .496 
IQ (NART) 105.9 ± 9.0 114.6 ± 4.9 p = .001 
SPQ total score NA 21.0 ± 7.8  
BPRS total score 28.4 ± 8.4 NA  
DDD 1.53 ± .51 NA  
Duration of disease 14.5 ±7.2 NA  
Family history of 
schizophrenia 
   
First-degree 2 0  
Second-degree 3 1  
Third-degree 4 0  
No history 11 19  
 
 
8.2.2. Stimuli and task – ERP experiment 
 
A delayed discrimination task (minor modifications from a previously published study 
(Haenschel et al. 2007)) that probes the effect of working memory load on visual 
information processing was presented on a personal computer using E-Prime software 
(http://www.pstnet.com/) (Figure 8.1). Thirty-six non-natural objects were presented 
in the center of a black screen (0.6 x 0.6 visual angles). The participants were 
instructed to encode one, two or three subsequently presented images into WM. After 
the delay (maintenance) period a target probe appeared on the screen and the 
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participants had to indicate whether it was part of the initial sample set by pressing a 
button. Each block consisted of 60 trials, 20 of each working memory load. The trials 
were intermixed pseudorandomly. All subjects included in the analysis completed 4 
blocks.  
 
 
 
Figure 8.1. Working memory event-related potential task. During encoding one, two 
or three images were presented for 400 ms seconds each separated by an 
interstimulus interval of 600 ms. A delay period of 6 seconds ensued (maintenance 
phase). A target image then appeared and remained on the screen for 3 seconds and 
the participants were required to indicate by pressing a button whether it was shown 
during the encoding phase or not (retrieval phase). An interstimulus interval of 1 
second separated the trials. 
 
 
8.2.3. ERP data acquisition, processing and analysis 
 
Continuous EEG recording was obtained using ActiveTwo BioSemi electrode system 
(BioSemi, Amsterdam, the Netherlands) from 72 electrodes digitized at 512 Hz with 
an open passband from DC to 150 Hz. In the BioSemi system, the classical ‘ground’ 
electrodes are replaced with two separate ones: Common Mode Sense (CMS) active 
electrode and Driven Right Leg (DRL) passive electrode. These 2 electrodes form a 
feedback loop, which drives the average potential of the subject (the Common Mode 
voltage) as close as possible to the ADC reference voltage in the AD-box (the ADC 
reference can be considered as the amplifier ‘zero’). A detailed description of the 
   
Encoding  
phase 
Maintenance  
phase 
Retrieval and 
response 
phase 
600 ms 400 ms 600 ms 400 ms 600 ms 400 ms 6 sec 3 sec 1 sec 
Page |   
 
201 
BioSemi electrode referencing and grounding convention can be found at 
http://www.biosemi.com/faq/cms&drl.htm.  
 
Data were analyzed using BESA version 5.2 (Brain Electric Source Analysis, 
Gräfelfing, Germany). For the purpose of the analysis an averaged reference was 
employed. Only trials where the participants responded correctly were included in the 
analysis. The epoch within each trial was defined as the period starting at 400 ms 
prestimulus and ending at 1000 ms poststimulus. For the encoding phase, the stimulus 
was defined as the last object to appear within the encoding series (object 1 in load 1, 
object 2 in load 2 and object 3 in load 3). For the retrieval phase, the stimulus was the 
target image. Baseline was defined as the period -100 to 0 ms. An automatic 
predefined source model was used for artifact correction in the period from 400 ms 
prestimulus to 1000 ms poststimulus (Ille et al. 2002). The model included 
topographies for horizontal, vertical eye movements and blinks. These standard 
templates were used to apply weighted corrections to all channels in trials in which 
the signal amplitude in the horizontal or vertical channels oculomotor channels 
exceeded ±250 µV and ±150 µV respectively. The continuous data was then 
examined for outstanding blink artifacts and those were removed manually. The trials 
that survived artifact correction were averaged together with a low-pass filter of 
forward phase shift of 0.3 Hz (6 dB/octave) applied before the procedure.  A high-
pass filter of 0-phase shift of 30 Hz (24 dB/octave) was used after averaging.  The 
mean percentage acceptance rate and the standard deviation for the two groups is as 
follows: schizophrenia patients - encoding 91.2 ± 6.7 % and retrieval 91.8 ± 10.1%, 
controls - encoding 97.8 ± 2.7 % and retrieval 98.5 ± 1.7%. This difference was 
statistically significant for both encoding and retrieval (p < .001 and p < .01, 
respectively).  
 
Because the task was designed to probe the early visual components (P1, N1, P2), 
data from three pairs of occipital electrodes were used in the analysis (PO4/PO3, 
PO8/PO7, O2/O1). Utilizing the fact that the P1 and N1 visual potentials are well 
characterized (Di Russo et al. 2002), global field power was employed to identify P1 
and N1 as the first two major consecutively occurring peaks of respectively positive 
and negative voltage in the 50-200 ms post-stimulus period. Their latencies were 
defined as the time points of maximum amplitude in the respective peaks. The P1 
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amplitude was defined as the mean amplitude of the 20 ms window around the P1 
peak (local mean amplitude) (Luck 2005). The same approach was used for N1, 
whereby mean amplitude was calculated for a 30 ms centered on the N1 peak. The 
mean amplitudes and latencies of the P1 and N1 peaks were entered into repeated 
measures ANOVAs with within-subjects factors of WM load and electrode and a 
between-subject factor of group (patients and healthy volunteers). In case of a 
significant main effect of WM load, we used polynomial contrast to determine the 
character of the effect.  
 
8.2.4. Time-frequency analysis  
 
The retained trials were subjected to a complex Morlet wavelet transformation and 
signal power and phase-locking factor values were calculated for each time point 
according to Tallon-Baudry et al. in frequency steps of 1Hz (Tallon-Baudry et al. 
1997). The wavelet transformation results in complex coefficients of the 
decomposition of EEG signal as a weighted sum of the wavelet functions. It can be 
seen as a convolution of signal with wavelet functions: windowed, complex sinusoids, 
with the distinctive property that the width of the Gaussian window is coupled to the 
sinusoid frequency. Therefore as the frequency increases the time resolution 
increases, whereas the frequency resolution decreases (Tallon-Baudry et al. 1997). 
Signal power is a measure of the magnitude, i.e. the absolute value of the wavelet 
coefficients. The phase-locking factor (PLF) is a quantitative approach for measuring 
the phase synchronization that tests the consistency of phases across trials in the EEG 
spectrum at particular frequencies. The PLF at frequency f and time point t is defined 
as  
  
Where  is the phase of the complex wavelet coefficients  and L is the number 
of trials. This corresponds to projecting of wavelet coefficients onto a unit circle in 
the complex plane, and therefore is independent of the signal power. 
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PLF is a measure of the phase variability across trials within each electrode. It 
provides information regarding the degree of synchronization between the oscillations 
and the event onset, separate from its signal power. PLF ranges between 0 and 1, 0 
indicating completely random phase distribution across trials and 1 perfectly 
synchronized phase angles across trials (Roach et al. 2008). The measures were 
calculated for three frequency bands (4-14, 14-30 and 30-80 Hz). Inspection of the 
time-frequency plots revealed peaks of activity in the 100-250 ms period post-
stimulus in subsets of each of the three time-frequency range (5-8, 14-28 and 30-50 
Hz ranges). Topography plots showed that the activity was confined to two separate 
sets of electrodes: fronto-central (FC1, FC2, FCz, C1, C2 and Cz) and occipital (PO8, 
PO4, 02, O1, PO3, PO7, Oz and POZ). The mean power and PLF values of these two 
sets of electrodes were extracted for each level of the task for encoding and retrieval 
separately. The repeated measures ANOVA therefore included two within-subject 
factors (WM load and electrode region: occipital and fronto-central) and one between-
subject factor (group: patients and healthy volunteers). Spearman’s correlations were 
performed to determine whether the activity in the two sets of electrodes is correlated.  
 
8.2.5. Covariate analysis 
 
The potential influence of disease duration, symptom severity and medication dose on 
the electrophysiological measures was investigated by including them as covariates in 
a secondary analysis on the patient group only. Disease chronicity was expressed in 
years of illness; symptom severity was represented by the total score on the Brief 
Psychiatric Rating Scale (BPRS, (Overall et al. 1962); medication dose was described 
using Defined Daily Dose (DDD). DDD is a statistical measure of drug consumption 
developed by the World Health Organisation 
(http://www.whocc.no/ddd/definition_and_general_considera/). It is defined as the 
assumed average maintenance dose per day for a drug used for its main indication in 
adults. DDD was preferred to the conventionally used chlorpromazine equivalents due 
to its good reliability (Nose et al. 2008) and the lack of agreement on the 
chlorpromazine equivalence of clozapine (Rey et al. 1989; Woods 2003). Significant 
effects were followed by correlations between the outcome variable and the covariate 
to determine the direction of the effect.     
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8.2.6. Ethical Approval 
 
The study has been approved by 11th Regional Ethics Committee, Preston (reference 
number 09/H175/90) and has been carried out in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki. 
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8.3. Results 
 
8.3.1. Behavioural data 
 
Data on reaction time and accuracy of responses on the task is presented on Figure 
8.2. In terms of reaction times, there was a trend for slower responses in the 
schizophrenia group compared to controls (F(1,38) = 3.033, p = .090). There was a 
main effect of WM load (F(2,76) = 95.599, p < .001), the reaction time increasing 
linearly with demand (F (1,38) = 130.029, p < .001) in both groups.  
 
The patient group also had significantly lower accuracy (F(1,38) = 46.424, p < .001) 
compared to controls. The effect of WM load on the percentage correct variable was 
significant (F(2,76) = 32.809, p < .001) due to linear decrease in accuracy with 
demand/or load (F(1,38) = 726.097, p < .001) in both groups. 
 
 
 
 
Figure 8.2. Reaction times and accuracy of the ERP task in both study groups. 
 
8.3.2. ERP data 
 
P1 component 
The patient group had a significantly reduced P1 amplitude during encoding (P1 at 
128 ms; F(1,39) = 5.763, p = .02, Figure 8.3) and retrieval (P1 at 118 ms; F(1,39) = 
7.138, p = .01, Figure 8.3) compared to controls. There was no main effect of WM 
load on amplitude and it did not interact with diagnosis.  There was no effect of group 
or WM load on latency, not did they interact. 
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Figure 8.3. P1 amplitude in response to encoding and retrieval stimuli across the 
three WM loads in both groups. 
 
N1 component 
The amplitude of the N1 potential was significantly reduced in the patient group 
during retrieval (N1 at 180 ms, F(1,38) = 5.830, p =.02) but not encoding (N1 at 177 
ms).  There was no main effect of WM load, but it interacted with group during 
retrieval (F(2,76) = 4.354, p = .02, Figure 8.4). The effect was due to reduction of N1 
amplitude with load in patients but a reversed pattern in controls (F(1,38) = 5.608, p 
=.02). 
 
 
 
 
 
 
 
 
Figure 8.4. N1 amplitude in response to encoding and retrieval stimuli across the 
three WM loads in both groups. 
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8.3.3. Time-frequency analysis 
 
8.3.3.1. Phase-locking factor data 
 
Table 8.2 presents a summary of the results concerning PLF.  
 
Table 8.2: Summary of PLF results  
PLF Encoding Retrieval 
 5-8 Hz 16-28 Hz 30-50 Hz 5-8 Hz 16-28 Hz 30-50 Hz 
ANOVA: p 
values       
Group < .001 .02 .01 < .001 .04 NS 
load  NS NS .07 .04 NS NS 
Group-by-load NS NS NS NS NS NS 
Clinical 
correlates:  
p values 
   
   
Severity NS NS NS . NS NS NS 
Duration .05 NS NS .08 NS NS 
Drug dose NS NS NS .06 .07 NS 
 
PLF: Theta and alpha band range 
In the 5-8 Hz range (Figure 8.5), the patient group had significantly lower PLF values 
relative to the controls in both encoding (F(1,38) = 14.730, p < .001) and retrieval 
(F(1,38) = 12.559, p = .001). There was a main effect of WM load only during 
retrieval (F(2,76) = 3.382, p = .039), due to a linear increase of PLF with load. The 
factor electrode region was highly significant in encoding (F1, 38) = 33.862, p < .001) 
and at trend in retrieval (F(1,38) = 3.451, p = .071). This was due to greater PLF 
values in the occipital electrodes when compared with the fronto-central electrodes. 
The two sets of electrodes however were highly correlated in all WM loads in both 
encoding (WM load 1 (r = .59, p < .001), 2 (r = .61, p < .001) and 3 (r = .76, p < 
.001)) and retrieval (WM load 1 (r = .58, p < .001), 2 (r = .62, p < .001) and 3 (r = .57, 
p < .001)). There was no interaction between WM load and group. 
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. 
 
 
 
 
 
 
 
Figure 8.5. Topography plot of the phase-locking factor values of the 5-8 Hz 
oscillations in the 100-250 ms post-stimulus period in both study groups. View from 
above; frontal electrodes facing upwards and occipital electrodes facing downwards 
 
PLF: Beta band range 
In the 16-28 Hz range (Figure 8.6), the main effect of group was significant in both 
encoding (F(1,38) = .6.962, p = .02) and retrieval (F(1,38) = 4.491, p = .04). This was 
due to higher PLF values in healthy controls relative to patients. The factor of 
electrode region was significant during encoding (F(1,38) = 30.616, p < .001) and 
retrieval (F(1,38) = 4.407, p = .04). This was due to higher values in the occipital 
region relative to the fronto-central region. The two sets of electrodes were correlated 
in encoding (WM load 1 (r = .62, p < .001), 2 (r = .58, p < .001) and 3 (r = .34, p = 
.03)) and in retrieval (WM load 2 (r = .36, p = .02) and 3 (r = .44, p < .01), but not 
WM load 1). There was no main effect of WM load nor did it interact with group. 
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Figure 8.6. Topography plot of the phase-locking factor values of the 14-28 Hz 
oscillations in the 100-250 ms post-stimulus period in both study groups. View from 
above; frontal electrodes facing upwards and occipital electrodes facing downwards 
 
PLF: Gamma band range 
In the 30-50 Hz range (Figure 8.7), the patient group had significantly lower PLF 
values during encoding only (F(1,38) = 7.276, p = .01). PLF increased in encoding 
with WM demand, producing a trend for significant main effect of WM load (F(2,76) 
= 4.592, p =.07). There was no main effect of region nor did WM load interact with 
group. The two electrode regions were correlated during encoding (at trend in WM 
load 1 (r = .29, p = .07) and significantly at WM load 3 (r = .62, p < .01)) and retrieval 
(WM load 1 (r = .63, p < .001), load 2 (r = .36, p = .02) and 3 (r = .54, p < .01)). 
 
 
 
 
 
 
 
 
Figure 8.7. Topography plot of the phase-locking factor values of the 30-50 Hz 
oscillations in the 100-250 ms post-stimulus period in both study groups. View from 
above; frontal electrodes facing upwards and occipital electrodes facing downwards 
 
Page |   
 
210 
8.3.3.2. Signal power 
 
Table 8.3 presents a summary of the results concerning signal power.  
 
Table 8.3: Summary of power results  
Power Encoding Retrieval 
 5-8 Hz 16-28 Hz 30-50 Hz 5-8 Hz 16-28 Hz 30-50 Hz 
ANOVA: p 
values       
Group .01 NS NS .008 NS NS 
load  NS NS NS NS NS NS 
Group-by-load NS .04 NS NS NS .06 
Clinical 
correlates:  
p values 
   
   
Severity NS NS NS NS NS NS 
Duration NS NS NS NS NS NS 
Drug dose NS .04 NS .02 NS NS 
 
 
The only significant effects of interest occurred in the 5-8 Hz range (Figure 8.8). The 
controls had significantly greater signal power than the patients in encoding (F(1,38) 
= 6.611, p = .01) and retrieval (F(1,38) = 7.959, p <.01). The main effect of region 
was also significant due to the greater activation in the occipital electrodes when 
compared with the fronto-central ones (F(1,38) = 9.493, p <.01 and F(1,38) = 9.901, p 
<.01 for encoding and retrieval respectively). This effect of region was significantly 
more pronounced in the controls relative to the patients (F(1,38) = 4.290, p = .045) 
during encoding. The occipital and fronto-central electrodes were nonetheless 
significantly correlated in encoding (WM load 1 (r = .58, p < .001), 2 (r = .58, p < 
.001) and 3 (r = .67, p < .001)) and retrieval (WM load 1 (r = .78, p < .001), 2 (r = .78, 
p < .001) and 3 (r = .87, p < .001)). WM load exerted no main effect and did not 
interact with the other factors.  
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Figure 8.8. Topography plot of the signal power values of the 5-8 Hz oscillations in 
the 100-250 ms post-stimulus period in both study groups. View from above; frontal 
electrodes facing upwards and occipital electrodes facing downwards 
 
8.3.4. Effects of symptom severity, medication and chronicity  
 
There were no significant covariates in the ERP analysis. Symptom severity was not a 
significant confounding factor in any of the analyses.    
 
The covariate of DDD was significant at trend in retrieval in the 5-8 Hz band PLF 
comparisons (F(1,16) =3.990, p = .06). The effect was due to an increase of PLF with 
medication dose. DDD was also a significant covariate in the 5-8 Hz band signal 
power analysis in retrieval (F(1,16) = 6.860, p = .02) but not in encoding. The effect 
was due to a decrease in power with increasing medication dose.  
 
Duration of illness approached significance in encoding and retrieval with respect to 
the 5-8 Hz PLF values (F(1,16) = 4.390, p = .05 and F(1,16) = 3.442, p = .08, 
respectively). This was due to a decrease in PLF with increase in disease duration. A 
similar trend was observed in respect to 14-28 Hz band PLF in retrieval (F(1,16) = 
3.850, p = .07) but not in encoding.  
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8.4. Discussion 
 
In this study we sought to clarify the neural oscillatory patterns that underlie early 
visual information processing abnormalities in schizophrenia. In a sample of 
medicated patients with chronic schizophrenia we found that the widely replicated 
reductions of in the P1 visual evoked potential were associated with reduction in the 
PLF values of theta, beta and gamma oscillations, as well as reductions in the signal 
power of theta oscillations. Importantly, these oscillatory abnormalities were confined 
to a fronto-occipital network that is similar to the one we described in non-medicated 
high schizotypy individuals using identical experiment settings (see Chapter 7). We 
will proceed to discuss how these individual findings relate to our goal of defining a 
sensitive and specific dysconnectivity biomarker of the cognitive symptom domain in 
schizophrenia. As cognition has been proposed to be a core, trait characteristic of the 
disorder we will assess the evidence regarding the trait status of the measures. 
 
8.4.1. ERP results 
  
Reduction in the amplitude of the early P1 VEP is a well replicated finding in 
schizophrenia (Butler et al. 2007; Yeap et al. 2008; Yeap et al. 2008). This 
abnormality has been shown to be unaffected by disease chronicity or medication 
dosage (Yeap et al. 2008) and was demonstrated in a sample of non-medicated first-
episode patients (Yeap et al. 2008). Diminished P1 was also reported both in 
unaffected relatives of schizophrenia patients (Yeap et al. 2006) and schizotypal 
individuals (Koychev et al. 2010). This evidence argues that the reduction in P1 
amplitude is a trait biomarker of schizophrenia: it is associated with the vulnerability 
to the disease and not the overt clinical phenotype. In support of this we did not find a 
correlation between symptom severity, disease duration or neuroleptic dosage and the 
extent of P1 amplitude reduction.  
 
The literature concerning N1 in schizophrenia is so far inconclusive with some but not 
all studies reporting normal amplitude (Foxe et al. 2001; Doniger et al. 2002; Foxe et 
al. 2005; Dias et al. 2011). We found that the schizophrenia group had a reduced N1, 
an effect which reached significance only in respect to the retrieval conditions. On the 
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basis of data showing that N1 represents discriminatory visual processes(Vogel et al. 
2000), it could be argued that the requirements for object discrimination in the 
retrieval condition were higher than in the encoding condition, a demand which could 
not be sustained by the schizophrenia patients. From this interpretation it would 
follow that that N1 impairment in schizophrenia can be elicited preferentially by 
cognitively demanding paradigms. This interpretation fits with the available literature, 
as the negative (Foxe et al. 2001; Doniger et al. 2002; Foxe et al. 2005) and positive 
(Dias et al. 2011) studies have used purely perceptual and cognitively demanding 
tasks respectively.  
 
In summary, our results confirm that the early visual ERPs and P1 in particular are a 
sensitive trait biomarkers to the schizophrenia spectrum disorders, as we have 
demonstrated the abnormality both in patients and schizotypal individuals. Its role in 
addressing the diagnostic and classification issues of schizophrenia however may be 
limited by its lack of specificity as outlined in the introduction. The main value of the 
P1 measure may therefore lie in being used as part of a screening procedure to 
confirm the presence of early visual processing deficits whose specificity to 
schizophrenia may then be clarified using more elaborate biomarkers of 
dysconnectivity. Its added benefit is that it is easily transferable to animal models, 
which could aid drug development.  
 
8.4.2. Oscillatory results 
 
The finding of oscillatory abnormalities in schizophrenia patients is also in line with 
existing evidence. Studies commonly report reductions in evoked PLF indicating 
higher variability of the neuronal response (coined ‘cortical noise’ (Winterer et al. 
2004)). Abnormal signal power of the evoked oscillations is also a frequent finding 
but some authors find increases in power, while others report diminished values 
(Uhlhaas et al. 2008). This raises suggestions that the abnormalities in both measures 
may reflect of the proposed state of neuronal dysconnectivity in schizophrenia, with 
PLF being the more consistent measure. The findings from our study lend some 
support for this: PLF reductions were evident across the theta, beta and gamma bands, 
while signal power reduction was present only in the theta band. Perhaps PLF is the 
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more sensitive measure in respect to activity in the higher frequency bands where the 
magnitude of the signal is not strong enough to produce reliable effects in signal 
power. The oscillatory abnormalities also appear to be state-independent, as both our 
study and previous research failed to establish significant effect of medication, 
duration of disease or state (See section 3.3.6 of Chapter 3 for review). Instead, the 
oscillatory deficits are likely to represent a vulnerability trait for schizophrenia. In 
demonstration of this, one study reported evoked PLF reductions in ultra high risk 
individuals, a finding we replicated in a study in high schizotypy (See Chapter 7). 
 
Therefore, the evoked oscillatory abnormalities appear to also be a sensitive probe for 
the vulnerability to schizophrenia. Their advantage over ERPs is that they provide 
information not only regarding the strength of the neural response but also its 
variability (PLF). This may be a critical measure given that the key abnormality may 
be not so much in frank neural damage but neural dysconnectivity. The data on the 
specificity of oscillatory abnormalities to schizophrenia spectrum disorders is so far 
limited with some evidence for disruptions in bipolar disorder (Ozerdem et al. 2008; 
Ozerdem et al. 2008). However, given the proposed central role of neural oscillations 
in coordinating brain activity (Singer 1999), it appears unlikely that oscillatory 
abnormalities will be restricted to schizophrenia and not feature in other conditions 
that involve disruption of normal neural function. 
 
8.4.3. Top-down dysfunction pattern  
 
A finding which furthered the case of a dysconnectivity phenomenon in our patient 
group was that the oscillatory abnormalities were confined to two sets of correlated 
fronto-central and occipital electrodes. In controls, perception of stimuli lead to 
increase of theta, beta and gamma band PLF and theta power in these two regions. In 
patients the same pattern was evident, but the degree of activation was significantly 
lower than in controls. Importantly, this replicates the disturbance we observed in the 
high schizotypy group where we found decreased PLF in the same frequency bands 
and in the same two sets of electrodes (See Chapter 7). These results argue that under 
normal conditions a network connecting sensory and higher order cortical structures is 
formed in the earliest stages of perception. Extensive research has highlighted that at 
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least a part of these connections underpin top-down information exchange (Engel et 
al. 2001). Top-down modulation biases the sensory cortex to process preferentially 
behaviourally relevant data. This control mechanism might be particularly enhanced 
in tasks such as ours, where the interstimulus interval is constant and the participant 
anticipates the appearance of the image. This suggests that the down-regulated 
network in patients and high schizotypes can be interpreted as evidence for disturbed 
top-down regulation of perception in the schizophrenia spectrum. Such top-down 
deficit could be a mid-point in the schizophrenia pathophysiology – arising from long-
range and local dysconnectivity and causing basic perceptual and electrophysiological 
deficits (such as P1 amplitude reduction).  
 
The case for top-down dysfunction in schizophrenia has already been supported by 
direct and indirect evidence (Dima et al. 2009; Dima et al. 2010; Koh et al. 2010).  A 
recent MEG study exploring oscillations during auditory stimulation in patients, ultra-
high-risk individuals and controls found a very similar pattern (Koh et al. 2010). The 
authors reported decreased alpha band PLF and power in a parieto-occipital network 
in both patients and at-risk individuals when compared with controls. The degree of 
PLF abnormality was higher in patients than in the ultra-high-risk group. Koh et al. 
(Koh et al. 2010)  interpreted this as an indication that the extent of top-down 
dysfunction reflects the vulnerability to schizophrenia. Also, Dima et al. used both 
ERP and fMRI techniques to directly demonstrate that perception in patients is less 
restrained by top-down modulation than in controls (Dima et al. 2009; Dima et al. 
2010). Finally, in a set of behavioural experiments Dakin et al. have shown that 
patients are less responsive to an optical illusion that depends on global feature 
integration (Dakin et al. 2005). Therefore, these data indicate that top-down 
abnormalities during perception might be a highly replicable finding in schizophrenia 
patients and high risk individuals. The temporal and spatial characteristics of this 
phenomenon could be used to further increase the specificity of the oscillatory 
abnormalities to the schizophrenia spectrum. In addition, it could provide a theoretical 
framework to understand the pathogenesis of perceptual and higher order level 
cognitive problems in schizophrenia and provide a biological correlate of the 
cognitive symptom domain.  
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8.4.4. Limitations 
 
A potential limitation of this analysis is the method of window of interest selection for 
the time-frequency analysis. In a slight modification from Tallon-Baudry et al. 
(Tallon-Baudry et al. 1997)we defined the windows of interest based on the activity in 
the control group on the basis of their stronger signal. I recognize this method as a 
potential bias towards the TF activity in the control groups. However examination of 
the time-frequency plots of the patients sample did indicate the presence of activities 
unique to them that might have been omitted from the analysis.  
 
Another limitation of this study is that while it suggests that the early visual 
processing and top-down abnormalities may be specific of the schizophrenia 
spectrum, it does not directly test this hypothesis by including a group from a 
different diagnostic entity (e.g. bipolar disorder). Some direct evidence in respect to 
the specificity of the P1 abnormality with data demonstrating diminished P1 in bipolar 
disorder (Yeap et al. 2009) and in patients with frontal cortex lesions (Barcelo et al. 
2000). This suggests that early visual processing deficits may be a shared abnormality 
across mental health and neurological disorder. However, the etiology of these 
deficits may be different. Data from visual-backward masking studies for example 
argues that while both schizophrenia and bipolar disorder may have abnormal VBM 
performance, the pathophysiology of these abnormalities may occur through different 
visual pathway mechanisms (Green et al. 1994; Green et al. 1994).  
 
It should also be noted that despite the considerable evidence suggesting an early 
dysfunctional top-down network in the schizophrenia spectrum, our finding of 
correlated fronto-central occipital activity could equally represent the same response 
that is volume conducted rather that the activation of separate neural populations. This 
limitation is inherent to voltage data subjected to laplacian transformation. 
 
Finally, although we have used a standard approach to ERP identification, it is 
nonetheless possible that slow drifts or low frequency oscillations components might 
have been mistaken for the peaks of interest. However, given the short duration of the 
peaks of interest (20 and 30 ms for P1 and N1 respectively), their well-defined 
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characteristics and the application of 0.3 Hz high-pass and 30 Hz low-pass filters, it is 
very unlikely that signal drifts or noise would have systematically obscured the ERPs 
of interest.  
 
8.4.5. Conclusion  
 
In conclusion, this study provides evidence that the widely replicated P1 potential 
abnormality in schizophrenia is associated with evoked oscillatory abnormalities that 
are consistent with a dysfunctional top-down network. The lack of consistent 
relationship between these abnormalities and state indicators (symptom severity, 
disease duration and medication dose) along with similar findings in schizotypal 
individuals argue that early information processing abnormalities are part of the core 
schizophrenia deficit. More research into their specificity and relationship to the 
formation of executive function deficits can clarify their importance as biological 
correlates of the cognitive symptom domain in schizophrenia.  
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9. GENERAL DISCUSSION 
 
 
 
Abstract 
Chapter 9 is a summary of the results of this thesis placed in the context of the five 
hypotheses set out in Chapter 1. The proposed neuropsychological and 
electrophysiological biomarkers of the schizophrenia spectrum disorders are also 
evaluated according to the evidence of their sensitivity, specificity and reliability. The 
chapter concludes with a section devoted to future research directions that could be 
undertaken to clarify and extend the current results.  
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9.1 Introduction 
Schizophrenia is a clinical syndrome that can feature a number of mental and 
behavioural phenomena. Converging data from structural and functional 
neuroimaging studies, as well as cognitive experiments suggests that it is underpinned 
by an organic cause. Despite this progress, currently there are no laboratory measures 
to confirm or reject the presence of schizophrenia defect. The current thesis aimed to 
address this limitation by developing and validating candidate biomarkers.  
 
The development of objective measures of the disease process (biomarkers) in 
schizophrenia could help bridge the gap that exists between the scientific evidence for 
an organic abnormality in schizophrenia and its clinical diagnosis. Biomarkers hold 
the potential for a long overdue paradigm shift in schizophrenia research and clinical 
practice with wide ranging implications. These include revision of the schizophrenia 
classification, expansion of our understanding of its pathophysiology and 
augmentation of the efficacy of the currently used drug development procedures 
(Breier 2005).  
 
The biomarkers that were researched in this thesis probed processes relevant to the 
cognitive symptom domain in schizophrenia. The rationale for this choice was based 
on evidence that cognition is a core component of the schizophrenia phenotype that 
predicts the functional and social outcome of patients (Heinrichs 2005). Furthermore, 
this domain remains largely unaffected by the available antipsychotic therapy and 
discovery of novel treatments to address this is a major unmet need (Heinrichs 2005). 
Therefore, research aimed at cognitive processes has the potential to fully exploit the 
utility of biomarkers both in respect to aetiology clarification and drug development.  
 
This PhD focused on the potential of cognitive biomarkers to aid one specific aspect 
of novel drug development: the successful translation of novel compounds from the 
preclinical to the clinical stages. The growing interest in cognitive enhancing agents 
has led to a number of novel agents emerging from the preclinical stages of drug 
development. However, their success rate has been very poor, a trend that is mainly 
due to lack of efficacy at Phase 2 and 3 clinical trials (Hurko 2009; Hurko 2010). One 
strategy to counter this trend is to try and identify the compounds destined to fail as 
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early as possible in their development. One possibility is to test the potential of a 
novel drug to improve cognition in small Phase 1 clinical trials involving surrogate 
populations for schizophrenia. These are populations that feature some of the 
characteristics of the main disorder without having the full-blown condition. Such 
proof of concept studies require the availability of validated cognitive biomarkers to 
swiftly assess the effect of the novel compound on cognition. The work in this thesis 
therefore concentrated on defining the sensitivity and reliability of several promising 
cognitive and information processing biomarkers to the phenotype of schizophrenia 
and its surrogate populations. Another line of work was to explore the response of the 
biomarkers to psychotropic medication, as well as their possible relevance to the 
pathophysiology of the schizophrenia spectrum. In accordance with this, several 
hypotheses were stated at the onset of this thesis. They were based on previous 
research on the cognitive impairment associated with schizophrenia and the next 
chapter will review the evidence relevant to each hypothesis in turn.   
 
9.2. Hypothesis 1: Schizophrenia is the extreme of a spectrum of 
disorders that is characterized by cognitive deficits 
 
The first hypothesis was based on the idea that schizophrenia lies on a continuum with 
related mental health disorders of varying severity. The evidence for this comes from 
studies that show elevated vulnerability of individuals with familial history of 
schizophrenia to certain psychiatric illnesses (schizoaffective disorder) and 
personality disorders (schizotypal, paranoid and schizoid personality disorders) with 
similar clinical features (Kendler et al. 1993; Kendler et al. 1993; Kendler et al. 1993; 
Kendler et al. 1994). This has led researchers to propose that these disorders and 
schizophrenia form a spectrum of disorders with common pathogenesis, i.e. the 
schizophrenia spectrum (Meehl 1989; Lenzenweger 2006). 
 
Developing biomarkers that probe dysfunction in the milder disorders of the 
schizophrenia spectrum can help to determine the core deficit in schizophrenia, to 
inform understanding of its pathophysiology, and to validate drug targets. These 
populations can also be used for early assessment of novel drug efficacy, which 
represents the major focus of this thesis.    
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Existing evidence has already pointed out that cognition might be a shared 
abnormality in the schizophrenia spectrum. Indeed, a number of cognitive 
abnormalities are present in schizotypal personality disorder and in the unaffected 
relatives of schizophrenia patients (Raine 2006; Allen et al. 2009). Their severity is 
typically intermediate between that of patients and healthy volunteers at low risk for 
schizophrenia, consistent with a continuum of symptom severity in schizophrenia.  
 
9.2.1. Prediction 1.1: 
Schizotypy is associated with cognitive deficits similar to these found in 
schizophrenia.  
 
The first prediction was therefore that subjects with psychometrically defined 
schizotypy will also feature cognitive deficits similar to those found in the clinical 
population. The experiment reported in Chapter 4 used a number of candidate 
neuropsychological biomarker to compare the cognitive performance of a large cohort 
of high (HS) and average (AS) scoring schizotypes. There was an overall effect of 
schizotypy on tasks that tested working memory and verbal fluency performance.  
 
The results in Chapter 5 extended these data by demonstrating that the working 
memory impairment is also evident when comparing high and low schizotypy. In the 
same study high schizotypy scores were associated with worse performance than low 
scorers on an antisaccade eye-tracking task.  
 
Further, in Chapter 6 a modified Sternberg working memory paradigm was 
administered to high and low schizotypy scorers. Again, working memory 
performance in high schizotypy was significantly impaired relative to controls.  
 
The relevance of these results to schizophrenia was underlined in Chapter 8, in which 
the Chapter 6 working memory paradigm was administered to a sample of patients. 
As expected, the schizophrenia patients performed significantly worse than the 
healthy volunteer group. In accordance with previous research working memory 
impairment in the high schizotypy group was between that of patients and controls. 
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These results support the prediction that psychometrically defined schizotypy is 
characterised by cognitive deficits. Whilst this is unsurprising given the evidence of 
cognitive impairment in clinically defined Schizotypal Personality Disorder (SPD), 
the results from Chapter 4 demonstrate the utility of psychometrically defined 
schizotypy for identifying individuals exhibiting schizophrenia-like cognitive deficits. 
It should be noted, however, that an effect of schizotypy effect was only evident for 
the most taxing conditions in the tasks. This suggests that the study designs chosen for 
these experiments may have led to the recruitment of a high functioning schizotypy 
sample presenting only subtle cognitive abnormalities. These recruitment factors 
were: 1) exclusion of volunteers with previous mental health history; 2) exclusion of 
volunteers who smoked heavily or had history of drug dependence. The case for a 
high functioning HS group in Chapter 4 was supported by their higher number of 
years of education relative to AS controls. Despite this, the effect of schizotypy was 
still evident on the more difficult cognitive tasks, probably aided by the large sample 
size reported in Chapter 4. This highlights the importance of the inclusion and 
exclusion criteria as major factors influencing the detectability of cognitive 
abnormalities in psychometrically defined schizotypy.  
 
9.2.2. Prediction 1.2:  
Schizotypy will feature abnormalities in trait but not state dependent 
cognitive domains as it represents a less extreme deviation from the norm 
than schizophrenia 
 
The second prediction regarding hypothesis 1 stated that schizotypy will feature 
abnormalities in some but not all cognitive domains relative to schizophrenia. There 
were two sets of findings that supported this prediction.  
 
Firstly, in Chapter 5 two tests demonstrated no effect of schizotypy: the Salience 
Attribution (SAT) and the Smooth Pursuit Eye Movement (SPEM) tasks. The SAT 
results appear to contradict one previous study that found a link between schizotypy 
and aberrant salience attribution (Roiser et al. 2009). In this study, Roiser et al. found 
a correlation between Introvertive Anhedonia OLIFE scores and aberrant salience 
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attribution, a pattern that was not replicated here. The current results are, however, in 
line with pharmacological evidence showing that SAT is a state biomarker given that 
i) Roiser et al. (2009) report a normalisation of aberrant salience with adequate 
antipsychotic treatments and ii) imaging studies have demonstrated that the 
antipsychotic drugs haloperidol (Pessiglione et al. 2006) and olanzapine (Abler et al. 
2007) attenuate reward-related activity in ventral striatum. In light of this evidence the 
response of SAT abnormalities to antipsychotic treatment reported by Rosier et al 
(2009) suggests that the underlying abnormality might have been secondary to acute 
psychotic state. The lack of frank psychosis in schizotypy sample could therefore 
account for the negative result reported in Chapter 5.  
 
Secondly, the SPEM test also yielded a negative schizotypy effect in Chapter 5. The 
average and high schizotypy groups in Chapter 5 were recruited as part of a larger 
sample (same as the one reported in Chapter 4) and the SPEM analysis of this larger 
cohort also revealed no effect of group. As discussed in Chapter 5, this result adds to a 
background of mixed results regarding the effect of schizotypy on SPEM. Indeed 
some studies have found no effect (Siever et al. 1994), while another found reduced 
gain but normal saccade rate (Gooding et al. 2000). Also, a large study reported 
disrupted SPEM performance in extremely high scorers on the disorganisation 
subscale of the SPQ (Smyrnis et al. 2007). A pattern begins to emerge when Thaker et 
al.’s studies on schizotypy individuals with and without family risk of schizophrenia 
are considered (Thaker et al. 1996). They show that the SPEM abnormality is specific 
to the schizotypal individuals who have family history of schizophrenia and argued 
that the SPEM deficit is specifically associated with the familial risk for 
schizophrenia. It could therefore be speculated that the mixed results in the SPEM 
schizotypy literature could be due to the varying levels of genetic load in the different 
sample. Smyrnis et al. (2007) did not report the genetic loading in their sample, but 
the established link between negative and disorgantisational schizotypal traits and 
familial risk for schizophrenia (Kendler et al. 1995) suggest that the positive SPEM 
result could have been due to genetic loading. Indeed, only a small proportion of the 
Chapter 5 sample reported having a first-degree relative with schizophrenia. One 
could also argue that the negative result in our study might have been due to the high 
functioning of our sample. However, we did not find a significant effect of years of 
education or IQ on the SPEM measures.  
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9.2.3. Limitations to the data corroborating with Hypothesis 1 
 
The schizotypy effect also did not reach significance on the spatial working memory 
task in Chapter 4 and on two CANTAB tasks that probed memory and executive 
function in Chapter 6. These results contrast with the schizotypy effect on working 
memory tasks in the same studies. This discrepancy could be attributed to the 
difference in presentation times in these tasks. The working memory paradigms that 
detected an effect used presentation times of 400 ms (Chapter 4) and 1 second 
(Chapter 6), while the negative results came from tasks using encoding periods that 
were either longer (2 seconds in the case of the executive function CANTAB task in 
Chapter 6) or unlimited (Spatial Working Memory task in Chapter 4 and memory 
CANTAB task in Chapter 6). As argued earlier, these data highlight the importance of 
early information processing for the formation of higher-order cognitive deficits. A 
relationship between indices of early information processing abnormality and 
cognitive impairment has already been demonstrated in schizophrenia patients (Butler 
et al. 2007; Haenschel et al. 2007). The findings of reduced early visual evoked 
potentials in schizotypy argue that this pattern is generalisable to the whole 
schizophrenia spectrum.  
 
The choice of control group is likely to have been an important contributing factor in 
the case of SWM task in Chapter 4. This was demonstrated in Chapter 5 by the 
significant difference obtained when low rather than average schizotypes are used as 
controls against the high schizotypes. In addition, as it was argued earlier, the high 
schizotypy sample in Chapters 4 and 5 may have been particularly high functioning. 
Therefore, several confounding factors might have concealed the schizotypy effect in 
respect to the SWM and CANTAB tasks.   
 
The conclusions from the experiments aimed at addressing hypothesis 1 indicate that 
i) psychometrically defined schizotypy has detectable cognitive deficits; ii) the 
cognitive deficits are confined to working memory, verbal fluency and antisaccade 
eye-tracking measures; iii) cognitive studies in psychometrically defined schizotypy 
should employ tasks that are sufficiently difficult to demonstrate the schizotypy 
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effect; iv) not all tasks that detect an abnormality in schizophrenia are sensitive to the 
schizotypy effect which could be due to state-dependence or specificity to genetic risk 
rather than schizotypy symptoms per se; v) the choice of exclusion and inclusion 
criteria may affect the likelihood of detecting the cognitive abnormalities associated 
with schizotypy.  
 
9.3. Hypothesis 2: Cognitive abnormality in the schizophrenia 
spectrum is a continuously distributed trait 
 
The work relating to hypothesis 2 sought to further clarify the relationship between 
schizotypy and cognitive impairment. As pointed out in Chapter 5, there are two 
competing frameworks addressing this issue. The threshold model derived from 
Matthysse’s and Meehl’s works (Matthysse et al. 1986; Meehl 1989)  states that 
cognitive abnormalities are present only in the “disease” end of the schizophrenia 
spectrum: extremely high schizotypy scorers and schizophrenia-related mental health 
disorders (Figure 9.1, dashed line). Therefore, according to this theory, there should 
be no difference in the neurocognitive performance of non-high schizotypy scorers. 
The second theoretical framework defines schizotypal personality traits as continuum 
from health to schizophrenia (“full dimensional model”). Authors, such as Eysenck, 
argue that there is no need to introduce arbitrary cut-off points above which 
schizotypy lies (Eyseneck et al. 1976; Claridge 1994). Instead, the vulnerability to 
schizophrenia has a continuous distribution in the population and is correlated with 
both schizotypal symptoms and neurocognitive deficits (Figure 9.1, solid line). 
According to this model, average schizotypy scorers will have performance that is 
inferior to the low scorers and superior to the high scorers.  
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Figure 9.1. Relationship between severity of schizophrenia-related psychopathology 
and cognitive impairment according to the threshold (dotted) and full dimensional 
(solid) models of schizotypy. Degree of cognitive impairment on the vertical axis, 
severity of schizophrenia-related psychopathology on the horizontal axis. A dotted 
bell-shaped curve in the background describing the frequency of schizophrenia-
related psychopathology in the general population.  
 
This theoretical debate has implications that reach beyond the pathophysiology of the 
schizophrenia spectrum. In the context of this thesis, concerned with proof-of-concept 
studies of novel cognitive enhancing agents in schizotypy, this issue is particularly 
relevant, as it can help guide the choice of the most appropriate control group in such 
clinical trials. This is particularly important in light of the marginal size of the 
schizotypy effect reported in Chapter 4.  
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9.3.1. Prediction 2.1:  
Cognitive performance decreases with increase of schizotypal personality 
traits 
 
This prediction was addressed in Chapter 5 where the cognitive performance of low, 
average and high schizotypy scorers is compared. On three of the tasks that were 
sensitive to the effect of schizotypy, there was a linear relationship between 
schizotypy and cognitive performance (N-back, SWM and antisaccade tasks). These 
results are generally in line with reports on the correlation between schizotypy scores 
and executive function in a healthy population. Some (Park et al. 1997; Gooding et al. 
2006; Matheson et al. 2008) but not all (Jahshan et al. 2007; Noguchi et al. 2008) 
have found an inverse relationship between schizotypy scores and neurocognitive 
performance. One of the studies that did not find such a correlation also failed to 
detect impairment of executive function in the high scorers (Jahshan et al. 2007). It 
could therefore be hypothesised that the tasks in the negative studies were not 
sufficiently difficult to demonstrate the subtle schizotypy deficit. Therefore, these 
results and previously published data collectively argue in favour of the full 
dimensional model and by extension to the choice of low over average schizotypy 
group in comparisons versus high scorers to detect a schizotypy effect on cognition.  
 
The practical implications of this research are evident when the results from the SWM 
task in Chapter 4 and 5 are compared. While the comparison between average and 
high schizotypes did not reach significance in Chapter 5, adding a group of low 
schizotypy scorers produced a significant main effect of schizotypy. These data argue 
that perhaps some of the true main effects of schizotypy and schizotypy-by-drug 
interactions in Chapter 4 might have been obscured by a suboptimal choice of control 
group.  
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9.3.2. Limitations to the data corroborating with Hypothesis 2 
 
A potentially serious limitation of the results from Chapter 5 is the fact that unlike the 
average and high schizotypy groups the low schizotypy group was not treated with 
placebo. One could therefore argue that the difference between the low and average 
schizotypy groups was due to a placebo effect in the average group, rather than a 
genuine linear relationship between schizotypy and cognitive ability. Several points 
argue against this. Firstly, if a placebo effect was behind the difference between two 
otherwise indistinguishable groups, one would expect that a number of tasks and 
measures would be affected. However, the positive results related only to the working 
memory and antisaccade tasks while SAT and SPEM were unaffected. Moreover, on 
the verbal fluency task the average schizotypy group performed better than the low 
schizotypy. Therefore, the pattern of differences argues against a generalised placebo 
effect being a major contributing factor for the difference in cognition between the 
average and low schizotypy groups.  Secondly, if the placebo effect was one of 
fatigue, then it would be expected that the difference in cognition between the two 
control groups would be accompanied by latency differences. However, there was no 
effect of schizotypy group on the reaction times of any of the three tasks where a 
linear effect of schizotypy was evident. Thus we believe that the working memory and 
antisaccade-specific differences between average and low schizotypes are unlikely to 
be due to a placebo effect.   
 
Another important limitation of the Chapter 5 results is that they did not include a 
correlation between the level of schizotypal symptoms and cognitive impairment. 
Such an approach would be a more direct way of testing the prediction than 
comparing the performance of low, average and high schizotypy scorers. However, 
the choice of SPQ cut-off scores for average and high schizotypy in the Chapter 4 
study design lead to a poor spread of schizotypy scores present in the database. A 
large sample study exploring directly the proposed correlation would be an 
appropriate future research direction.  
 
In conclusion, these results provide indirect support for the hypothesis that cognitive 
abnormality in schizotypy is a continuously distributed trait. In the light of proof-of-
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concept studies, these data argue in favour of using low schizotypy scorers in 
cognitive comparisons against high scorers to maximise the size of the schizotypy 
effect. 
 
9.4. Hypothesis 3: The cognitive deficits in schizophrenia are 
modulated by dopamine 
 
Hypothesis 3 dealt with the neurochemical basis of the cognitive abnormality in the 
schizophrenia spectrum. Converging evidence from neuroimaging studies in patients 
using metabolic tracing neuroimaging (Ingvar et al. 1974) and fMRI (Weinberger et 
al. 1986; Wolkin et al. 1992; Kawasaki et al. 1993) has indicated that the cognitive 
deficit associated with schizophrenia is due to a prefrontal cortex dysregulation. 
Therefore, if cognitive abnormality is generalisable to the schizophrenia spectrum 
disorder as hypotheses 1 and 2 suggest, does this translate into a frontal cortex 
dopamine dysfunction that is continuously distributed and correlated with the risk for 
schizophrenia?  
 
9.4.1. Prediction 3.1:  
Cognitive deficits would be affected by drugs altering dopamine 
 
This issue was addressed in Chapter 4 where the schizotypy effect on cognition was 
challenged with acutely administered risperidone, amisulpride and nicotine in a 
double-blind placebo-controlled design. Full D2-receptor antagonists such as 
risperidone have been shown to impair cognition in healthy volunteers when 
administered acutely (Barch 2004). Nicotine is an agonist to the nicotinic receptor of 
the acetylcholine system and as a result has a general neurostimulating effect. 
Amisulpride is also a D2 receptor antagonist, but when given in small doses (less than 
10 mg per kg) has a dopamine enhancing action due to binding to the presynaptic D2 
receptors (Schoemaker et al. 1997). The dose used in Chapter 4 was 400 mg and as 
none of the included participants in this study weighed less than 40 kg, this should be 
considered a small dose with predominantly dopamine enhancement effects.  
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The results showed that out of the three agents only amisulpride reversed the 
schizotypy effect on cognition: it improved the high schizotypy group but impaired 
the average schizotypy group. This effect was significant in respect to the N-back and 
verbal fluency task, while the SWM results showed the same trend but did not reach 
statistical significance. We interpreted these results in the light of the theories that see 
the relationship between prefrontal dopamine and cognition as a reversed U-shape 
curve (Figure 9.2). According to this model intact cognition requires optimal 
prefrontal cortex dopamine activity, with hypo- and hyperdopaminergic states leading 
to cognitive impairment (Barch 2005). Studies in humans and in primates support this 
by showing that dopamine enhancement benefits the poor baseline performers while 
impairing the individuals with high level of cognitive abilities (Barch 2004). In 
Chapter 4, the improvement of the high schizotypy group by dopamine enhancement 
suggests that they had low baseline dopamine activity which approached optimum 
levels with the pharmacological challenge. In contrast, the average schizotypy results 
indicate that their baseline prefrontal dopamine activity was nearer to the top of the 
curve and that dopamine enhancement tipped them into hyperdopaminergic state. 
These results suggest that a moderate degree of prefrontal hypodopaminergia is a trait 
of the schizophrenia spectrum. This conclusion is supported by a study showing 
improvement of cognition in Schizotypal Personality Disorder after a 4-week 
treatment with a combined D1/D2-receptor agonist (McClure et al. 2010). The 
moderate degree of cognitive impairment would also suggest that the frontal 
hypodopaminergic state in high schizotypy is of intermediate severity in between that 
of schizophrenia patients and healthy volunteers (Figure 9.2). 
 
Whether the frontal hypodopaminergia trait is continuously distributed and correlated 
with schizotypal symptoms in non-high schizotypy healthy volunteers is unclear. The 
full dimensional model would predict that average schizotypy has lower baseline 
dopamine activity compared to low schizotypy (figure 9.2A) while the threshold 
model would argue that both groups have optimum or near-optimum dopamine 
activity (Figure 9.2B). The linear relationship between schizotypal personality traits 
and cognitive ability established in Chapter 5 favours the full dimensional model but 
there is currently no direct pharmacological evidence to support this.  
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Figure 9.2. Relationship between extent of schizophrenia spectrum 
psychopathological symptoms and frontal dopaminergic activity according to the full 
dimensional and threshold model. 
 
One way to test this hypothesis would be to challenge the cognitive performance of 
low, average and high schizotypy scorers with a potent dopamine agonist at gradually 
increasing doses (for example low, moderate and high doses of methylphenidate). A 
result that would support the dimensional model would see average but not low 
schizotypes improve under the very low agonist dose, while both groups should be 
impaired by moderate and high doses (Figure 9.3). In contrast, the threshold model 
would be supported by a uniform response by the average and low schizotypy groups 
to the agonist challenge, irrespective of the dose.  
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Figure 9.3. Hypothetical relationship between cognitive performance in schizotypy 
and low, moderate and high doses of a dopamine agonist according to the threshold 
and full dimensional models. Abbreviations: LS – Low schizotypy; AS – Average 
schizotypy; HS – high schizotypy.  
 
9.4.2. Limitations to the data corroborating with Hypothesis 3 
 
It should be noted that the study featuring in Chapter 5 has several limitations that 
may have affected the results relevant to Hypothesis 3. Firstly, as discussed 
previously some of the tasks might have been of insufficient difficulty allowing 
ceiling effects to obscure the true relationship between dopamine and schizotypy. 
Secondly, despite the evidence linking low dose amisulpride to enhancement of 
dopamine action and the direction of our results, it is nonetheless an indirect method 
to test Hypothesis 3. Given that both the average and high schizotypy samples were 
high functioning, a full dopamine agonist might have been better suited as it would 
have produced stronger results, particularly in respect to selective impairment of the 
control group. Finally, as it was argued earlier, choosing a different control group 
(low schizotypy instead of average schizotypy) might have maximised the effect of 
schizotypy and its interaction with the study drug.  
 
Despite the shortcomings of this study design, its large sample size ensured the 
detection of a consistent pattern implicating prefrontal cortex hypodopaminergia in 
genesis of the cognitive abnormality in schizotypy.  
Page |   
 
234 
9.5. Hypothesis 4: Cognitive impairment in schizophrenia is part of a 
larger information processing abnormality 
 
The rationale for this hypothesis rests on growing evidence against a centralised 
aberration driving the various deficits and symptoms in schizophrenia. Instead, the 
pattern of behavioural, structural and cognitive abnormalities in this syndrome are 
more consistent with a distributed neural defect affecting most if not all cortical areas 
and levels of neural functioning.  
 
9.5.1. Prediction 4.1:  
Information encoding in both schizotypes and schizophrenia patients is 
associated with gross electrophysiological abnormalities – reductions in 
early visual ERPs 
 
One set of results in schizophrenia that has been particularly difficult to reconcile with 
a localised prefrontal cortex abnormality are the reports of purely perceptual problems 
in patients (Javitt 2009). Experiments using EEG and MEG have demonstrated 
electrophysiological correlates of these early perceptual deficits (Javitt 2009). It is 
therefore possible that a pervasive information processing abnormality may underpin 
both the perceptual and higher-order executive problems in schizophrenia. The 
relevance of this hypothesis to the schizophrenia spectrum model was tested by 
examining the characteristics of early visual information processing in high 
schizotypes and schizophrenia patients. In line with suggestions of visual processing 
deficits being trait markers of schizophrenia (Yeap et al. 2008), we hypothesised that 
both patients and high schizotypes will have abnormal early visual evoked potentials.  
 
The experiment in Chapter 8 replicated previous reports of attenuated P1 visually 
evoked potential in schizophrenia patients (Yeap et al. 2008). P1 is considered an 
indicator of the quality of the early visual processing, underpinning basic pattern 
detection. Reductions of P1 amplitude have been reported in multiple sclerosis 
(Fulgente et al. 1996; Weinstock-Guttman et al. 2003) and in patients with prefrontal 
cortical lesions (Barcelo et al. 2000), providing evidence for the involvement of 
sensory and prefrontal cortices, respectively. This suggests that the neural generators 
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of P1 are modulated by converging bottom-up and top-down projections and such a 
deficit may potentially  be caused by a localised (prefrontal or sensory visual cortex 
aberration) or a distributed abnormality. Therefore, from a pathophysiological point of 
view the P1 deficit does not contribute significantly to the debate of whether a 
centralised or a distributed abnormality contributes to symptoms of schizophrenia. 
Decomposing the temporal and spatial characteristics of the signal that constitutes P1 
potential could help address this issue, an approach we have taken in the analysis 
aimed at testing Hypothesis 5.   
 
Whatever the underlying pathology of the P1 amplitude reduction in schizophrenia, 
the results from Chapter 6 demonstrate that it is present across the schizophrenia 
spectrum. The finding of P1 deficit in a psychometrically defined schizotypy argues 
that the same finding in schizophrenia patients in Chapter 8 and previous studies is 
not the result of repeated psychotic episodes, chronic medication or profound negative 
symptoms. Instead, the aberration is more likely to be a trait marker of schizophrenia, 
a biological manifestation of the core pathophysiology associated with the risk for 
schizophrenia. In support of this conclusion, one study found a P1 reduction in a 
sample of first-degree relatives of schizophrenia patients (Yeap et al. 2006). In 
conclusion, we consider the findings from Chapters 6 and 8 to support our prediction 
that the ERP abnormality will be present across the schizophrenia spectrum.  
 
9.5.2. Prediction 4.2:  
Early perceptual deficits correlate with cognitive deficits 
 
The second prediction focused on the relationship between the quality of early visual 
processing and cognitive performance. Specifically, we predicted that P1 amplitude 
would correlate with performance on the WM task. This was based on two previous 
studies showing that P1 amplitude predicts cognitive performance in schizophrenia 
patients (Haenschel et al. 2007; Butler et al. 2009). The results from Chapters 6 and 8 
in this respect were inconclusive. In Chapter 6 we found a modest correlation between 
WM task performance and the P1 amplitude. However, this relationship was not 
replicated in Chapter 8 for either of the two groups. One possible explanation for this 
discrepancy is the decision to use the P1 amplitude of the correct trials only. If a true 
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relationship between P1 and cognition exists, one would expect to see a lower P1 for 
the incorrect trials. This type of analysis however is restricted by the number of 
incorrect trials in the healthy volunteer groups. Low and average schizotypes had less 
than 10 % error rate leaving far too few trials for a reliable statistical comparison. The 
schizotypy and schizophrenia groups made more incorrect trials. The analysis of 
incorrect trials in these populations however is limited by the possibility that the 
participants may not have been attending the trials at all. Therefore, the 
electrophysiological information from these trials may be irrelevant to the question of 
whether encoding deficits correlate with cognitive performance. 
 
9.5.3 Limitations to the data corroborating with Hypothesis 4 
 
One approach that may clarify the relationship between P1 and cognition would 
require the administration of a more challenging cognitive task to healthy volunteers 
only. Careful design of the task could ensure that the volunteers are making a similar 
number of correct and incorrect trials. A simple t-test might be sufficient to 
demonstrate a difference in the amplitude of the P1 potentials between correct and 
incorrect trials.  
 
In conclusion, we believe that our findings support the case that the schizophrenia 
spectrum is characterised by broad information processing abnormalities, as 
manifested by the reduction in P1 potential amplitude. The predictive validity of such 
indicators of early visual processing with regards to cognitive performance may need 
further clarification.  
 
9.6. Hypothesis 5: The information processing deficit is underpinned 
by dysconnectivity  
 
As mentioned in the previous section, the finding of a P1 abnormality across the 
schizophrenia spectrum makes no assumption regarding its pathophysiology: either 
localised or distributed abnormality could cause a P1 deficit. Based on the mounting 
evidence of dysconnectivity in schizophrenia, Hypothesis 5 proposed that the early 
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visual deficits in the schizophrenia spectrum are the product of a distributed, rather 
than a localised deficit.  
 
This hypothesis was addressed by analysing the local and long-range oscillatory 
patterns during visual perception in a sample of high schizotypy individuals (Chapter 
7) and schizophrenia patients (Chapter 8).  
 
9.6.1. Predictions 5.1 and 5.2.  
 
Prediction 5.1: Schizotypes and schizophrenia patients both have local 
sensory cortex connectivity abnormalities: abnormalities in the power 
and PLF of neural oscillations. 
 
Prediction 5.2: Both groups have evidence of dysfunctional long-range 
connectivity during tasks that require top-down modulation: down-
regulation of networks connecting the sensory and higher-order cortices 
 
In both studies there was a very similar pattern of local sensory cortex abnormalities 
in the schizotypy and schizophrenia samples. There was evidence for PLF and power 
reduction in early theta band activity (approximately 150–250 ms post-stimulus). This 
burst of activity had bilateral occipital distribution, similar to the P1 potential which 
was also abnormal in these two groups. This observation and the studies showing that 
theta and alpha band synchronization give rise to the P1 potential (Klimesch et al. 
2004; Gruber et al. 2005), suggest that the theta band results are oscillatory correlates 
of the P1 potential reduction. An interesting finding in our studies was that both the 
high schizotypes and schizophrenia patients lacked a normally occurring up-
regulation of the theta band visual cortex response with task demand. These results 
argue in favour of a significant top-down contribution to the deficit.  
 
In addition to the theta band results, oscillatory abnormalities were also evident in 
beta and gamma frequency bands, particularly in respect to the PLF. This higher 
frequency activity burst occurred earlier than the theta band activity and had a central 
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occipital distribution. This evidence suggested that the observed higher-frequency 
activity represented a process that was not accounted for by the ERP analysis. The 
occipital beta and gamma band activity was also correlated with an increase in 
activity at a fronto-central site that occurred at the same time window and frequencies 
range. This correlation in activity was interpreted as an indication that the two regions 
(central-occipital and fronto-central) were functionally coupled during the earliest 
stages of perception. The fact that they precede the theta band activation, as well as 
the P1 and N1 potentials, suggests that this fronto-occipital network may be involved 
in a top-down driven preparation of the visual cortex for stimulus encoding. This 
interpretation would be in line with research showing that perception in schizophrenia 
patients is constrained to a lesser extent by top-down factors (Dima et al. 2009; Dima 
et al. 2010). The findings from Chapter 7 extend this to schizotypy individuals and 
suggest that the perceptual problems in the schizophrenia spectrum may be primarily 
the result of a top-down dysfunction.  
 
9.6.2. Limitations to the data corroborating with Hypothesis 5 
 
The issue of whether this top-down dysfunction is the product of a localised higher-
order abnormality, e.g. prefrontal cortex or a dysfunctional long-range connectivity is 
not directly addressed by the analyses featured in Chapters 7 and 8. However, the fact 
that PLF but not power is reduced argues in favour of a disorder of connectivity. If a 
localised prefrontal cortex was driving the dysfunction, as in the case of prefrontal 
cortex lesions, one would expect a reduction in the power of the oscillations. Instead 
the results reveal a pattern of increased variability of the neural responses in two 
functionally correlated brain regions. This pattern is consistent with generalised 
dysconnectivity aberration that leads to inconsistent neural activity on both a local and 
a global level. However, the data supporting such interpretation is, so far, indirect and 
more focused research is needed to determine the origin of top-down dysfunction in 
schizophrenia.  
 
Experiments using pharmacological or transmagnetic stimulation (TMS) challenges in 
healthy volunteer populations may be useful in exploring the putative role of top-
down dysfunction in the pathogenesis of schizophrenia. Firstly, a glutamate 
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antagonist, such as ketamine may be used to induce a temporary hypodopaminergic 
state in healthy volunteers (See Chapter 3 for detailed review). As glutamate is the 
major excitatory neurotransmitter (Meldrum 2000), it has been argued that such an 
intervention would induce a connectivity deficit that will be distributed and not 
specific to a brain region. Therefore, if a ketamine challenge replicates the pattern of 
oscillatory abnormality observed in the schizophrenia spectrum, it could be claimed 
that the top-down dysfunction is indeed the product of a generalised dysconnectivity. 
 
The results of this experiment could be complemented by a study using TMS to 
induce a localised disruption to the fronto-central topographical region described in 
Chapters 7 and 8. If the top-down dysfunction in schizophrenia is the product of a 
localised disruption in this brain region, one would predict that the TMS would 
recreate the PLF oscillatory abnormalities reported in the current thesis. Alternatively, 
if dysconnectivity is implicated then the TMS-driven abnormalities in the occipital 
cortex should be of a different character, possibly involving reductions in both PLF 
and power of occipital higher frequency band oscillations.   
 
In conclusion, the results from Chapters 7 and 8 broadly support the predictions in 
regards to Hypothesis 5: there was evidence for a local sensory cortex dysconnectivity 
underlying the early information processing abnormalities in the schizophrenia 
spectrum. In addition, the pattern of abnormalities suggested that an earlier, top-down 
mediated process may be implicated in the sensory cortex dysfunction. Therefore the 
results suggest a dysconnectivity mechanism in the pathophysiology of this top-down 
abnormality, but more research is needed to provide corroborative evidence for this.  
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9.7. A proposal for a framework of the relationships between the 
various manifestations of schizophrenia 
 
Overall, the current findings showed that schizotypy is associated with abnormalities 
in two cognitive functions – working memory and inhibition. The ERP experiments 
indicated that these cognitive deficits are part of a larger pattern of information 
processing abnormalities affecting local and long-range connectivity. These 
abnormalities appear to be continuously distributed in the population and are likely to 
be correlated with psychopathological indicators of risk for schizophrenia, such as 
schizotypal personality traits.  
 
One framework to try and explain the relationship between these manifestations of the 
schizophrenia spectrum phenotype in presented in Figure 9.4. The cause of the 
disorder is likely to be the product of an interaction between genetic and 
environmental factors resulting in an abnormality that affects normal 
neurodevelopment (Tandon et al. 2009). This neurodevelopmental abnormality has 
variable severity according to the number of risk and protective factors and is 
distributed continuously in the population. A key manifestation of this core 
developmental abnormality is an abnormality of inter-neuronal connectivity, affecting 
the capacity of spontaneous neural oscillatory activity to transmit information 
effectively (Andreasen 1999). Oscillatory activity of the glutamatergic pyramidal 
cortical cells is governed primarily by the activity of GABA-mediated inter-neurons 
(Fries et al. 2007). Therefore, dysconnectivity is likely to involve both these 
neurotransmitter systems early in the pathophysiological cascade (Deakin et al. 1989; 
Krystal et al. 1999). The deficit brought about by a neural connectivity defect is likely 
to be pervasive and could account for the various manifestations of schizophrenia, 
including the aberration of early information processing (e.g. reductions in P1 peak 
amplitude), executive function abnormalities (e.g. working memory and inhibition 
deficits), as well as the various psychopathological features of the schizophrenia 
spectrum disorders (e.g. disorganised behaviour, cognitive-perceptual and 
interpersonal symptoms). All these pathophysiological events happen before the 
development of the psychotic illness or even in at-risk individuals who will ultimately 
remain unaffected by psychotic disorders. The gravity of the original risk factors, or 
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experiencing additional environmental insults, may cause certain individuals from this 
at-risk group to develop the ultimate complication of the basic neurodevelopmental 
abnormality – schizophrenia. The development of psychotic illness leads to a dramatic 
increase in severity of the trait abnormalities, as well as the emergence of new, state-
specific deficits.  
 
 
 
 
 
Figure 9.4. Proposed framework to explain the relationships between the various 
manifestations of schizophrenia. Dysfunctional connectivity with a 
neurodevelopmental pathogenesis drives diverse trait abnormalities. Transition from 
the vulnerability stage into psychosis manifests itself through state-related symptoms 
that augment the expression of the trait abnormalities. 
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9.8. Relevance of the findings to proof-of-concept biomarker studies 
in the schizophrenia spectrum disorders 
 
The main focus of the thesis was the development of biomarkers to objectively and 
reliably define the core schizophrenia pathology, as well as foster drug development 
through proof-of-concept studies in surrogate populations. Cognitive biomarkers were 
the measures of interest due to their relevance to the key unmet need of cognitive 
impairment in schizophrenia and the good evidence for similar cognitive deficits in 
the surrogate population of schizotypal individuals. Biomarkers are evaluated in terms 
of their sensitivity to the disease process and therapeutic intervention, specificity and 
reliability. The following section will provide a review of the evidence presented in 
this thesis in respect to the extent that the behavioural cognitive and 
electrophysiological measures of interest satisfy these criteria.  
 
9.8.1. Sensitivity to the schizophrenia spectrum phenotype: 
Neuropsychological measures 
 
The experiments showed that tasks probing several but not all cognitive functions can 
be used to detect the schizophrenia spectrum phenotype. Working memory tasks stand 
out as the most reliable in this respect, but caution should be exerted in the design of 
the paradigm. As Chapter 4 and 5 showed, tasks that allow only brief encoding (e.g. 
N-back) may be more suitable than paradigms with unlimited stimulus presentation 
(SWM).  
 
The results also demonstrate that the antisaccade task was sensitive to the 
schizophrenia spectrum phenotype. However, schizotypy effect was evident only in 
respect to the antisaccade error rate, but not in other eye-movement measures such as 
spatial accuracy or latency of the saccades. This implies that the detected abnormality 
may be due to a general inhibitory deficit rather than an eye-tracking dysfunction per 
se. Therefore, paradigms probing inhibition may be useful as biomarkers in 
schizotypy proof of concept studies.    
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Measures such as SAT and SPEM appear to be sensitive to state- and genetic-risk 
related abnormalities and their use in proof of concept studies in schizotypy may be 
limited.  
 
An important consideration that was shown to affect the sensitivity of a biomarker is 
the choice of control group. Specifically, choosing an average over a low schizotypy 
group may obscure the schizotypy effect. Therefore in proof of concept studies the 
sensitivity of working memory and inhibitory paradigms may benefit significantly by 
instead comparing low and high schizotypy groups.  
 
9.8.2. Sensitivity to the schizophrenia spectrum phenotype: 
Electrophysiological measures 
 
The results from Chapter 6 and 8 suggest that the amplitude of the P1 visual evoked 
potential peak is a sensitive measure of the information processing deficit associated 
with schizophrenia and schizotypy. This is in line with previous research showing that 
the P1 deficit is highly replicable in schizophrenia patients (Yeap et al. 2008). P1 
could be used in proof of concept studies as a method to screen for individuals with 
early information processing deficits. Combining this approach with other indicators 
of risk for cognitive impairment, such as schizotypy, could allow the identification of 
groups with homogeneous schizophrenia spectrum-related cognitive impairment. 
Equally, P1 in itself could be used as a biomarker to detect the effect of drugs 
designed to improve cognitive abilities through efficient information encoding.  
 
The evoked oscillations also distinguished well schizophrenia spectrum individuals 
from healthy volunteers (Chapter 7 and 8). Out of the two outcome variables of 
oscillatory activity (power and PLF), PLF appeared to be the more sensitive measure, 
particularly in the higher-frequency bands (beta and gamma). The specific 
topographical distribution and timing of the beta and gamma PLF abnormalities 
suggested that they may be biomarkers for a top-down dysfunction in the 
schizophrenia spectrum. Power differences were noted mainly in respect to the theta 
band oscillations suggesting that theta band activity may be the oscillatory correlate of 
the P1 deficit.    
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Therefore, proof of concept studies in schizotypy could use theta band power and PLF 
to confirm and possibly augment the sensitivity of the P1 peak biomarker. 
Additionally, beta and gamma band PLF could be employed to assess the potential of 
interventions aimed am improving long-range connectivity in schizophrenia.   
 
9.8.3. Sensitivity to drug challenges: Neuropsychological measures 
 
The data from Chapter 4 showed that tasks sensitive to the schizophrenia spectrum 
phenotype are also responsive to psychotropic challenges. Specifically, acute 
enhancement of dopamine function was associated with improvement of cognitive 
function while dopamine antagonism led to worsening of cognition. These data 
support the idea that cognitive biomarkers probing working memory and inhibition-
related cognitive processes are adequate outcome measures for the assessment of 
cognitive enhancing agents in schizophrenia spectrum populations.  
 
  
9.8.4. Sensitivity to drug challenges: Electrophysiological measures 
 
The current thesis did not explore the sensitivity of the electroencephalographic 
measures to drug challenge, and this is a recognised limitation. Two studies 
addressing this are underway at the point of the submission of this thesis. The first one 
examines the effect of premedication with risperidone on the cognitive and 
electroencephalographic effects of the NMDA-receptor antagonist ketamine. The 
second one probes only the effects of ketamine on ERP and evoked oscillatory 
activity using the same WM task as the one reported in Chapter 6, 7 and 8.  
 
9.8.5. Specificity to the schizophrenia spectrum: Neuropsychological 
and electrophysiological measures 
 
The current thesis did not address the issue of specificity of the behavioural and 
electroencephalographic biomarkers and this represents another limitation. The 
available evidence suggests that cognitive impairment is present in a number of 
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mental health diagnostic entities (Martinez-Aran et al. 2004) and this pattern is likely 
to extend to connectivity measures.  
 
The greatest promise for specificity may lie in biomarkers that probe for 
topographical and temporal patterns of neural connectivity which may be different in 
the separate major psychiatric disorders. The down-regulated fronto-occipital PLF 
network in schizotypy may be a particularly promising biomarker in this respect. 
More research is needed to test the hypothesis that major psychiatric disorders, such 
as bipolar disorder and schizophrenia, differ in the patterns of their long-range 
connectivity.  
 
9.8.6. Test-retest and inter-site reliability: Neuropsychological and 
electrophysiological measures 
 
The current thesis did not investigate the test-retest reliability of the two types of 
biomarkers. The available evidence suggests that executive function and eye-tracking 
measures have good reliability (See Chapter 3 for detailed review). More research is 
needed to establish the reliability parameters for the electroencephalographic 
biomarkers, however.  
 
Chapter 4 examined the inter-site reliability in respect to the cognitive biomarkers and 
no significant differences were noted between the three UK sites. The analysis of the 
eye-tracking data from the same dataset did not find any effects of site either. Inter-
site reliability of the electroencephalographic measures was not explored and this is 
another area that will require clarification before these biomarkers can be used in 
proof of concept studies.   
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9.9. Future research directions  
 
The work featuring in this thesis can be extended in a variety of directions, some of 
which have already been touched upon.  
 
Firstly, future research should continue to characterise the pathophysiology of the 
information processing abnormality in the schizophrenia spectrum. As it was 
mentioned previously, the work in this thesis suggests a distributed rather than 
localised cause but falls short of unequivocally proving this. Section 9.6.2 outlined 
two complementary experiments using NMDA-challenge and TMS that may help to 
address this limitation of the current thesis. In addition, further analysis of the datasets 
reported in Chapters 6, 7 and 8 may provide more evidence to support either 
hypothesis. One approach would be to analyse the inter-electrode coherence within 
and between the prefrontal and occipital cortices in the period immediately before the 
onset of the stimulus. Reduced within-prefrontal cortex synchrony that precedes the 
fronto-occipital network activation would argue in favour of primary localised 
prefrontal cortex deficit. Simultaneous disruption of intra- and inter-regional 
synchrony would serve the case of a dysconnectivity deficit. Additionally, 
examination of the inter-electrode coherence and induced oscillations during the delay 
periods of the WM paradigm could indicate whether the schizophrenia spectrum 
individuals fail to support distributed or localised prefrontal cortex networks during 
sustained cognitive effort.  
 
Secondly, as it was outlined earlier, the question of whether the frontal 
hypodopaminergia trait is continuously distributed in the general population is still 
unclear. Addressing this question using a study, such as the one suggested in section 
9.3. (dopamine agonist challenge of cognitive performance in low, average and high 
schizotypy) could help define the neurotransmitter basis of the risk for schizophrenia. 
The results of such a study could help to map the line beyond which mental health 
states become abnormal. It could also help to define the likely benefits and ethical 
caveats associated with cognitive enhancement in the general population.  
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Thirdly, the lack of a schizotypy effect on the SPEM task in Chapter 5 indicates the 
complex link between genetic and psychopathological risk for schizophrenia (Thaker 
et al. 1996). Some authors have already argued that perhaps two types of schizotypy 
exist in respect to their genetic background - ‘true genetic’ and ‘wild’ types - and that 
distinct pathophysiological mechanisms may be involved (Bergman et al. 2000). 
Future research may focus on defining the relative importance of these factors for the 
formation of specific cognitive deficits. One design that may be well suited to address 
this would compare the cognitive performance of four groups of volunteers: i) 
relatives of patients with high levels schizotypal personality traits; ii) relatives of 
patients with low levels of schizotypal personality traits; iii) volunteers with no family 
history of schizophrenia with high levels schizotypal personality traits; iv) volunteers 
with no family history of schizophrenia with low levels schizotypal personality traits. 
Recruitment for such a study would be demanding, but its results may provide 
important information on the contributions of genetics and psychopathological factors 
to the formation of cognitive and information processing abnormalities.  
 
Fourthly, as outlined in section 9.6, a number of key characteristics that define the 
usefulness of a biomarker are yet to be explored in respect to the cognitive and 
electroencephalographic measures used in this thesis. Further exploration of 
reliability, specificity and sensitivity to drug action is required to justify their use in 
proof of concept studies of novel cognitive enhancing agents.  
 
A fifth direction would be to further define the causal link between early information 
processing abnormalities and higher-order cognitive deficits. This type of research 
would identify the potential for cognitive improvement with therapies aimed at 
improving the encoding capabilities. 
 
Lastly, the main rationale for pursuing agents rests on the evidence showing that 
cognitive deficits are linked to worse functional outcome (Green 1996). There is 
however relatively little evidence that  improving cognition in developed cases of 
schizophrenia will automatically lead to better functional outcome (Breier 2005). 
Meta-analyses and reviews of studies using cognitive remediation therapy to improve 
cognition in schizophrenia have indicated that modest improvement in cognitive 
abilities does not readily translate into better functioning (Kurtz et al. 2001; Pilling et 
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al. 2002; Krabbendam et al. 2003; McGurk et al. 2007). Therefore, once a compound 
demonstrates an effect on cognition, one of the next key research priorities would be 
to explore its relevance to the ultimate unmet need in schizophrenia: functional 
outcome. 
 
9.10. Conclusion  
 
In conclusion, both cognitive and electroencephalographic biomarkers showed good 
sensitivity to the schizophrenia spectrum phenotype. Together with the evidence for 
sensitivity to drug action in the case of the cognitive measures, these results argue in 
favour of the feasibility of proof of concept studies using such biomarkers to detect 
the effect of novel agents on cognition in schizophrenia spectrum populations. The 
results in this thesis indicate that several key considerations should be taken into 
account when designing a proof of concept study in schizotypy. These are as follows: 
i) choice of biomarkers that probe trait rather than state-dependent cognitive 
abnormalities; ii) manipulation of the difficulty of a cognitive biomarker, to avoid 
floor or ceiling effects; iii) Choice of control group that would allow the 
demonstration of maximum schizotypy effect; iv) Inclusion of a dopamine enhancing 
comparator drug to examine critically the benefit provided by the novel compound.     
 
The lack of specificity of the biomarkers evaluated here to schizophrenia probably 
reflects the non-specific nature of the cognitive abnormalities in mental health 
disorders. This should not be solely as a limitation, given that any agents found to be 
effective in improving cognition in one psychiatric population are likely to be 
beneficial in other mental health disorders.  
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APPENDIX 1: Schizotypy Personality Questionnaire (SPQ) 
Please answer each of the items by circling either Yes or No.  Answer all items even 
if unsure of your answer.  When you have finished, check over each one to make sure 
that you have answered them. 
 
1. Do you sometimes feel that things you see on the TV or read in 
the newspaper have a special meaning for you? 
Yes No 
2. I sometimes avoid going to places where there will be many 
people because I will get anxious. 
Yes No 
3. Have you had experiences with the supernatural? Yes No 
4. Have you often mistaken objects or shadows for people, or 
noises for voices? 
Yes No 
5. Other people see me as slightly eccentric (odd). Yes No 
6. I have little interest in getting to know other people. Yes No 
7. People sometimes find it hard to understand what I am saying. Yes No 
8. People sometimes find me aloof and distant. Yes No 
9. I am sure I am being talked about behind my back. Yes No 
10. I am aware that people notice me when I go out for a meal or 
to see a film. 
Yes No 
11. I get very nervous when I have to make polite conversation. Yes No 
12. Do you believe in telepathy (mind-reading)? Yes No 
13. Have you ever had the sense that some person or force is 
around you, even though you cannot see anyone? 
Yes No 
14. People sometimes comment on my unusual mannerisms and 
habits. 
Yes No 
15. I prefer to keep to myself. Yes No 
16. I sometimes jump quickly from one topic to another when 
speaking. 
Yes No 
17. I am poor at expressing my true feelings by the way I talk and 
look. 
Yes No 
18. Do you often feel that other people have got it in for you? Yes No 
19. Do some people drop hints about you or say things with a Yes No 
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double meaning? 
20. Do you ever get nervous when someone is walking behind 
you? 
Yes No 
21. Are you sometimes sure that other people can tell what you 
are thinking? 
Yes No 
22. When you look at a person, or yourself in a mirror, have you 
ever see the face change right before your eyes? 
Yes No 
23. Sometimes other people think I am a little strange? Yes No 
24. I am mostly quiet when with other people. Yes No 
25. I sometimes forget what I am trying to say Yes No 
26. I rarely laugh and smile. Yes No 
27. Do you sometimes get concerned that friends or co-workers 
are not really loyal or trustworthy? 
Yes No 
28. Have you ever noticed a common event or object that seemed 
to be a special sign for you? 
Yes No 
29. I get anxious when meeting people for the first time. Yes No 
30. Do you believe in clairvoyancy (psychic forces, fortune 
telling)? 
Yes No 
31. I often hear a voice speaking my thoughts aloud? Yes No 
32. Some people think I am a very bizarre person. Yes No 
33. I find it hard to be emotionally close to other people. Yes No 
34. I often ramble on too much when speaking. Yes No 
35. My "non-verbal" communication (smiling and nodding during 
a conversation) is poor. 
Yes No 
36. I feel I have to be on my guard even with my friends. Yes No 
37. Do you sometimes see special meaning in advertisements, 
shop windows, or in the way things are arranged around you? 
Yes No 
38. Do you often feel nervous when you are in a group of 
unfamiliar people? 
Yes No 
39. Can other people feel your feelings when they are not there? Yes No 
40. Have you ever seen things invisible to other people? Yes No 
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41. Do you feel that there is no one you are really close to outside 
of your immediate family or people you can confide in or talk to 
about personal problems? 
Yes No 
42. Some people find me a bit vague and elusive during a 
conversation. 
Yes No 
43. I am poor at returning social courtesies or gestures. Yes No 
44. Do you often pick up hidden threats or put-downs from what 
people say or do? 
Yes No 
45. When shopping do you get the feeling that other people are 
taking notice of you? 
Yes No 
46. I feel very uncomfortable in social situations involving 
unfamiliar people. 
Yes No 
47. Have you had experiences with astrology, seeing the future, 
UFOs, ESP or a sixth sense? 
Yes No 
48. Do everyday things seem unusually large or small? Yes No 
49. Writing letters to friends is more trouble than it is worth. Yes No 
50. I sometimes use words in unusual ways. Yes No 
51. I tend to avoid eye contact when conversing with others. Yes No 
52. Have you found that it is best not to let other people know too 
much about you? 
Yes No 
53. When you see people talking to each other, do you often 
wonder if they are talking about you? 
Yes No 
54. I would feel very anxious if I had to give a speech in front of a 
large group of people. 
Yes No 
55. Have you ever felt that you are communicating with another 
person telepathically (by mind reading)? 
Yes No 
56. Does your sense of smell sometimes become unusually 
strong? 
Yes No 
57. I tend to keep in the background on social occasions. Yes No 
58. Do you tend to wander off the topic when having a 
conversation? 
Yes No 
59. I often feel that others have it in for me. Yes No 
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60. Do you sometimes feel that other people are watching you? Yes No 
61. Do you ever suddenly feel distracted by distant sounds that 
you are not normally aware of? 
Yes No 
62. I attach little importance to having close friends. Yes No 
63. Do you sometimes feel that people are talking about you? Yes No 
64. Are your thoughts sometimes so strong that you can almost 
hear them? 
Yes No 
65. Do you often have to keep an eye out to stop people from 
taking advantage of you? 
Yes No 
66. Do you feel that you are unable to get "close" to people? Yes No 
67. I am an odd, unusual person. Yes No 
68. I do not have an expressive and lively way of speaking. Yes No 
69. I find it hard to communicate clearly what I want to say to 
people. 
Yes No 
70. I have some eccentric (odd) habits. Yes No 
71. I feel very uneasy talking to people I do not know well. Yes No 
72. People occasionally comment that my conversation is 
confusing. 
Yes No 
73. I tend to keep my feelings to myself. Yes No 
74. People sometimes stare at me because of my odd appearance. Yes No 
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APPENDIX 2: Brief Version of the SPQ (SPQ-B)  
 
Please answer each item by clicking Y (Yes) or N (No). Answer all items even if 
unsure of your answer. When you have finished, check over each one to make sure 
you have answered them all.  
 
1. People sometimes find me aloof and distant. 
2. Have you ever had the sense that some person or force is around you, even though 
you cannot see anyone?  
3. People sometimes comment on my unusual mannerisms and habits.  
4. Are you sometimes sure that other people can tell what you are thinking? 
5. Have you ever noticed a common event or object that seemed to be a special sign 
for you? 
6. Some people think that I am a very bizarre person. 
7. I feel I have to be on my guard even with friends. 
8. Some people find me a bit vague and elusive during a conversation. 
9. Do you often pick up hidden threats or put-downs from what people say or do?  
10. When shopping do you get the feeling that other people are taking notice of you? 
11. I feel very uncomfortable in social situations involving unfamiliar people. 
12. Have you had experiences with astrology, seeing the future, UFOs, ESP or a sixth 
sense? 
13. I sometimes use words in unusual ways. 
14. Have you found that it is best not to let other people know too much about you?  
15. I tend to keep in the background on social occasions. 
16. Do you ever suddenly feel distracted by distant sounds that you are not normally 
aware of? 
17. Do you often have to keep an eye out to stop people from taking advantage of 
you?  
18. Do you feel that you are unable to get "close" to people? 
19. I am an odd, unusual person. 
20. I find it hard to communicate clearly what I want to say to people. 
21. I feel very uneasy talking to people I do not know well. 
 22. I tend to keep my feelings to myself. 
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APPENDIX 3: O-LIFE Questionnaire  
 
These questions relate to your thoughts, feelings, experiences and preferences.  There 
are no right or wrong answers or trick questions so please be as honest as possible.  
For each question please choose either YES or NO and circle this on the form.  Please 
do not spend too much time thinking about it – choose the answer closest to your 
own.  
 
 Experience 
1. Do you often hesitate when you are going to say something in a 
group of people whom you more or less know? 
Yes No 
2. Do you often overindulge in alcohol or food? Yes No 
3. Are the sounds you hear in your daydreams really clear and 
distinct? 
Yes No 
4. Do you enjoy many different kinds of play and recreation? Yes No 
5. Do your thoughts sometimes seem real as actual events in your 
life? 
Yes No 
6. Does it often happen that nearly every thought immediately and 
automatically suggests an enormous number of ideas? 
Yes No 
7. When in a group of people do you usually prefer to let someone 
else be the centre of attention? 
Yes No 
8. Do you frequently have difficulty in starting to do things? Yes No 
9. Has dancing or the idea of it always seemed dull to you? Yes No 
10. When you catch a train do you often arrive at the last minute? Yes No 
11. Is trying new foods something you have always enjoyed? Yes No 
12. Do you often change between intense liking and disliking the 
same person? 
Yes No 
13. Have you ever cheated at a game? Yes No 
14. Are there very few things that you have ever really enjoyed 
doing? 
Yes 
 
No 
15. Do you at times have an urge to do something harmful or 
shocking? 
Yes No 
16. Do you often worry about things you should not have done or 
said? 
Yes No 
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17. Are your thoughts sometimes so strong that you can almost hear 
them? 
Yes No 
18. Are you usually in an average sort of mood, not too high and not 
too low? 
Yes No 
19. Would you take drugs, which may have strange or dangerous 
effects? 
Yes No 
20. Do you think you could learn to read other's minds if you wanted 
to? 
Yes No 
21. When in a crowded room, do you often have difficulty in 
following a conversation? 
Yes No 
22. No matter how hard you try to concentrate, do unrelated thoughts 
creep into your mind? 
Yes No 
23. Are you easily hurt when people find fault with you or the work 
you do? 
Yes No 
24. Do you stop to think things over before doing anything? Yes No 
25. Have you ever felt that you have special, almost magical powers? Yes No 
26. Are you much too independent to really get involved with other 
people? 
Yes No 
27. Do ideas and insights sometimes come to you so fast that you 
cannot express them all? 
Yes No 
28. Do you easily lose your courage when criticised or failing in 
something? 
Yes No 
29. Can some people make you aware of them just by thinking about 
you? 
Yes No 
30. Does a passing thought ever seem so real it frightens you? Yes No 
31. Have you ever blamed someone for doing something you know 
was really your fault? 
Yes No 
32. Are you a person whose mood goes up and down easily? Yes No 
33. Does your voice ever seem distant or far away? Yes No 
34. Do you think having close friends is not as important as some 
people say? 
Yes No 
35. Are you rather lively? Yes No 
36. Are you sometimes so nervous that you are "blocked"? Yes No 
37. Do you find it difficult to keep interested in the same thing for a Yes No 
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long time? 
38. Do you dread going into a room by yourself where other people 
have already gathered and are talking? 
Yes No 
39. Does it often feel good to massage your muscles when they are 
tired or sore? 
Yes No 
40. Do you sometimes feel that your accidents are caused by 
mysterious forces? 
Yes No 
41. Do you like mixing with people? Yes No 
42. On seeing soft thick carpet have you sometimes had the impulse 
to take off your shoes and walk barefoot on it? 
Yes No 
43. Do you often have difficulties in controlling your thoughts? Yes No 
44. Do the people in your daydreams seem so true to life that you 
sometimes think they are real? 
Yes No 
45. Are people usually better off if they stay aloof from emotional 
involvements with people? 
Yes No 
46. Can just being with friends make you feel really good? Yes No 
47. Is your hearing sometimes so sensitive that ordinary sounds 
become uncomfortable? 
Yes No 
48. Have you often felt uncomfortable when your friends touch you? Yes No 
49. When things are bothering you do you like to talk to other people 
about it? 
Yes No 
50. Do you have many friends? Yes No 
51. Would being in debt worry you? Yes No 
52. Do you think people spend too much time safeguarding their 
future with savings and insurance? 
Yes No 
53. Do you ever have the urge to break or smash things? Yes No 
54. Do you often feel that there is no purpose to life? Yes No 
55. Do you worry about awful things that might happen? Yes No 
56. Have you ever felt the urge to injure yourself? Yes No 
57. Would it make you nervous to play the clown in front of other 
people? 
Yes No 
58. Have you felt that you might cause something to happen just by 
thinking too much about it? 
Yes No 
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59. Have you had very little fun from physical activities like walking, 
swimming or sports? 
Yes No 
60. Do you feel sometimes so good at controlling others that it 
sometimes scares you? 
Yes No 
61. Are you easily distracted from work by daydreams? Yes No 
62. Are you easily confused if too much happens at the same time? Yes No 
63. Do you ever have a sense of vague danger or sudden dread for 
reasons that you do not understand? 
Yes No 
64. Is it true that your relationships with other people never get very 
intense? 
Yes No 
65. Have you sometimes had the feeling of gaining or losing energy 
when certain people look at you or touch you? 
Yes No 
66. Do you worry too long after an embarrassing experience? Yes No 
67. Do you love having your back massaged? Yes No 
68. Do you consider yourself to be pretty much an average kind of 
person? 
Yes No 
69. Have you ever taken advantage of someone? Yes No 
70. Would you like other people to be afraid of you? Yes No 
71. Have you ever thought you heard people talking only to discover 
that it was in fact some nondescript noise? 
Yes No 
72. Have you occasionally felt that your body did not exist? Yes No 
73. Do you often feel lonely? Yes No 
74. Do you often have an urge to hit someone? Yes No 
75. Do you often experience an overwhelming sense of emptiness? Yes No 
76. On occasions, have you seen a person's face in front of you when 
no one was in fact there? 
Yes No 
77. Is it fun to sing with other people? Yes No 
78. Do you often have days when indoor lights seem so bright that 
they bother your eyes? 
Yes No 
79. Have you wondered whether spirits of the dead can influence the 
living? 
Yes No 
80. Do people who try to get to know you better usually give up after 
a while? 
Yes No 
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81. Do you often feel ‘fed up’? Yes No 
82. Have you felt as though your head or limbs were somehow not 
your own? 
Yes No 
83. When you look into the mirror does your face sometimes seem 
quite different from usual? 
Yes No 
84. Do people who drive carefully annoy you? Yes No 
85. Would you call yourself a nervous person? Yes No 
86. Can you usually let yourself go and enjoy yourself at a lively 
party? 
Yes No 
87. Do you ever suddenly feel distracted by distant sounds that you 
are not normally aware of? 
Yes No 
88. Do you sometimes talk about things you know nothing about? Yes No 
89. When in the dark do you often see shapes and forms even though 
there's nothing there? 
Yes No 
90. Have you sometimes sensed an evil presence around you, even 
though you could not see it? 
Yes No 
91. Is it hard for you to make decisions? Yes No 
92. Do you find the bright lights of a city exciting to look at? Yes No 
93. Does your sense of smell sometimes become unusually strong? Yes No 
94. Do you usually have very little desire to buy new kinds of food? Yes No 
95. Do you ever feel that your speech is difficult to understand 
because the words are all mixed up and don't make sense? 
Yes No 
96. Do you often feel like doing the opposite of what other people 
suggest, even though you know they are right? 
Yes No 
97. Do you like going out a lot? Yes No 
98. Do you feel very close to your friends? Yes No 
99. Do you ever feel sure that something is about to happen, even 
though there does not seem to be any reason for you thinking that? 
Yes No 
100. Do you often feel the impulse to spend money which you know 
you can't afford? 
Yes No 
101. Are you easily distracted when you read or talk to someone? Yes No 
102. Do you feel that making new friends isn't worth the energy it 
takes? 
Yes No 
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103. Do you believe in telepathy Yes No 
104. Do you prefer watching television to going out with other 
people? 
Yes No 
 
Thank you very much for taking the time and effort to fill this in. 
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APPENDIX 4: National Adult Reading Test (NART) 
 
Instructions for NART: These words are pronounced differently to how they read. 
Please speak each word out loud and clearly so that the experimenter can hear. Please 
try to pronounce each word as best you can even though some of the words may be 
quite difficult. 
List of words (2nd edition)  
 
CHORD SUPERFLUOUS 
ACHE SIMILE 
DEPOT BANAL 
AISLE QUADRUPED 
BOUQUET CELLIST 
PSALM FACADE 
CAPON ZEALOT 
DENY DRACHM 
NAUSEA AEON 
DEBT PLACEBO 
COURTEOUS ABSTEMIOUS 
RAREFY DETENTE 
EQUIVOCAL IDYLL 
NAIVE PUERPERAL 
CATACOMB AVER 
GAOLED GAUCHE 
THYME TOPIARY 
HEIR LEVIATHAN 
RADIX BEATIFY 
ASSIGNATE PRELATE 
HIATUS SIDEREAL 
SUBTLE DEMESNE 
PROCREATE SYNCOPE 
GIST LABILE 
GOUGE CAMPANILE 
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APPENDIX 5: Neurocognitive Biomarkers for the MATRICS Domains  
 
N-back task 
A computer controls the presentation of a series of alphabet letters on a colour 
monitor and record responses on clearly marked response keys.  Participants are 
instructed not to respond until they see two specific letters following one another with 
a varying number of letters between the two target letters.  The letters remain on the 
screen for 1 second and a blank screen of 1 second separates the stimuli. The letters 
are presented in a centrally and have dimensions of 4 visual degrees vertically and 
horizontally. This task has three levels of difficulty each increasing the load on 
working memory.  In the 1-back test the two target letters are separated by one letter, 
in the 2-back test the target letters are separated by two letters and so on. 
Consequently, the 1-back test exerts the lowest load on working memory and the 3-
back task the highest. There are also blocks to control for attending to the task where 
participants simply need to respond when they see a target letter (attention or 0-back). 
Before the beginning of the task participants complete a practice trial consisting of 1 
block of each condition. During the main task participants complete 3 blocks of each 
condition (attention, 1-back, 2-back and 3-back). The 12 blocks are intermixed 
pseudorandomly. At the beginning of each block a title screen informs the participant 
what the condition is. In each block 14 stimuli are presented pseudorandomly, so that 
there are 3 target and 11 non-target images. Overall, there is a maximum of 9 correct 
answers and 33 errors of commission per working memory load. The outcome 
variables are the percentage of correct responses, number of errors of commission and 
the latencies of correct and incorrect responses.  
 
 
Spatial working memory task (SWM) 
A computer controls the presentation of stimuli on a colour monitor and records 
responses made via the computer mouse. Participants are given the task of searching 
treasure troves for coins. There is the same number of coins as there are treasure 
chests. The participants attempt to search for all the coins without choosing treasure 
chests they have previously searched or already found coins in on previous choices. 
The task has one practise attempt with 3 treasure chests, followed by test blocks 
which include four repetitions each with four treasure chests, six chests, and eight 
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chests. Between each block the configuration of the boxes on the page is altered so as 
to reduce the likelihood of stereotypical searching strategies. The levels of task 
difficulty are increased by increasing the number of treasure chests to be searched. 
Once the participants complete four successful choices at each level of task difficulty 
they move on to the next level of difficulty. The SWM task involves the maintenance 
and manipulation aspects of working memory. The performance indices for this task 
are number of completed trials for the 8 treasure chest blocks (maximum score 4), 
number of within trial errors (already searched a chest within that trial), number of 
between trial errors (where they have previously found coins), and searching strategy 
score.  
 
 
Verbal fluency task 
Letter and category verbal fluency and word production is assessed during a 
succession of one minute periods. For the letter verbal fluency test participants are 
asked to verbally report as many words as they can beginning with the letters F, A and 
S in one minute for each letter (FAS condition). The experimenter writes down the 
words.  For the category fluency test participants are first asked to name all the 
vegetables and animals they can think of in one minute for each category (category 
naming condition). Participants are then asked to verbally report as many words as 
they can in one minute, alternately from two categories: fruit and furniture (category 
swap condition). The main outcome variable of all three conditions is the number of 
correctly produced words. For the FAS and category naming conditions, the number 
of set and repetition errors is recorded. The number of correct transitions is an 
outcome variable in the category swap condition. 
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APPENDIX 6: Eye Movement Procedures 
 
General Set-up 
The eye movement procedures take place in a window-less, light-dimmed, quiet 
room. The lights are dimmed in order to secure accurate eye movement recordings yet 
without subjecting the participants to complete darkness.  
 
The general set-up of the procedures involves the participant sitting in a comfortable 
chair in front of a desk-mounted computer screen. The distance between the 
participant’s eyes and the screen is 57 cm.  Participants with contact lenses or glasses 
are allowed to wear these during assessments.  
 
In order to minimise head and body movements the participant is required to keep still 
and rest their arms on the desk. Additionally, a custom built chin rest is used to further 
reduce head movements.  
 
Equipment for the Recording of Eye Movements 
Eye movements will be recorded using an eye movement tracker such as the Eyelink 
1000 Desktop System (SR Research Ltd., Mississauga, Ontario, Canada). The Eyelink 
system is a video-based pupil tracker with high resolution and fast data acquisition 
(1000 Hz sampling frequency). The “desktop mount” version of this well-established 
and widely used system avoids any contact between hardware and the participant’s 
head as it tracks the participant’s eye with a camera positioned below the monitor on 
the desktop. This set-up minimises any discomfort to the participant.  
The research team at the Institute of Psychiatry has previously conducted several 
hundred experimental sessions examining eye movements in healthy individuals and 
patients with schizophrenia (Ettinger et al. 2003, 2004a,b, 2005, 2006).  Only minimal 
problems with compliance have been encountered in the patient and volunteer groups, 
and there are no reports of discomfort or physical damage to any participants.  
 
Procedure 
The participant is seated in the chair and is given some preliminary instructions 
concerning the eye movement experiments.  These instructions include a brief lay 
language description of the technical principles of eye movement recording, a 
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statement regarding its risks (e.g. dry eyes), and a brief introduction to the tasks that 
are to be conducted. Participants are told that they will be required to sit in the chair 
provided, keep their head in a chinrest, and respond to a simple visual stimulus 
presented on a computer screen. The eye movement measurement device is shown to 
the participants. They are also told that they will be given more detailed instructions 
regarding each individual task as the assessment proceeds.  
Once the participant has indicated that they are comfortable with the equipment they 
are asked to rest their head on the chin rest provided, and to bring their arms forward 
to rest on the desk (to ensure minimal body movements during the procedures). The 
chinrest consists of a height-adjustable, small plastic cup shaped to accommodate the 
participant’s chin. The participant is informed that they will have to keep still in that 
position, moving their head or body as little as possible.  
 
Next the eye-tracker is calibrated. This requires the participant to focus their gaze 
successively, as instructed by the experimenter, on one of three small dots presented 
on the computer screen. The stimuli are presented in the mid-horizontal plane on the 
screen, corresponding to amplitudes of 0°, -12°, and +12° of centre (thus 
corresponding to three of the target positions later used in the actual tasks). 
Calibration takes about 5 minutes. Re-calibration (lasting only several seconds) is 
carried out before each task.  
 
Once the eye-tracker is calibrated a brief verbal warning is issued by the experimenter 
and the lights in the room are dimmed. The participant is given a few seconds to 
adjust their eyes to the new light conditions before the first task begins. Each task is 
initiated individually by the experimenter. The participant can talk to the experimenter 
between tasks (but is strongly encouraged not to speak during a task). Anonymised 
file names are entered for data saving and the task is started once the participant is 
ready. The experimenter reminds the participant before each new block to keep their 
head still.  
 
Four different sets of eye movement tasks are carried out, in the following order: (1) 
fixation, (2) smooth pursuit, (3) prosaccade, and (4) antisaccade (NB: the order can be 
counter-balanced if necessary).  
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Stimuli and Tasks 
The target stimulus that is displayed on the computer screen consists of a small, white 
dot of circular shape (0.2° of visual angle), presented against a black background for 
all tasks.  
 
In the fixation task, the target appears for 30 seconds in each of three locations 
(centre=0°, left=-12°, right=+12°). The participant is required to keep their eyes on 
the target as closely as possible.  
 
In the smooth pursuit eye movement (SPEM) task the target moves horizontally at a 
sinusoidal waveform (frequency 0.4Hz) across the screen for 60 seconds (range 
±12°). The participant is required to keep their eyes on the target as closely as 
possible. Participants are allowed 10 seconds practice before the actual task begins.  
 
In a prosaccade trial (or reflexive saccade trial) the target jumps from the central 
location to a peripheral location (±6°, ±12°). The participant is required to keep their 
eyes on the target as closely as possible. There are 60 such trials, with each trial 
lasting on average 2.5 seconds (overall task duration on average is 2.5 minutes). 
Participants perform 4 practice trials before the actual task.  
 
In an antisaccade task the target again jumps from the central location to a peripheral 
location (±6°, ±12°), with the same timing as in the prosaccade task. In this task 
however, the participant is required to look at the target while it is in the central 
location and then look immediately in the opposite direction when it jumps to the 
side. For example, if the target jumps to 12° on the right, the participant has to look to 
12° to the left of the centre. Participants perform 4 practice trials before the actual 
task.  
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APPENDIX 7: Salience Attribution Test  
 
On the Salience Attribution Test (SAT), participants make a speeded response to the 
onset of a probe (white square) in order to earn money. The maximum win for all 
trials is set at £20. Prior to the main test, participants complete a computerized 
tutorial. Two practice sessions are embedded into the tutorial to familiarize 
participants with the test and provide a measure of baseline response time (RT).  On 
these practice sessions, a fixation cross appears on the computer screen at the 
beginning of each trial. Following a variable interval (minimum 0.5 seconds, 
maximum 1.5 seconds) the probe appeared, and participants respond by pressing a 
button as quickly as possible. Participants are instructed to try to respond before the 
box disappears. During the first practice session the probe is on the screen for 
randomised variable periods, with a maximum duration of 1.5 s, minimum duration 
0.5 s and mean duration 1 s. Feedback is provided after 2 s as: (i) “Good” if the 
participant responds before the box disappears, (ii) “Try to respond faster” if they 
respond after the box disappears, (iii) “Too early” if they respond before the box 
appeared, and (iv) “No key pressed” if they do not make a response.  On the second 
practice session, the mean probe duration is set to be the mean RT from the first, 
ensuring participants are responding as quickly as possible and to link task difficulty 
to individual performance. The standard deviation (SD) of the fastest half of the trials 
(SDF) is also calculated, and is used to set the minimum and maximum probe 
durations for the second practice session (mean from first practice session ± 2*SDF).  
For the main test, the mean, minimum and maximum probe durations are calculated 
from the second practice session in the same way.  No reinforcement is provided 
during the practice sessions. 
 
Participants then complete two blocks of 64 trials on the main test, where money is 
available on 50% of trials.  The likelihood that money is available on a trial is 
signaled by one of four conditioned stimuli (CSs) that appear at the top and bottom of 
the screen before the onset of the probe.  CSs vary on two different visual dimensions: 
color (blue or red) and shape (animal or household object). Therefore, there are four 
different types of CS: blue animals; red animals; blue household objects and red 
household objects. One of these dimensions (e.g. color) is task-relevant so that one 
level of the dimension is reinforced on 28/32 (87.5%) of the trials while only 4/32 
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(12.5%) trials of the other are reinforced.  For example, if ‘color’ is the reinforced 
dimensions, 14/16 blue animals and 14/16 blue household objects will be reinforced, 
compared to only 2/16 red animals and 2/16 red household objects. The other 
dimension, in this example ‘shape’, are task-irrelevant, so that 16/32 (50%) of both 
levels are reinforced. Participants are not informed of these contingencies. 
 
At the beginning of each trial a fixation cross appeared; after 1000ms, while the 
fixation cross remains on-screen, one of the four CSs is displayed at the top and 
bottom of the screen and remains on-screen until the end of the trial. After a variable 
period of time (between 0.5 and 1.5 s) the probe appears and participants attempt to 
respond before it disappears. The probe duration is calculated according to the 
participant’s responses on the second practice block, as described above.  After 2.25 s, 
auditory and visual feedback is presented for 1.5 s. Four different versions of the SAT 
are used, each with a different stimulus feature (blue, red, animal or household object) 
reinforced with high probability. Each participant is administered the same version for 
both blocks of the SAT. 
 
If the trial is not reinforced, the message “Sorry – no money available” is displayed. If 
the trial is reinforced, participants win between 5 and 100 pence, depending on the 
latency of their response. On reinforced trials where participants either make no 
response or respond after the probe has disappeared, the message “Missed: 5 pence” is 
displayed. If participants respond prematurely (<100ms after the onset of the probe), 
the message displayed is “Too early: 5 pence”. On reinforced trials where participants 
respond before the probe disappears, but slower than their mean RT, the message “Hit 
– good: 10 pence” is displayed. When participants respond more quickly than their 
mean RT, the message “Quick – very good: X pence” is displayed (for responses up 
to 1.0 SDFs faster than their mean) and “Very quick– excellent: X pence” (for 
responses faster than their mean by 1.5 SDFs). The reward is scaled according to X = 
10 + 90 x (mean RT – trial RT)/(3 x SDF), up to a maximum of 100 pence. For 
example, a response 1 SDF faster than the mean is reinforced with 40 pence, while a 
response 2 SDFs faster is reinforced with 70 pence. The money won on each trial is 
added to the participant’s running total for that block. On reinforced trials, a 0.5 s tone 
is sounded, frequency: (300 + (10 x X)) Hz. At the end of each block, participants 
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indicate, using 10mm visual analogue scales (VAS), their estimate of the 
reinforcement probabilities for each of the four different CSs. 
 
